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General Introduction
 
 
Estrogen receptors and cancer: A Ying-Yang relationship 
Estrogens are a family of steroid hormones that are needed for normal developmental, 
physiological, and reproductive processes in vertebrates (1). In addition to the natural 
estrogens including 17β-estradiol (E2), there are many estrogen-like chemicals that can 
mimic the function of E2. For many decades, exposure to estrogen-like compounds has been 
related to adverse health effects including increased cancer risks. Increased exposure to 
estrogens has been linked to increased risk of developing breast and uterus cancer in women 
(2) and increased occurrence of prostate and testicular cancer in men (3, 4). 
 
In contrast to these adverse effects also beneficial health effects and even reduced instead 
of increased cancer incidences have been related to estrogen exposure. Estrogen deficiency, 
as occurring in menopausal women, is the main cause of osteoporosis and heart diseases (5). 
A reduction of cancer risks (6), cardiovascular diseases (7) and osteoporosis (8) have been 
reported especially upon high intake of soy-based phyto-estrogens.  
 
The exact mechanisms underlying the differential biological responses towards estrogen-
like compounds have not been elucidated yet, but may be related to a differential biological 
response of the two estrogen receptors, ERα and ERβ, and their mutual interaction. Pettersson 
and Gustafsson (9) hypothesised that ERβ may act as an inhibitor of the ERα mediated 
transcription activation. Interestingly, ERβ activation does not only result in a dominant 
suppression of all ERα inducible genes, it also inhibits proliferation of ERα-negative breast 
cancer cells (10, 11). Most studies have shown decreased ERβ expression in cancer tissues as 
compared to benign tumours or normal tissues, whereas ERα expression persists (10, 12). 
Hence ERα and ERβ may have different roles in gene regulation and their relative levels or 
ratios within the tissues may influence cellular responses to estrogens. It is known that the 
ratio of ERα/ERβ expression is higher in breast tumors than in normal tissues due to lower 
expression of ERβ (10) and that ERα and ERβ are antagonistic to each other; for example, 
ERβ appears to reduce the cell proliferation induced by ERα activation (13). Such modulating 
interactions provide support for the hypothesis of the present project that estrogen-like 
compounds that will activate the ERα may lead to adverse effects including stimulation of 
cell proliferation, whereas compounds stimulating the ERβ may be beneficial through their 
direct or indirect interaction with the ERα protein and down-regulation of the ERα response 
thereby reducing cell proliferation and stimulating apoptosis (Figure 1).  
 
The overall aim of the work presented in this thesis was to obtain insight in the role of 
ERα, ERβ and the ratio of ERα/ERβ present within a cell, in the cellular response to estrogen- 
like compounds. To this end, the thesis addresses the transcriptional activity and effects on 
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cell proliferation under the influence of specifically-acting estrogen-like molecules when 
varying the ratio of ERα/ERβ present in the cells under study and links these results on cell 
proliferation as the biological end-point to the genomics and proteomics data. The results 
obtained should provide better insight in the mechanisms underlying the differential effects of 
estrogen-like compounds on cell proliferation and, ultimately, cancer incidences, and the role 
of the two estrogen receptors in these mechanisms. 
 
 
Ligand 
 
 
 
 
 
 
 
 
 
Figure 1: Illustration of the working hypothesis. Because estrogen-induced activation of ERα or ERβ mediated 
gene expression activates different genes and pathways the ultimate biological outcome may depend on the ratio 
of ERα/ERβ present in the cells. (* indicates binding, + indicates stimulation, - indicates inhibition). 
Estrogen receptor and signalling function 
Estrogen receptors are members of the nuclear receptor subfamily and they are involved 
in a broad range of physiological effects, such as growth, differentiation and physiology of 
the reproductive processes (14). The role of ERs in non-reproductive tissues is at least as 
important as in reproductive ones, since they are affecting bones, the cardiovascular system, 
brain and liver (15). Until 1996, only one human ER was known. At that time Kuiper et al. 
revealed a novel nuclear estrogen receptor cloned from rat prostate. The known ER was 
renamed and called ERα to differentiate it from the novel ER, ERβ (16). The complete human 
ERβ cDNA was sequenced in 1998 by Ogawa et al. (17).  
 
Estrogen receptors are products of distinct genes localized on different chromosomes, 
ERα is encoded on chromosome 6q24-q27 (18), while the gene encoding ERβ is localized on 
chromosome 14q22-q24 (19). Despite their distinct localization, gene organization of the two 
receptors is well conserved. ESR1 (ERα) and ESR2 (ERβ) genes contain eight exons, 
separated by seven long intronic sequences. As members of the nuclear receptor superfamily, 
ERs contain 6 regions in their protein structure common for all nuclear receptors, namely: A, 
B, C, D, E and F which form functionally different but interacting domains (Figure 2). Exon 
ERα ERβ
Cell proliferation
* *
-
Apoptosis 
+ +
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1 encodes the A/B region in ERα and ERβ, exons 2 and 3 encode part of the C region. Exon 4 
encodes the remaining part of region C, all region D and part of the region E. Exons 4 to 8 
contain the rest of the region E sequence and region F is encoded by part of exon 8 [reviewed 
in (20)]. 
 
Although ERα and ERβ are encoded separately they share a high degree of homology. 
The most conserved domain among ERs is the DNA binding domain (DBD) corresponding to 
the C region, with 96% homology between α and β ER subtypes. The DBD is responsible for 
binding to the specific DNA sequences (Estrogen Responsive Elements or ERE) in target 
gene promoter regions. The A/B region located in the N-terminal protein site encompasses 
the AF-1 domain responsible for ligand independent transactivation. The AF-1 domain is the 
least conserved part among the two ERs with only 30% homology and it is functional only in 
the ERα subtype (21). The C-terminal protein part encloses the ligand dependent 
transactivation domain AF-2 together with the ligand binding domain (LBD) and homo-
heterodimerization site. Identity between the E/F regions of both proteins is 53%, which 
results in differences in ligand binding affinities between both receptors. The hinge region 
localized in the D domain contains the nuclear localization site of the ERs as well as post 
translational modification sites (22). Information on the structure/function relationship of this 
region is very limited. The domain appears to be a variable and not well conserved part of the 
ERs (only 30% homology).  
 
 
 
Figure 2: The domain structure of human the ERα and ERβ proteins. Based on  Matthews  and Gustafsson (23). 
 
Estrogen binding to the receptor induces the LBD to undergo a conformational change, 
upon which the receptor dimerizes, binds to DNA, and consequently stimulates gene 
expression (24, 25). 
13 
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Estrogen receptor distribution 
The distribution of ERs varies both between and within human tissues (see Table 1). The  
cardiovascular system, brain, and bones express both receptors. ERβ is predominant in the 
male reproductive system. Expression of both ERα and ERβ has been found in all major 
human uterine cell types at every menstrual stage. However, expression varies from cell-type 
to cell-type with expression of ERα mRNA being generally greater than that of ERβ (26). 
Changes in expression of estrogen receptors has been found in certain tumour types. Normal 
mammary tissue in man has been shown to express predominantly ERβ mRNA, whereas 
most ER-positive breast tumours appear to exhibit increased ratios of ERα/ERβ (27). 
Likewise, an increased ratio in ERα/ERβ mRNA has been demonstrated in ovarian carcinoma 
compared with normal tissue or cysts (12). High concentrations of ERβ have also been found 
within the human gut (19).  
Table 1: Tissue distribution of ER subtypes in humans. 
 
Organ/Tissue Human ER subtype Organ/Tissue 
Human 
ER subtype 
  ERα ERβ   ERα ERβ 
Heart 9 9 Adrenal 9 - 
Lung - 9 Kidney 9 9 
Vascular 9 9 Prostate - 9 
Bladder - 9 Testes - 9 
Epididymus - 9 Brain 9 9 
Pituitary - 9 Thymus - 9 
Liver 9 - Breast 9 9 
Muscle - - Uterus 9 9 
Fat - - Endometrium 9 9 
Gastrointestinal tract - 9 Vagina 9 - 
Colon - 9 Fallopian tube - 9 
Small intestine - 9 Ovary 9 9 
Bone 9 9     
 
Therefore, the ultimate estrogenic effect of a certain compound on cells or tissues will be 
dependent on the receptor phenotype of these cells or tissues. 
Mechanism of estrogen action 
Estrogens act on target tissues by binding to ERs. These proteins function as 
transcription factors when they are bound to a ligand. Biological action of ERs involves 
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complex and broad mechanisms. For the ERs two main mechanisms of action have been 
described,  including a genomic and a non-genomic pathway (Figure 3).  
 
The genomic action of ERs occurs in the nucleus of the cell, when the receptor binds 
specific DNA sequences directly (“direct activation”or classical pathway) or indirectly 
(“indirect activation” or non-classical pathway). In the absence of ligand, ERs are associated 
with heat-shock proteins. The Hsp90 and Hsp70 associated chaperone machinery stabilizes 
the ligand binding domain (LBD) and makes it accessible to the ligand. Ligand-ER is 
activated through phosphorylation and dissociates from the heat-shock proteins. Then, the 
ligand-bound activated ER changes its conformation, dimerizes, and binds to specific DNA 
sequences called estrogen responsive elements (ERE) in order to regulate transcription (28). 
In the presence of the natural ligand 17β-estradiol (E2), ER induces chromatin remodelling 
and increased transcription of estrogen regulated genes (29). 
 
In the non-classical pathway, AP-1 (30) and SP-1 (31) are alternative regulatory DNA 
sequences used by both isoforms of the receptor, ERα and ERβ, to modulate gene expression. 
In this case, ER does not interact directly with DNA but interacts with other DNA-bound 
transcription factors such as c-Jun or c-Fos, or with other coactivator proteins (32). Both AF-
1 and AF-2 domains of ER are required for the interaction with Fos/Jun complex and both 
receptors differentially affect AP-1 dependent genes. In the presence of ERα, E2 works as 
AP-1 agonist by enhancing activity of the coactivators at AP-1 sites (33), while in the 
presence of ERβ it antagonizes AP-1 activity (28). When both receptors are present, ERβ 
inhibits the action of ERα on AP-1 promoters (34). Interactions of ERs with other 
transcription factors might be also selectively modulated by different ligands, such as 
genistein and quercetin, which are not able to stimulate AP-1 dependent transcription (35, 
36). 
 
Even though ERs are considered transcription factors they can act through non-genomic 
mechanisms. Rapid ER effects were first observed in 1960s when administration of a 
physiological dose of E2 was reported to increase uterine cAMP levels in ovariectomized rats 
within 15 seconds (37), a time scale that is considered too fast for a genomic action. There is 
still no agreement if receptors responsible for rapid actions of estrogens are the same proteins 
as nuclear ERs or distinct G-protein coupled steroid receptors (38-41). However, a broad 
range of other rapid pathways induced by E2 has been identified so far. Some of these 
pathways include MAPK/ERK pathway, activation of endothelial nitric oxide synthase 
(eNOS) PLC stimulated IP3 production, calcium influx and PI3K/Akt pathway activation (42, 
43) (20). Similarly to non-classic mechanisms of activation, phytoestrogens might affect 
rapid pathways in a different way than E2. Quercetin for example has been shown to fail to 
phosphorylate ERK-2 kinase (opposite to E2) nor did it stimulate transcription of Cyclin D1, 
15 
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the transcription of which depends on rapid ER pathways (42). The stimulation of eNOS, 
which plays a positive role in cardiovascular health effects induced by E2 also seems to be 
regulated differently by phytoestrogens. Rapid activation of eNOS in the presence of E2 is 
dependent on ERα (44), while both receptors are required for prolonged effects. However 
phytoestrogens do not activate eNOS in a rapid manner but seem to activate it through a 
prolonged, ERβ dependent transcriptional mechanism (44). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Mechanisms of estrogen receptor (ER) action. In the direct activation, ERs dimerize after ligand 
binding and attach to the ERE in the promoter of target genes. In the indirect activation manner, ligand-bound 
ER dimers might activate transcription of non-ERE containing genes, by binding to other transcription factors 
(e.g. AP1 or SP1). In the non-genomic pathway, ligand-bound ERs interact directly with and change the 
function of proteins some of which function as 'second messengers' (SM). ERs can also be activated by 
phosphorylation in the absence of ER ligands (ligand-independent activation). Based on Morani et al. 2008 
(45).  
 
In addition to ligand dependent mechanisms, ERα has ligand independent activity 
mediated through AF-1, which has been shown to be associated with stimulation of MAPK 
through growth factors such as Insulin like Growth Factor – 1 (IGF-1) and Epidermal Growth 
Factor (EGF). Activity of AF-1 is dependent on phosphorylation of Ser 118. A good example 
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of the cross-talk between ER and growth factor signalling is phosphorylation of Ser 118 by 
MAPK in response to growth factors, such as IGF-1 and EGF (46). The importance of growth 
factors in ER signalling is well illustrated by the fact that EGF can mimic effects of E2 in the 
mouse reproductive tract (28).   
Ligand dependent effects 
The overall biological effects of E2 and other estrogenic compounds are the result of 
complex interplay between various mechanisms, which largely depend on cellular context, 
ratio between ER subtypes, expression of coactivators in the cell, sequences of target EREs 
but also cross-talk with growth factor pathways and activity of kinases and phosphatases. All 
these factors together enable a precise and targeted response to the natural hormone. However 
a broad range of pathways involved in ER signaling provides many points of possible signal 
modulation by estrogens and estrogen-like compounds and small structural changes between 
different ligands might result in significantly different responses.   
 
Structural differences in the LBD underlie differences in affinity and transcriptional 
activity induced, for certain ligands and provide one of the mechanisms for selective 
modulation of ER responses. ERβ has an impaired AF-1 domain compared with ERα and the 
necessary synergy with AF-2 is dramatically reduced (47). These differences suggest that it is 
possible to develop ligands with different affinities, potencies, and agonist vs antagonist 
behavior for the two ER subtypes.  
 
 
Figure 4: Chemical structure of estradiol, genistein and quercetin. 
 
It has been demonstrated that E2 has higher affinity towards ERα than to ERβ (48, 49), 
and certain selective estrogen receptor modulators (SERMs) might exhibit a preference 
towards one of the receptors (50). Plant derived phytoestrogens, which are structurally similar 
to E2 (Figure 4) are a good example of ligand selectivity (51). Genistein, is the major 
isoflavone present in soy and fava beans whereas quercetin is present in red onions, apples, 
cappers or red grapes among others (51). In vitro studies with reporter gene assays proved 
that phytoestrogens are able to stimulate ERE-dependent genes at high concentrations. 
Therefore they are considered weak ER agonists with the majority of them preferentially 
17 
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binding to ERβ (52, 53). The main hypothesis on the positive role of phytoestrogens in 
modulation of ER signaling is their higher affinity towards the ERβ subtype, which can 
silence ERα dependent signaling and decrease overall cell sensitivity to E2 (21), which is 
thought to be significant in cancer prevention and will be further discussed in this thesis.  
 
Objective, approach and outline of this thesis 
The overall aim of the work presented in this thesis was to obtain insight in the role of 
ERα, ERβ and the ratio of ERα/ERβ present within a cell, in the cellular response to estrogen-
like compounds. To this end, the thesis addresses the transcriptional activity and effects on 
cell proliferation under the influence of specifically-acting estrogen-like molecules when 
varying the ratio of ERα/ERβ present in the cells under study. The ultimate aim was to link 
the resulting cell proliferation as the biological end-point to the genomics and proteomics 
data. 
 
Chapter 1 presents the background and aim of this thesis. Chapter 2 presents studies 
investigating how variable cellular expression ratios of the estrogen receptors ERα and ERβ, 
modulate the effects on cell growth induced by ERα or ERβ agonists, respectively. Using 
human osteosarcoma (U2OS) ERα or ERβ reporter cells, and T47D human breast cancer cells 
with tetracycline dependent expression of ERβ (T47D-ERβ), effects on ERα and ERβ 
mediated transcriptional activation as well as on cell proliferation was characterised for E2 
and two selected selective estrogen receptor modulators (SERMs). In chapter 3, based on the 
interest in the potential health effects of dietary phytoestrogens, two plant derived compound, 
genistein and quercetin were tested in the same in vitro model systems.  
 
Chapter 4 of the thesis presents results from studies investigating the possible 
mechanisms and biological relevance underlying the phenomenon referred to as 
superinduction of estrogen receptor mediated gene expression in luciferase based reporter 
gene assays. Using in vitro luciferase-based reporter-gene bioassays for testing estrogenicity, 
several estrogenic model compounds including the isoflavonoid model compound of the 
present thesis, genistein, have been reported to induce a higher maximal response than E2. 
The phenomenon has been referred to as superinduction. So far, the mechanism underlying 
this effect and thus also its biological relevance remain to be elucidated. Chapter 4 reports 
results from studies investigating several hypotheses for the possible mechanisms underlying 
this superinduction using genistein as the model compound known to induce the effect. 
 
In chapter 5, and 6 the consequences of the intracellular ERα/ERβ ratio for the effects 
induced by genistein was investigated in more detail using “omics” technologies, 
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characterizing both gene and protein expression patterns and comparing the results obtained 
to those previously reported for estradiol in the same model system (54). To this end, state-
of-the-art high-throughput methods for systems-wide gene and protein expression analysis 
were applied. These methods included DNA microarrays, commonly used for global analysis 
of gene expression changes. In addition we applied stable isotope labeling by amino acids in 
cell culture (SILAC) which is a differential and quantitative proteomics technique based on 
mass spectrometry (MS) analysis (55). Since the metabolic incorporation of the labels does 
not affect the integrity of genes or proteins, the transcriptomics and SILAC proteomics 
experiments could be performed on the same cell samples allowing comparison of the data 
sets. 
 
 In Chapter 5 data analysis focussed on the functional analysis of the differential 
behaviour of ER-mediated activation of gene and protein expression towards cell 
proliferation and cell apoptosis, whereas protein data analysis in Chapter 6 pointed at the 
immune modulation by genistein. These mechanisms of action were related to the difference 
in presence and relative amount of the two estrogen receptors ERα and ERβ. 
 
Finally, chapter 7 presents a summary of the results obtained in this thesis, a discussion 
of the new physiologically based, functional mechanistic insights obtained as well as some 
future perspectives. 
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Abstract 
Breast cancer cells show overexpression of estrogen receptor (ER) α relative to ERβ 
compared to normal breast tissues. This observation has lead to the hypothesis that ERβ may 
modulate the proliferative effect of ERα. This study investigated how variable cellular 
expression ratios of the ERα and ERβ modulate the effects on cell proliferation induced by 
ERα or ERβ agonists, respectively. Using human osteosarcoma (U2OS) ERα or ERβ reporter 
cells, propyl-pyrazole-triol (PPT) was shown to be a selective ERα and diarylpropionitrile 
(DPN) a preferential ERβ modulator. The effects of these selective estrogen receptor 
modulators (SERMs) and of the model compound E2 on the proliferation of T47D human 
breast cancer cells with tetracycline-dependent expression of ERβ (T47D-ERβ) were 
characterized. E2-induced cell proliferation of cells in which ERβ expression was inhibited 
was similar to that of the T47D wild-type cells, whereas this E2-induced cell proliferation 
was no longer observed when ERβ expression in the T47D-ERβ cells was increased. In the 
T47D-ERβ cell line, DPN also appeared to be able to suppress cell proliferation when levels 
of ERβ expression were high. In the T47D-ERβ cell line, PPT was unable to suppress cell 
proliferation at all ratios of ERα/ERβ expression, reflecting its ability to activate only ERα 
and not ERβ. It is concluded that effects of estrogen-like compounds on cell proliferation are 
dependent on the actual ERα/ERβ expression levels in these cells or tissues and the potential 
of the estrogen agonists to activate ERα and/or ERβ. 
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 Introduction 
Steroid hormones such as estrogens are needed for normal developmental, physiological,  
and reproductive processes in vertebrates (1). Many of these events are modulated by the 
activity of estrogen receptor α (ERα) and estrogen receptor β (ERβ) (2, 3). These two 
receptors are encoded by distinct genes and differ in their relative and absolute tissue 
distribution (4). In the absence of estrogen, ERs are sequestered within the nucleus and 
preserved in an inactive state by association with heat-shock proteins. Binding of estrogen or 
estrogen-like compounds induces a conformational change in the receptor, an event that 
promotes ER homo- or heterodimerization (5). Once the estrogen receptor protein complex is 
bound to the DNA, it regulates the expression of estrogen-responsive genes. The ER homo- 
and heterodimers activate different signalling pathways and, therefore, different sets of genes 
(6-8).  
 
During the last few years, an increasing number of studies have reported that xenobiotic 
compounds from different sources are able to mimic the natural estrogens, thus exerting 
comparable effects by activating gene transcription through ERα and/or ERβ (9-14). 
Estrogens stimulate cell proliferation in normal developing breast tissues and may prevent 
osteoporosis by increasing bone mineral density (15). However, several studies also suggest 
that estrogens may stimulate the growth of a large proportion of ERα-positive breast cancers 
(16-20). It has been shown that the ratio of ERα/ERβ expression is higher in breast tumors 
than in normal tissues due to lower expression of ERβ (21) and that ERα and ERβ are 
antagonistic to each other; for example, ERβ appears to reduce the cell proliferation induced 
by ERα activation, as shown in in vitro cell transfection studies (22-24). Different breast 
cancer cell lines have been used for these studies, mainly MCF-7 cells, which all have a high 
ERα/ERβ ratio (25-27). It is proposed that differential responses and tissue-specific effects 
induced by food-born endocrine disrupters, including selective estrogen receptor modulators 
(SERMs), might be influenced by their relative affinity for the two ERs and the interactive 
effects of the estrogen-ER complex with the regulating proteins.  
 
The overall objective of the present study was to quantitatively determine the 
proliferative/antiproliferative effect of two model-selective ER agonists in T47D human 
breast cancer cells in the presence of increasing amounts of intracellular ERβ. The model 
compounds studied were propyl-pyrazole-triol (PPT), a selective ERα agonist, and 
diarylpropionitrile (DPN), a preferential ERβ agonist. For comparison and validation of the 
different cellular model systems, estradiol (E2) was included in the studies as well. 
 
ERα/ERβ ratio
 
The natural ligand E2 is known to stimulate both ERs, with an approximately 10-fold 
higher affinity for ERα than for ERβ (28, 29). DPN was reported to have a 70-fold higher 
relative binding affinity for ERβ than for ERα, and PPT has a reported 40-fold higher binding 
affinity for ERα than for ERβ (30-32). In the present study, the relative isoform-specific 
activity of the three model compounds was characterised using the human osteosarcoma 
(U2OS) reporter cell lines, stably transfected with ERα or ERβ and a luciferase reporter gene 
with an 3xestrogen responsive element(ERE)-TATA containing minimal promoter region 
(29).  
 
In subsequent experiments, the effect of the three compounds on proliferation of T47D-
ERβ cells with varying ratios of ERα/ERβ expression was quantified.  In wild-type T47D 
cells, ERα/ERβ mRNA levels were found to be present in a ratio of 9:1 (23). The T47D-ERβ 
cells are T47D cells stably transfected with a tetracycline-inducible ERβ which allows 
studying the influence of SERMs on cell proliferation in cells with varying ratio of ERα/ERβ 
expression, by altering expression of ERβ. Inhibition of the expression of the exogenous ERβ 
is expected to make the T47D-ERβ cell line function as a “pseudo”-wild-type T47D cell. 
Since in concurrence with the expression of ERβ, an enhanced green fluorescent protein 
(EGFP) from a bidirectional tetracycline-responsive promoter is coexpressed in the T47D-
ERβ cells, the levels of ERβ expression can be monitored on the basis of EGFP fluorescence. 
To better quantify the relative levels of ERβ expression in the T47D-ERβ cells, a method to 
quantify the EGFP fluorescence in the cell lysate was developed in the present study. 
 
 With the newly developed method to quantify the relative ERβ expression, the effects 
of E2, DPN, and PPT on the T47D-ERβ cell proliferation were studied at different levels of 
ERβ expression to determine to what extent the estrogen-induced cell proliferation depends 
on the balance between the two major ER subtypes. In addition, it was investigated whether 
the effects observed match those that would have been predicted based on the U2OS reporter 
gene test results for these compounds and the hypothesis that stimulation of ERα activates 
and of ERβ reduces estrogen mediated cell proliferation. 
 
Materials and Methods 
Materials: 17β-Estradiol (E2)(>98 %) and ANTI-FLAG M2® Monoclonal antibody 
peroxidase conjugate was purchased from Sigma (Zwijndrecht, The Netherlands). 2,3-Bis(4-
hydroxyphenyl)-propionitrile (DPN) and 4,4',4''-(4-propyl-[1H]pyrazole-1,3,5-triyl) tris-
phenol (PPT) were purchased from Tocris Cookson Ltd (Bristol, UK). Dimethyl sulfoxide 
(DMSO)(>99%) was obtained from Acros Organics (Pittsburgh, PA, USA). Tetracycline, 
streptomycin, penicillin and puromycin were acquired from Gibco (Paisley, Scotland). Fetal 
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calf serum (FCS)(Australian origin, 10099), resazurin and geneticin were provided by 
Invitrogen Life Technologies (Paisley, Scotland). Hyclone dextran-charcoal-treated FCS 
(DCC-FCS, #SH30068.05) obtained from Perbio  Science NV  (Etten-Leur, The Netherlands) 
was heat inactivated (30 min at 56°C) followed by two 45-min DCC-treatment at 45°C (33). 
Phosphate-buffered saline (PBS)(without Ca2+ and Mg2+), nonessential amino acids (100×, 
11140-035), growth medium 1:1 mixture of Ham's nutrient mixture F12 and Dulbecco’s 
modified Eagle’s medium (DMEM)(31331-038 and 31331-028), phenol red-free exposure 
medium (21041-025) were supplied by Gibco (Paisley, Scotland). Trypsin 0.25 g/100 ml in 
PBS was obtained from Difco (Detroit, USA). Sodium bicarbonate (NaHCO3 >99.5%), 
sodium hydroxide (NaOH) ethylenedinitrotetraacetic acid (EDTA . 2H2O; Titriplex), 
magnesium sulphate (MgSO4 . 7H2O), and 1,4-dithiothreitol (DTT) were obtained from 
Merck (Darmstadt, Germany). Magnesium carbonate ((MgCO3)4Mg(OH)2 . 5H2O) was 
obtained from Aldrich (Saint Louis, MO, USA). trans-1,2-diaminocyclohexane-N,N,N,‘N‘-
tetraacetic acid monohydrate (CDTA) was obtained from Fluka (Buchs, Switzerland). 
Hygromycin and D-luciferin were obtained from Duchefa (Haarlem, The Netherlands). ATP 
and the BrdU kit (colorimetric, 11647229001) were obtained from Roche Diagnostics 
(Mannheim, Germany). BSA Protein Assay Kit was purchased from Pierce (Germany). 
Tween 20 was obtained from Merck (Bonn, Germany). SDS (sodium dodecyl sulphate) was 
obtained from BDH (United Kingdom). Acrylamide (30% acrylamide/bis solution 29:1), 
N,N,N′,N′-tetramethylethylenediamine (TEMED), ammonium persulphate (APS), and the 
precision plus dual colour protein marker were obtained from BioRad (The Netherlands). 
Milk solution was provided by Campina (The Netherlands). Nitrocellulose membrane was 
purchased from Whatman (The Netherlands). ERβ specific primary (Ab288/14C8) and 
secondary antibody (rabbit anti mouse) were provided by Abcam (Cambridge, MA, USA). 
Chemiluminescent detection ECL kit and photographic hyperfilm were provided by 
Amersham (United Kingdom).  
 
Cell lines: T47D human breast cancer cells were purchased from the American Type 
Culture Collection (Manassas, VA, USA). The stably transfected T47D tetracycline-inducible 
cell line (T47D-ERβ) was made and provided by Ström (23). The human osteosarcoma 
(U2OS) cell lines stably expressing ERα or ERβ, in addition to 3xERE-tata-luciferase were 
used as described before (29). 
 
Cell culture conditions: The T47D wild-type cell line was cultured in a 1:1 mixture of 
Ham's nutrient mixture F12 and DMEM (31331-038) supplemented with 5 % FCS. The cells 
were incubated at 37° C and 5% CO2 in a humidified atmosphere. T47D-ERβ cells were 
cultured at the same conditions but in the presence of 1000 ng/ml tetracycline to fully inhibit 
ERβ expression. Every 10 passages (about 3 weeks) the cells were reselected with 0.5 µg 
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puromycin/ml as a selection marker to prevent loss of ERβ and EGFP expression and a 
concurrent change in phenotype. 
 
ERα- and ERβ-U2OS cells were cultured in a 1:1 mixture of DMEM and F12 (31331-
028) buffered with 1260 mg/L NaHCO3, supplemented with 7.5% Australian FCS, and 0.5% 
nonessential amino acids. ERα-U2OS-Luc growth medium was supplemented with geneticin 
(200 µg/ml) and hygromycin (50 µg/ml) as selection markers. ERβ-U2OS-Luc growth 
medium was supplemented with geneticin (200 µg/ml) as selection marker. Cells were 
cultured at 37ºC at 7.5% CO2 in a humidified atmosphere. 
 
Behaviour of T47D-wt and T47D-ERβ cells during culturing and exposure: The 
T47D-wt cells were growing well and nicely attached to the bottom when cultured in flasks at 
no more than 85% confluency. Higher cell densities resulted in cluster formation and 
reduction of cell size. The T47D-ERβ cells, however, were much more difficult to grow. 
Especially when ERβ-expression was present, the cells often started to round up and detach. 
This loss of cell attachment hampered the application of methods to quantify cell 
proliferation in the cases where ERβ was expressed. Both the resazurin and BrdU method 
gave good results when compared to protein measurement assay and cell counting, and we 
chose to mostly apply the resazurin method as this method requires less cell handling than the 
BrdU method.  
 
Exposure conditions for T47D and T47D-ERβ cells: Because of estrogenic activity of 
phenol red (34), experiments were performed in phenol red-free exposure medium 
supplemented with 5% DCC-FCS. Cells were seeded in 96-well plates (100 µL/well; Costar, 
Cat. Nr. 3548) at densities of 105 cells/ml for proliferation and 1.8x105 cells/ml for 
fluorescence assays in the presence of different concentrations of tetracycline (0-1000 ng/ml) 
as indicated. The starting percentage of coverage for fluorescence experiments was higher 
than for proliferation experiments because wells had to be fully confluent for optimal 
sensitivity in the fluorescence measurements, whereas less confluent wells were needed for 
proliferation assays. Plates were incubated overnight at 37ºC and 5% CO2. After 24 h, cells 
were washed with PBS to remove any trace of tetracycline and exposed to different 
concentrations of tetracycline and/or the test compounds as indicated.   
 
Cell proliferation measurements: After 24 h of exposure, proliferation was determined 
by measuring 5-bromo-2’-deoxy-uridine (BrdU) incorporated into DNA following BrdU 
Roche’s colorimetric protocol and/or after 96 h of exposure by measuring mitochondrial 
activity of viable cells on the basis of chemical reduction of resazurin to resorufin as 
previously described (35). Measurement of incorporated BrdU was performed in a 
spectrophotometer at 370 nm excitation wavelength and 492 nm emission wavelength, and 
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resorufin was measured with a fluorometer at an excitation wavelength of 530 nm and 
emission wavelength of 590 nm. Other methods for studying cell proliferation included cell 
counting and measurement of protein content, the latter by Bicinchoninic Acid (BCA) Protein 
Assay. 
 
Measurement of ERβ expression-related fluorescence: To quantify ERβ expression-
related EGFP fluorescence after 24 h of exposure, medium was removed from the wells and 
the cells were washed with 100 µL of diluted PBS (0.5x PBS in demiwater). To each well, 
110 µL of low-salt buffer, consisting of 10 mM tris-HCl pH 7.8 containing 2 mM DTT and 2 
mM CDTA, was added, and the cells were allowed to swell while the plates were kept on ice 
for 20 min. The plates were then frozen at -80º C for at least 1 h, and before analysis, they 
were thawed on ice and shaken briefly until reaching room temperature.  Then, 100-µL 
aliquots of cell lysates from each well were transferred to a 96-well transparent plate with 
rounded bottom (Greiner, Frickenhausen, Germany) to allow fluorescence measurement in 
the Millipore Cytofluor 2350 fluorometer. Excitation was at 485 nm (band width of 20 nm) 
and emission at 530 nm (band width of 25 nm). 
 
Protein Isolation and SDS-PAGE: For the analysis of the ERβ protein expression levels, 
T47D-ERβ cells were grown in growth medium with 1000 ng/ml of tetracycline in small cell 
culture flasks until 80-90% confluence. Cells were seeded in exposure medium with 
tetracycline for 24 h. Medium was removed, and cells were incubated for 24 h in new 
exposure medium with different tetracycline concentrations (0, 10 and 1000 ng/ml of 
tetracycline). Cells were collected with a scraper and suspended in PBS. After centrifugation 
(13000g, 5 min), PBS was removed and cells were suspended in lysis buffer supplemented 
with protease inhibitors. Lysis was done by three cycles of freezing in -80˚ C and thawing. 
Total protein content was determined using a bicinchonic acid protein assay kit and a total 
protein amount of 20 µg/lane plus  ¼ of 4x sample buffer (8% w/v SDS,  40% w/v glycerol, 
0.2 M Tris/HCl pH 6.8, 0.02% bromophenol blue, 25% v/v mercaptoethanol) was loaded 
onto the gel. Running gel (12% acrylamide) was prepared by mixing 9.9 ml of deionized 
water, 12 ml 30% acrylamide plus 0.8% bisacrylamide, 7.5 ml  1.5 M Tris-HCl pH 8.8, 300 
µl 10% SDS. Polymerization was started by addition of 150 µl 10% APS and 12 µl of 
TEMED. For the preparation of stacking gel (5% acrylamide) reagents were mixed in the 
following proportions: 6.66 ml water, 1.66 ml 30% acrylamide plus 0.8% bisacrylamide, 1.26 
ml 1.5 M Tris pH 8.8, 100 µl 10% SDS and 100 µl 10% APS together with 10 µl TEMED. 
Electrophoresis was run at 100V for approximately 2 h. After electrophoresis, gels were 
stained with Coomassie or used for Western blotting. 
 
Western blotting: Blotting was performed at 100V for 1 h.  After the transfer, unspecific 
binding sites on the membrane were blocked with 5% milk solution in tris-buffered saline 
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(TBS) 0.05% Tween 20 for 1-2 h. The membrane was washed in TBS with 0.05% Tween 20 
twice for 5 min.  For detection of the exogenous FLAG-ERβ, the monoclonal ANTI-FLAG 
M2® antibody was diluted in TBS with 0.05% Tween 20. For detection of ERβ in the control 
T47D cell line, ERβ mouse monoclonal 14C8 antibody was used. After incubation for 1 h at 
room temperature with ANTI-FLAG M2® antibody the membrane was washed with TBS 
with 0.05% Tween 20 six times for 5 min each time before ECL treatment. Incubation with 
the 14C8 antibody was performed overnight at 4°C. After incubation, the membrane was 
washed with TBS 0.1% Tween 20 three times for 10 min. Secondary antibodies was diluted 
5000 three times in TBS 0.1% Tween 20, and incubation was run for 45 min at room 
temperature. Rabbit anti-mouse antibody conjugated with peroxidase was used for ERβ. Final 
washing steps were done two times with TBS 0.1% Tween and one time with TBS only. 
Finally, the membrane was treated with peroxidase substrate (ECL kit) for protein detection. 
The reaction was run for 5-7 min, and bands were visualized using photographic film. As a 
final step, membranes were stained with coomassie blue. 
 
ERα- and ERβ-specific U2OS reporter gene assay: Cultured U2OS cells were washed 
with PBS, trypsinized, and seeded in transparent 96-well plates (Greiner, Frickenhausen, 
Germany) at 100 µL/well at a density of 10x104 cells/ml (U2OS-ERα) or 7.5x104 cells/ml 
(U2OS-ERβ) in a 1:1 mixture of DMEM and Ham’s F12 medium without phenol red, 
buffered with 1260 mg/L NaHCO3, and supplemented with 5% DCC-FCS and 0.5% 
nonessential amino acids. Culture medium was refreshed after 24 h. Forty-eight hours after 
seeding, the cells were exposed in triplicate to E2, DPN or PPT at the indicated 
concentrations (final DMSO concentration 0.2%) for 24 h at 37ºC and 7.5% CO2 in a 
humidified atmosphere. On each plate, the cells were exposed to different concentrations of 
test compounds and calibration points for E2 (EC10, EC50, E100) to be able to correct for plate 
to plate variations. After 24 h, the medium was removed, and cells were washed with 100 µL 
diluted PBS (0.5x in demiwater) per well. Cells were lysed with 30 µL of a hypotonic low-
salt buffer, consisting of 10 mM tris-HCl pH 7.8 containing 2 mM DTT and 2 mM CDTA. 
Plates were put on ice for 10 min and subsequently frozen at –80ºC. Before analysis, plates 
were thawed on ice for 20 min and shaken briefly until reaching room temperature. Analyses 
were performed in a Luminoskan (RS, Labsystems) at room temperature as follows: 
background light emission of each well was measured for 2 sec, then, 100 µL of flashmix 
was added (20 mM tricine buffer, pH 7.8, supplemented with 1.07 mM 
(MgCO3)4Mg(OH)2.5H2O, 2.67 mM MgSO4, 0.1 mM EDTA .2H2O, 2 mM DTT, 0.47 mM 
D-luciferin, and 5 mM ATP), light emission was immediately measured for 2 sec and 
extinguished with 50 µL 0.2 M NaOH to prevent cross-talk to the neighbouring wells.  
 
Data analysis: Relative light units (RLUs) in every well were corrected for the 
corresponding background signal, measured before luciferin addition. The response of the 
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solvent control was taken as 0% induction. The maximum induction of luciferase obtained at 
30 pM E2 for ERα-U2OS cells and at 300 pM E2 for ERβ-U2OS cells was set at 100%. The 
exposure concentration of the compound at which 50% of the maximum luciferase activity is 
reached (EC50) was determined using Slidewrite 6.10 for Windows. The estradiol 
equivalency factors (EEF) were calculated as EC50 estradiol/EC50 compound. The concentration of 
tetracycline at which 50% of the EGFP fluorescence is inhibited (IC50) was determined using 
Slidewrite 6.10 for Windows as well. EGFP fluorescence reflecting the level of ERβ 
induction was expressed relative to the fluorescence of cells exposed to the solvent control 
(PBS 0.2%) set at 100%. In addition, in each experiment calibration points for E2 were 
included to be able to correct for plate to plate variations The obtained data from proliferation 
quantified by the resazurin method was plotted after subtraction of background signal 
(obtained from a well containing all components except for the cells), as % proliferation. 
Results from BrdU were calculated as percentage of proliferation after background 
subtraction. The response of cells exposed to the solvent control (DMSO 0.2%) was set at 
100%. 
 
Results 
Characterisation of the selected selective estrogen receptor modulators (SERMs) 
The selectivity of PPT and DPN for ERα and ERβ was studied in the ERα-U2OS-Luc 
and ERβ-U2OS-Luc cells. Typical dose-response curves for the natural ligand E2 as well for 
the SERMs are shown in Figure 1.  
 
  
Figure 1: ERE-mediated luciferase activity in U2OS-ERα (A) and U2OS-ERβ (B) cells exposed to E2 (●), the 
ERα- selective PPT (▲) and the ERβ-selective DPN (♦). Induction was expressed relative to maximal estradiol 
response, set at 100%. Data points represent the mean of triplicates exposure ± standard deviation. 
 
As previously demonstrated, E2 showed higher binding affinity for ERα than for ERβ, 
with EC50-values of 8 and 65 pM respectively, but E2 is clearly both an ERα and ERβ 
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agonist. The ERα-selective PPT was unable to induce any transcription of the reporter gene in 
the ERβ-U2OS-Luc cell line, confirming its nature as a selective ERα modulator. The EC50 
for the ERα-dependent response was 140 pM (Figure 1A) resulting in an EEF compared to E2 
of 0.057, and the maximal induction was 120%. As expected, DPN showed ERβ selectivity 
with EC50 values of 2 nM and 59 nM for ERβ and ERα, respectively. At present, a more 
selective ERβ agonist could not be identified, and the ERβ specificity of DPN in the U2OS 
cells was at least higher than that of E2 since the ratios of the EC50 for ERα and the EC50 
for ERβ activation are respectively 0.12 and 29.5 for E2 and DPN. In the ERα-U2OS cells, 
DPN did not reach the maximal E2 induction level, but in the ERβ-U2OS the maximal 
induction level of DPN was 110% of the value obtained for E2 (Figure 1B). The EEFs for 
DPN were 1.3 *10-4 in the ERα-U2OS and 0.03 in the ERβ-U2OS cells. Table 1 shows an 
overview of the EC50, EEF, and maximum effect of PPT and DPN compared to E2 using the 
U2OS cell system. 
 
Table 1: Overview of the EC50, EEF values and maximum effect of E2, PPT and DPN tested using the U2OS 
cell system. 
 
 
ERα  
EC50 
Max effect as 
% relative to 
E2-max 
ERα  
EEF 
ERβ  
EC50 
Max effect as 
% relative to 
E2-max 
ERβ  
EEF 
E2    8 pM 100 1  65 pM 100 1 
PPT 140 pM  120 0.057 -- -- -- 
DPN   59 nM   73 1.3 x 10-4   2 nM 110 0.03 
 
Tetracycline-dependent expression of ERβ in the T47D-ERβ cell line quantified by  
measuring EGFP-Fluorescence 
T47D cells were stably transfected with the ERβ expression plasmid under tetracycline-
responsive promoter regulation and with an EGFP gene as a coexpressed reporter also under 
regulation of the same tetracycline-responsive promoter. This allows 
qualitative/semiquantitative confirmation of ERβ expression by fluorescence microscopy. 
Maximal levels of fluorescence were reached after 24 h of cultivation of the cells in the 
absence of tetracycline. A simple method for quantitative measurements of the EGFP as 
sensitive reporter molecule in cell lysate of the T47D-ERβ was developed. Wells seeded with 
high density number of the T47D-ERβ cells were exposed to different concentrations of 
tetracycline (Figure 2A). EGFP fluorescence was measured in the cell lysate. Tetracycline 
treatment suppressed EGFP fluorescence in T47D-ERβ cells, with concentrations above 150 
ng/ml, resulting in total fluorescence suppression. Values above 2000 ng/ml of tetracycline 
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not only completely depleted EGFP expression but also caused cytotoxicity (data not shown). 
The concentration of tetracycline at which 50% of the fluorescence, and thus ERβ expression, 
was inhibited (IC50) was determined to be 9.6 ng/ml tetracycline. Since the expression of 
EGFP is linked to the expression of recombinant ERβ, the presence of ERβ at protein level 
was confirmed using western blot (Figure 2B). No detectable FLAG-ERβ protein was 
expressed in the presence of 1000 ng tetracycline/ml . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: (A) Tetracycline-induced inhibition of ERβ expression in T47D-ERβ cells measured via the 
concurrent expression of EGFP after 24 h of exposure at 100% cell density. Fluorescence is expressed relative 
to maximum expression at 0 ng/ml of tetracycline set at 100%. No fluorescence is observed above 150 ng of 
tetracycline per ml. Each data point represents the mean of triplicate exposure ± standard deviation. (B) T47D-
ERβ tet-off FLAG-ERβ cell were cultured in the presence (1000ng/ml and 10 ng/ml) or absence of tetracycline 
for 24 h, 14C8 antibody was used to detect ERβ in the T47D wild-type, coomassie staining was used as loading 
control. Quantification of the intensity of the ERβ-FLAG bands was measured by ImageJ. 
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E2-induced proliferation of T47D-wt cells and of T47D-ERβ cells with inhibited ERβ 
expression 
T47D-wt cells showed a clear E2-dependent cell proliferation with a maximum of 131% 
maximal induction of proliferation at 100 pM E2 (Figure 3). T47D-ERβ cells in which ERβ 
expression was completely inhibited by incubating them in the presence of 1000 ng 
tetracycline/ml showed an E2-dependent cell proliferation that was comparable with the 
response obtained in wild-type cells (Figure 3). The T47D-ERβ transfected cells with no ERβ 
expression reached the same maximum proliferation of 131% at 1 nM of E2 as the wild-type 
cells. In both cell lines, the shape of the dose-response curves was similar and at 
concentrations above 1 nM E2, cell proliferation decreased when increasing the concentration 
of E2. The dose-response curves for E2-induced proliferation obtained by measuring BrdU 
incorporation during the last 4 h of the 24-h period exposure were comparable to those 
obtained when measuring mitochondrial activity during the last 4 h of 96-h exposure using 
the resazurin method with both cell lines.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: The effect of estradiol (E2) on cell proliferation of T47D-wt and T47D-ERβ cells the latter with 
maximum inhibition of ERβ expression by 1000 ng tetracycline/ml. Cell proliferation after 24 h of exposure is 
expressed relative to vehicle control (DMSO) set at 100%. Each data point represents the mean of triplicates 
exposure ± standard deviation. 
 
Expression of ERβ inhibits E2-induced cell proliferation of T47D-ERβ cells  
Mitochondrial activity of the T47D-ERβ cells treated with 1 nM E2 and an increasing 
concentration of tetracycline, causing decreasing cellular expression levels of ERβ, showed a 
tetracycline-related increase in proliferation (Figure 4). In absence of E2, the cells did not 
proliferate. The EC50 for tetracycline-dependent stimulation of E2-mediated cell proliferation 
was 41 ng tetracycline/ml. At tetracycline concentrations lower than 10 ng/ml, where ERβ 
expression levels were high, no E2 induced proliferation was observed.  
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Exposure of T47D-ERβ (Figure 5) cells to increasing E2 concentrations in combination 
with 41 ng/ml (EC50) and 1000 ng/ml of tetracycline resulted in a dose-dependent cell 
proliferation. E2-induced proliferation was almost absent in the presence of 0 and 9.6 ng 
(IC50 for fluorescence) tetracycline/ml. Altogether these data demonstrate the validity of the 
test system and support that E2 cannot induce cell proliferation under conditions where ERβ 
is expressed to relatively higher levels and able to suppress ERα-mediated induction of cell 
proliferation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Cell proliferation of T47D-ERβ cells in absence (■) or presence (●) of 1 nM E2 at different 
concentrations of tetracycline. Exposure was performed during 96 h, and proliferation was quantified as 
mitochondrial activity measured by the resazurin method with fluorescence as endpoint. Each data point 
represents the mean of triplicate exposure ± standard deviation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: E2-dependent cell proliferation in the T47D-ERβ cells after 96 h of exposure in combination with 0, 
9.6, 41, and 1000 ng tetracycline/ml to inhibit ERβ expression. Each data point represents the mean of triplicate 
exposure ± standard deviation. 
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The proliferative effect of two SERMs 
Figure 6 presents the results from experiments in which the proliferative effect of PPT 
(Figure 6A) and DPN (Figure 6B) was studied in the T47D-ERβ cells at the same four 
tetracycline concentration as used in the E2 study (Figure 4). The straight line drawn at 164% 
cell proliferation represents the maximum of T47D-ERβ (ERβ absent) and T47D cell 
proliferation at 1 nM of estradiol.  
 
Figure 6: The effect of PPT (A) and DPN (B) on T47D-ERβ cell proliferation after 96 h of exposure in 
combination with 0, 9.6, 41, and 1000 ng tetracycline/ml, quantified as fluorescence using the resazurin method. 
The line indicates the proliferation induced by 1 nM of E2 when ERβ expression was completely inhibited. Each 
data point represents the mean of triplicate exposure ± standard deviation. 
 
At 1000 ng/ml of tetracycline, when expression of ERβ is suppressed, PPT was able to 
induce cell proliferation to a level of 173%, an induction level that was slightly higher than 
the maximal induction of cell proliferation by E2 (164%) under these conditions. This is in 
spite of the fact that the affinity of ERα for PPT was lower than for E2. Although the E2-
induced proliferation with full expression of ERβ was reached at 3 nM of PPT (153%), no 
considerable reduction of proliferation compared with E2 (124%) was observed under all 
ERα/ERβ ratios studied due to the inability of PPT to activate ERβ. 
 
At the same tetracycline concentration (1000 ng/ml),  DPN induced similar proliferation 
maximums as E2 (164%) although at a higher concentration than required for maximal 
induction by E2. This can be due to the fact that ERα has a lower affinity for DPN than for 
E2. However, DPN appeared able to suppress cell proliferation when levels of ERβ 
expression were high. No differences in cell proliferation were observed at the two lowest 
tetracycline concentrations (0 and 9.6 ng tetracycline/ml) either for PPT, DPN, or E2. 
 
E2-induced proliferation with full expression of ERβ was lower than proliferation 
induced with PPT and DPN. The maximum induced proliferation in the absence of 
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tetracycline was 153% with 3 nM PPT, 128% with 100 nM DPN, and 124% with 1 nM E2. In 
the presence of high levels of ERβ, E2- and DPN-induced proliferation was 40% (from 164% 
to 124%) lower compared to the induced proliferation in absence of ERβ. 
Discussion 
Invasion, uncontrolled proliferation and metastasis are the most important properties of a 
malignant cancer. Thus, proliferation is not the only hallmark of malignant transformation, 
and proliferation and invasion may under certain conditions even be contrasting events (36). 
In the present study, proliferation was selected as the endpoint to characterize the influence of 
ERα/ ERβ ratios and not the invasiveness of the tumor cells since the T47D cell line in which 
the variable ERα/ ERβ ratios can be generated is a non- or poorly-invasive cell line (37). 
 
The ratio of ERα/ERβ expression in breast tumors is higher than in normal breast tissues 
due to a lower expression of ERβ. This has lead to the hypothesis that low levels of ERβ may 
result in high proliferation rates because of the absence of ERβ-mediated modulation of the 
proliferative effect of ERα. This would imply that high levels of ERβ stimulation lead to 
decreased cell proliferation whereas high levels of ERα stimulation lead to increased cell 
proliferation. Therefore, the objective of the present study was to quantify the differential 
effect of a selective ERα and a selective ERβ agonist on cell proliferation of human breast 
cancer cells with varying but well-defined ratios of ERα/ERβ expression. To this end, the 
T47D-ERβ cell model was applied in which the levels of the ERβ receptor could be reduced 
by adding tetracycline. In addition to the E2-induced cell proliferation under different levels 
of ERβ expression, also the effect of two pseudo-estrogens reported to be specific ERα or 
ERβ agonists was determined. 
 
Using human osteosarcoma (U2OS) ERα or ERβ reporter cell lines, it could be 
demonstrated that, compared to E2, PPT is a selective ERα modulator and DPN a preferential 
ERβ modulator. In the ERα- and ERβ-specific U2OS-Luc cells, E2 induced ER/ERE-
mediated luciferase activity with 8 times higher affinity for ERα than for ERβ. DPN was able 
to induce luciferase activity through both receptors with a 30 times higher potency through 
ERβ than ERα. PPT was found to be a fully ERα-specific inducer (EEFα = 0.057) while DPN 
only reasonably specifically induced ERβ (EEFα= 1.3 10-4, EEFβ = 0.03). This is in 
accordance with the results previously reported (38). The fact that PPT was not able to 
activate the transcription of the reporter gene in the ERβ-U2OS-Luc is in accordance with 
earlier observations (39). The maximum induction by the partial ERα agonists DPN did not 
reach the maximum induction induced by E2 in the ERα-U2OS system, but DPN induced an 
even slightly higher maximum response than E2 in the ERβ-U2OS system. 
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In normal breast tissues, the ERβ to ERα ratio is high, and decreases when breast tumour 
progresses (21). Earlier studies have suggested that when both receptors are expressed in the 
cell at the same mRNA levels, E2-induced proliferation of T47D cells is reduced compared to 
the E2-induced proliferation of cells in which only ERα is expressed (23). Our results in the 
T47D showed that cells proliferated in the absence of ERβ and presence of the natural ligand, 
E2, indicating that proliferation is E2-ERα mediated. Therefore, to study the role of ERβ in 
cell proliferation, we used the T47D-ERβ cell line with inducible ERβ expression to directly 
compare the effects of ERβ levels in the same cellular background. As a validation of the cell 
system, it could be demonstrated that the complete inhibition of ERβ expression with 1000 
ng/ml of tetracycline resulted in a “pseudo”-wild-type T47D cell with similar E2-induced 
proliferation responses whereas this E2-induced cell proliferation was no longer observed 
when ERβ expression in the T47D-ERβ cells was increased. Furthermore, given the fact that 
the T47D-ERβ cell line is derived from human breast cancer tissue, the expression levels of 
ERα and ERβ in the cells when grown in the presence of 1000 ng tetracycline/ml (no 
additional ERβ expression) can be expected to be physiologically relevant. Furthermore, 
previous data reported by Ström et al. (23) revealed that when the cells were grown in the 
absence of tetracycline (full ERβ expression), the level of ERβ, as judged from mRNA 
expression levels, appears to be 4-fold higher than that of ERα. Given the fact that 
physiological levels of ERα to ERβ may vary in such a way that either one of the two 
receptors is dominant (3, 40, 41) it can be concluded that the range of ERα to ERβ ratios in 
the T47D-ERβ line with increasing concentrations of tetracycline reflects physiologically 
relevant variations in the receptor ratio.  
 
The T47D-ERβ cell line was engineered to coexpress the EGFP in concurrence with 
ERβ, which allows indirect quantification of ERβ by measuring the fluorescence of EGFP. In 
the present study, a simple microtiter plate method was developed to be able to detect the 
expression levels of ERβ by measuring in the cell lysate the EGFP fluorescence. The IC50 for 
the EGFP expression after 24 h of exposure was 9.6 ng tetracycline/ml (Figure 2).  After 96 
h, the EC50 for tetracycline-mediated stimulation of E2-induced cell proliferation was 41 ng 
tetracycline/ml (Figure 4). The difference between the IC50 value for tetracycline-mediated 
suppression of EFGP an ERβ expression and the EC50 value for tetracycline-mediated 
stimulation of E2-mediated cell proliferation reflects that for 50% stimulation of E2-mediated 
cell proliferation, ERβ expression needs to be inhibited by more than by 50%. 
 
Our results clearly show an important role of the ERα/ERβ ratio in E2-induced cell 
proliferation. To better understand the interaction between ERα and ERβ, the quantification 
of the exact levels of expression of these receptors is crucial. Our findings also show that the 
ER subtype ratio determines the functional response to SERMs. Our results were consistent 
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with the hypothesis that ERβ opposes ERα proliferative effects in response to E2. Herein, we 
show that the proliferative actions in the T47D-ERß cells were mediated by the ERα, whereas 
ERβ played an important role in inhibiting the ERα effectiveness. It cannot yet be concluded 
whether the inhibition via ERβ results in a reduced transcription of genes involved in cell 
division or that possibly nongenomic signal transduction pathways are induced as well. It has 
been demonstrated that ERα/ERβ heterodimers and ERα homodimers are preferentially 
formed in intact cells and heterodimers bind to the ERE onto the DNA with similar affinity to 
that of ERα homodimers and higher affinity than that of ERβ homodimers (42).  
 
The ERα-selective agonist PPT was unable to induce luciferase activity through ERβ 
(U2OS cells) (Figure 1B), which implies that PPT does not activate ERβ homodimer-
mediated gene transcription. Moreover, it has been shown that ERα/ERβ heterodimers are 
only effective in coactivator interaction when both ERα and ERβ are doubly occupied with 
agonists (43).  DPN and PPT are as effective in stimulation of cell proliferation as E2 in the 
absence of ERβ (Figure 6). In the presence of ERβ, cell proliferation is decreased. DPN is 
more potent than PPT in inhibition of cell proliferation when both ERα and ERβ are present 
as in contrast to PPT DPN can activate ERβ.   
 
In contrast to exposure to E2 and DPN, exposure to PPT in the presence of high levels of 
ERβ expression did not give rise to visible cell death. This corroborates a role of the activated 
ERβ in the induction of cell death as previously reported (44, 45). Therefore, it is important 
to explain the specific roles of the ERα and ERβ when both receptors are present and link this 
to the proliferation outcome. 
 
The current results and developed method show that activation of ERβ can result in a 
reduction of ERα-mediated cell proliferation. In the T47D-ERβ cell line, PPT was unable to 
suppress cell proliferation at all ratios of ERα/ERβ expression, indicating its ability to 
activate only ERα. Whereas DPN appeared to be able to suppress cell proliferation when 
levels of ERβ expression were high since it was able to bind preferentially to ERβ. It is 
concluded that effects of estrogen-like compounds on cell proliferation are dependent on the 
actual ERα/ERβ expression levels in these cells or tissues, and the potential of the estrogen 
agonists to activate ERα and/or ERβ.  
 
Thus, the use of ERβ protein expression levels as a biomarker in tumour screening, in 
addition to protein expression levels of ERα, has the potential of more successful indication 
of therapeutic responses and course/outcome of the disease in ER-positive tumors. Future 
studies at a molecular level will be performed to further elucidate how ERβ exerts these 
effects. 
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Abstract 
This study investigates the importance of the intracellular ratio of the two estrogen 
receptors ERα and ERβ for the ultimate potential of the phytoestrogens genistein and 
quercetin to stimulate or inhibit cancer cell proliferation. This is of importance because i) 
ERβ has been postulated to play a role in modulating ERα-mediated cell proliferation, ii) 
genistein and quercetin may be agonists for both receptor types and iii) the ratio of ERα to 
ERβ is known to vary between tissues. Using human osteosarcoma (U2OS) ERα or ERβ 
reporter cells it was shown that compared to estradiol (E2), genistein and quercetin have not 
only a relatively greater preference for ERβ but also a higher maximal potential for activating 
ERβ-mediated gene expression. Using the human  T47D breast cancer cell line with 
tetracycline-dependent ERβ expression (T47D-ERβ), the effect of a varying intracellular 
ERα/ERβ ratio on E2- or pythoestrogen-induced cell proliferation was characterised. E2-
induced cell proliferation of cells in which ERβ expression was inhibited was similar to that 
of the T47D wild type cells, whereas this E2-induced cell proliferation was no longer 
observed when ERβ expression was increased. With increased expression of ERβ the 
phytoestrogen-induced cell proliferation was also reduced. These results point at the 
importance of the cellular ERα/ERβ ratio for the ultimate effect of (phyto)estrogens on cell 
proliferation. 
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 Introduction 
Phytoestrogens are a group of plant-derived compounds with estrogenic properties (1, 2). 
The major types of phytoestrogen are isoflavones, flavones, coumestans, lignans and 
stilbenes. Among the most studied flavonoids with respect to anti-tumour functions are 
genistein and quercetin. Phytoestrogens have been considered a natural alternative to 
hormone replacement therapy (HRT) since these chemicals are found in the regular diet (3). 
Genistein is mostly present in soybeans whereas quercetin is part of the colouring found in 
the skins of apples and red onions. High consumption of phytoestrogen-rich food has been 
reported to correlate with reduced incidence of breast cancer (4) and especially genistein and 
quercetin have been shown to exert potent anti-proliferative effects on tumour cells in vitro 
by halting the cell cycle and inducing apoptosis (5-7). 
 
Two main estrogen receptors (ERs), ERα and ERβ, have been identified in rats, mice, 
primates and humans (8). Different biological responses may occur when a phytoestrogen 
binds to the different ERs. Compared to ERα subtype, ERβ may mediate different biological 
effects and display different intracellular and tissue distribution patterns (9). ERα and ERβ 
subtypes can interact with a wide variety of different compounds although some ligands 
appear to have different relative affinities for the subtypes (10-13). The affinity of 
phytoestrogens for the ERs is related to their chemical structure. Indeed, although the 
phytoestrogens can bind to the ERα, they appear to prefer binding to the ERβ (2, 14-16).  
 
The protective role of ERβ in cancer research is now being studied widely. Most studies 
have shown decreased ERβ expression in cancer tissues as compared to benign tumours or 
normal tissues, whereas ERα expression persists (17, 18). Hence ERα and ERβ may have 
different roles in gene regulation and their relative levels or ratios within the tissues may 
influence cellular responses to estrogens.  
 
The aim of the present study was to identify the importance of the intracellular ratio of 
the two receptors ERα and ERβ for the ultimate potential of two model phytoestrogens, 
genistein and quercetin, to stimulate or inhibit cancer cell proliferation. To this end the 
activity of the two model compounds to activate either ERα- or ERβ-mediated gene 
transcription was characterised and compared to that of E2 using human osteosarcoma cells 
(U2OS) stably transfected with ERα or ERβ and a luciferase reporter gene with a 3xERE-
containing promoter region. This assay provided a quantitative indication of the estrogenic 
activity of the phytoestrogens relative to that of E2 at the receptor level. In addition, 
phytoestrogen-dependent cell proliferation was investigated in a T47D breast cancer cell line 
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with a tetracycline-inducible ERβ (19) to characterize the effect of phytoestrogens on cell 
proliferation when altering the intracellular ERα/ERβ ratio. 
 
Materials and methods 
Materials: 17β-estradiol (E2)(purity>98%), genistein and ANTI-FLAG M2® 
Monoclonal-antibody Peroxidase Conjugate were purchased from Sigma (Zwijndrecht, The 
Netherlands). Dimethyl sulfoxide (DMSO)(purity>99%) and quercetin dehydrate were 
purchased from Acros Organics (Pittsburgh, PA, USA). Tetracycline, streptomycin, penicillin 
and puromycin were acquired from Gibco (Paisley, Scotland). Fetal calf serum (FCS), and 
geneticin were provided by Invitrogen Life Technologies (Paisley, Scotland). Phosphate-
buffered saline (PBS), non-essential amino acids, growth medium 1:1 mixture of Ham's 
nutrient mixture F12 and DMEM, and exposure medium phenol-free were supplied by Gibco 
(Paisley, Scotland). Hyclone dextran-charcoal-treated FCS (DCC-FCS) obtained from Perbio 
Science NV (Etten-Leur, The Netherlands) was heat inactivated (20). Trypsin was obtained 
from Difco (Detroit, USA). Ascorbic acid, sodium bicarbonate, sodium hydroxide, 
ethylenedinitrotetraacetic acid (EDTA), magnesium sulphate, and 1,4-dithiothreitol (DTT) 
were obtained from Merck (Darmstadt, Germany). Magnesium carbonate was obtained from 
Aldrich (St. Louis, MO, USA). trans-1,2-diaminocyclohexane-N,N,N’,N‘-tetraacetic acid 
monohydrate (CDTA) was obtained from Fluka (Buchs, Switzerland). Hygromycin and 
diferin were obtained from Duchefa (Haarlem, The Netherlands). ATP, (BrdU)-Roche Cell 
proliferation ELISA, BrdU (colorimetric) kit and protease inhibitors mix were provided by 
Roche Diagnostics (Mannheim, Germany). BSA Protein Assay Kit was purchased from 
Pierce (Germany). Tween 20 was obtained from Merck (Germany). Sodium dodecyl sulphate 
(SDS) was obtained from BDH (United Kingdom). Acrylamide (30% acrylamide/bis), 
N,N,N′,N′-tetramethylethylenediamine (TEMED), ammonium persulphate (APS) and the 
precision plus dual colour protein marker were obtained from BioRad (The Netherlands). 
Milk solution ELK was provided by Campina (The Netherlands). Nitrocellulose membrane 
was purchased from Whatman (The Netherlands). Chemiluminescent detection ECL kit and 
photographic hyperfilm were provided by Amersham (United Kingdom).  
 
Cell lines: T47D human breast cancer wild type cells were purchased from the American 
Type Culture Collection (Manassas, VA, USA). The stably transfected T47D-ERβ 
tetracycline-inducible cell line were used as described before (19). The human osteosarcoma 
(U2OS) cell lines ERα-U2OS-Luc and ERβ-U2OS-Luc stably expressing either ERα or ERβ, 
respectively, in addition to 3xERE (Estrogen Responsive Element)-tata-luciferase were used 
as described before (21). 
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Cell culture conditions: ERα- and ERβ-U2OS-Luc, T47D wild type and T47D-ERβ 
cells were cultured as described before (22). 
 
Measurement of ERβ expression-related fluorescence: Quantification of ERβ 
expression-related EGFP fluorescence after 48 h of exposure was performed following the 
methods  previously described (22). 
 
Exposure conditions for T47D and T47D-ERβ cells: Experiments were performed in 
phenol red-free exposure medium supplemented with 5% dextran-charcoal-treated FCS 
(DCC-FCS). Confluent cells were seeded in 96-well plates (100 µl/well) at 105 cells/ml for 
the proliferation assays in the presence of tetracycline and at 1.8x105 cells/ml for fluorescence 
assays, in the presence of different concentrations of tetracycline (0 - 1000 ng/ml) as 
indicated. Plates were incubated overnight at 37ºC with 5% CO2. Three different tetracycline 
concentrations were used to obtain three different ERβ expression levels (for details see 
Results section); 1000 ng/ml tetracycline for full inhibition of ERβ expression, 40 ng/ml 
tetracycline for 50% inhibition of ERβ expression, and 0 ng/ml tetracycline for full 
expression of ERβ. After 24 h, cells were washed with phosphate-buffered saline and 
exposed to different concentrations of tetracycline as indicated (1000, 40 or 0 ng/ml) and/or 
the test compound at the concentrations indicated. For incubations with quercetin, 600 µM 
ascorbic acid was added for compound stabilization (23).  
 
Cell proliferation measurements: After 48 h of exposure, proliferation was determined 
by measuring 5-bromo-2’-deoxy-uridine (BrdU) incorporated into DNA following BrdU 
Roche’s colorimetric protocol. Measurements were performed in a spectrophotometer at 370 
nm excitation and 492 nm emission wavelengths.  
 
ERα- and ERβ-specific U2OS reporter gene assay: Cultured ER-U2OS-Luc cells were 
washed with PBS, trypsinized and seeded in transparent 96-well plates at 100 µl/well at a 
density of 10x104 cells/ml (ERα-U2OS-Luc) or 7.5x104 cells/ml (ERβ-U2OS-Luc) in a 1:1 
mixture of DMEM and Ham’s F12 medium without phenol red, buffered with 1260 mg/l 
NaHCO3 and supplemented with 5% dextran-charcoal-treated FCS (DCC-FCS) and 0.5% 
nonessential amino acids. Culture medium was refreshed after 24 h. Forty-eight hours after 
seeding cells were exposed in triplicate to E2, genistein or quercetin at the indicated 
concentrations (final DMSO concentration 0.2%) for 24 h at 37ºC and 7.5% CO2 in a 
humidified atmosphere. On each plate, cells were exposed to a full dose of test compound 
and calibration points for E2 were also included. After 24 h, the medium was removed and 
cells were washed with 100 µl of diluted PBS (0.5x PBS in demineralised water). Cells were 
lysed with 30 µl of a hypotonic low-salt buffer, consisting of 10 mM Tris-HCl pH 7.8 
containing 2 mM DTT and 2 mM CDTA. Plates were put on ice for 10 min and subsequently 
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frozen at –80ºC. Before analysis, plates were thawed on ice for 20 min and shaken briefly 
until reaching room temperature. Analyses were performed in a Luminoskan (RS, 
Labsystems) at room temperature as follows: background light emission of each well was 
measured for 2 sec, then 100 µl of flashmix was added (20 mM tricine buffer, pH 7.8, 
supplemented with 1.07 mM (MgCO3)4Mg(OH)2.5H2O, 2.67 mM MgSO4, 0.1 mM EDTA 
.2H2O, 2 mM DTT, 0.47 mM diferin, and 5 mM ATP), light emission was immediately 
measured for 2 sec and extinguished with 50 µl 0.2 M NaOH.  
 
Protein Isolation and SDS-PAGE: For the analysis of the ERβ protein expression levels, 
T47D-ERβ cells were grown in growth medium with 1000 ng/ml of tetracycline in small cell 
culture flasks until 80-90% confluence. Cells were seeded in exposure medium with 
tetracycline for 24 h. Medium was removed and cells were incubated for 48 h in new 
exposure medium with different tetracycline concentrations (0, 40 and 1000 ng/ml of 
tetracycline). Proteins samples were obtained as described previously (22). 
 
Western blotting: Blotting was performed at 100V for 1 h.  After the transfer unspecific 
binding sites on the membrane were blocked with 5% milk solution ELK in TBS 0.05% 
Tween 20 for 1-2 h. The membrane was washed in TBS with 0.05% Tween 20 twice for 5 
min.  Monoclonal ANTI-FLAG M2® antibody was diluted in TBS with 0.05% Tween 20 and 
after incubation for 1 h at room temperature the membrane was washed with TBS with 0.05% 
Tween 20 six times for 5 min each time. Next, the membrane was treated with peroxidase 
substrate (ECL kit) to detect the FLAG fusion protein. The reaction was run for 5-7 min and 
bands were visualized using photographic film. 
 
Calculations and statistics: Luciferase induction by quercetin and genistein in the U2OS 
cells was compared with the luciferase induction by the natural ligand E2. The background 
luciferase induction by the solvent control was set at 0% induction. The maximum induction 
of luciferase obtained at 12 pM E2 for ERα cells and at 300 pM E2 for ERβ cells was set at 
100%. The EC50 values, concentration of the compound at which 50% of the maximum 
luciferase activity is reached, were derived from the dose-response curves using R. The 
average EC50 values and their S.E. were calculated from taking the average of the EC50 
values of 3 independent experiments. Estradiol equivalency factors (EEF) were calculated as 
EC50 estradiol/EC50 compound.  
 
EGFP fluorescence, reflecting the level of ERβ induction, was expressed relative to the 
fluorescence of cells exposed to the solvent control without tetracycline (PBS 0.2%) set at 
100%. 
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Normalized data from breast cancer cell results were plotted as absorbance at A492 minus 
A370 nm where the maximal induction in the control cells cultured in the presence of 1000 ng  
tetracycline/ml was set as 1.  Statistical analysis of the data from T47D-ERβ proliferation 
assays was done with the Tukey HSD test (ANOVA) at 95% confidence level. For each 
compound concentration results obtained from cells with inhibited expression of recombinant 
ERβ (1000 ng/ml tetracycline) were compared to data obtained from cells expressing half (in 
the presence of 40 ng/ml tetracycline) and full (in the absence of tetracycline) recombinant 
ERβ levels to test whether the intracellular expression of recombinant ERβ has a statistically 
significant effect on E2- or phytoestrogen-induced cell proliferation.  
 
Results 
Activity of E2 and the model phytoestrogens in the ER-U2OS-Luc reporter gene cells 
The estrogenic potency of genistein and quercetin was measured using the human 
osteosarcoma (U2OS) ERα or ERβ reporter cell line, and compared to the activity of the 
natural ER ligand E2 in these cells. These cells were stably transfected with either ERα or 
ERβ and luciferase expression plasmid with 3x ERE. Initially treatment of the cells with 
quercetin resulted in no response (data not shown), except for the highest compound 
concentration. Addition of ascorbic acid at a concentration of 600 µM was previously shown 
to increase the stability of the quercetin and to have no toxic or inducing effects in the U2OS 
cell lines (12, 23). Our studies confirmed that ascorbic acid itself does not have an effect on 
ER-mediated gene expression (data not shown). Treatment of the ERα-U2OS-Luc and ERβ-
U2OS-Luc cells with E2, genistein and ascorbate-stabilized quercetin resulted in a 
concentration-dependent expression of luciferase (Figure 1). Table 1 presents the half 
maximal effective concentration (EC50) values derived from these curves for E2-, genistein- 
and quercetin-mediated induction of ERE-Luc activity in the U2OS cell lines. For E2 the 
EC50 value for ERα activation was lower (3.8 pM) than for ERβ activation (76 pM) 
suggesting an about 20-fold higher preference of E2 for ERα- than for ERβ-mediated 
induction of gene expression. Activation of both ERα- and ERβ-mediated induction of gene 
expression by genistein as well as quercetin required much higher agonist concentrations. 
Quercetin EC50 values were 6.5 µM and 9 µM for ERα and ERβ, respectively. Calculated 
EEFs were 5.85 x 10-7 for ERα and 8.44 x 10-6 for ERβ. The affinity of genistein, towards 
both ERs was higher than that of quercetin, and genistein preferentially activated ERβ as 
indicated by the EC50 values, which amounted to 100 nM for ERα and 7 nM for ERβ. 
Calculated EEFs for ERα and ERβ based on these EC50 values were 3.8 x 10-5 and 0.01, 
respectively.  
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Figure 1: Induction of ERE-mediated luciferase activity in the U2OS-ERα (A) and U2OS-ERβ (B) cells upon 
exposure to E2 (■), genistein (♦) and ascorbate stabilized quercetin (▲). Induction was expressed relative to 
maximal E2 response set at 100%. Data points represent the mean of triplicates exposure ± standard deviation. 
 
Even though both phytoestrogens were shown to bind to both ERs with much lower 
affinity (higher EC50) than the natural ligand E2, the maximum level of Luc activity induced 
was significantly higher. The maximal ERE-Luc activity induced by genistein treatment was 
168% and 293% of the maximal ERE Luc activity induced by E2 in the ERα- and ERβ-
U2OS-Luc cells, respectively (Figure 1). This effect was even more pronounced with 
quercetin, which resulted in a maximal ERE-Luc activity that amounted to 166% that induced 
by E2 in ERα-U2OS cells and to 598% that induced by E2 in ERβ-U2OS cells (Figure 1). 
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Table 1: Overview of the EC50, EEF and maximum effect of genistein and quercetin tested using the U2OS cell 
system compared to E2.  
 
 
 
ERα  
EC50  
Max effect 
% relative 
E2-max 
ERα  
EEF 
ERβ  
EC50  
Max effect
% relative 
E2-max 
ERβ  
EEF 
ERα EEF/ 
ERβ  EEF 
ratio 
E2 3.8 ± 1.2 pM 100 1 76 ± 4 pM 100 1 1 
Genistein 100 ± 8 nM 168 3.8 x 10-5 7 ± 4 nM 293 0.01 0.038 
Quercetin 6.5 µM 166 5.85 x 10-7 9 ± 0.02 µM 598 8.44 x 10-6  0.069 
 
(EC50: concentration of the compound at which 50% of the maximum luciferase activity is reached; EEF: 
estradiol equivalent factor calculated as EC50 (E2)/EC50 (test compound)). 
 
Tetracycline-dependent expression of ERβ in the T47D-ERβ cell line quantified by 
measuring EGFP Fluorescence and Western blot analysis   
T47D cells were stably transfected with the tagged ERβ and an Enhanced Green 
Fluorescence Protein (EGFP) gene as a co-expressed reporter under regulation of the same 
tetracycline-responsive promoter. Wells seeded at high-density number of the T47D-ERβ 
cells were exposed to different concentrations of tetracycline and after 48 h cultivation EGFP 
fluorescence was measured in the cell lysate. Figure 2A presents the EGFP fluorescence thus 
detected as a function of the tetracycline concentration. Maximal levels of fluorescence were 
reached after cultivation of the cells at the lowest tetracycline concentrations. Tetracycline 
treatment suppressed EGFP fluorescence in T47D-ERβ cells, resulting in total fluorescence 
suppression at concentrations above 150 ng/ml. The concentration of tetracycline at which 
50% of the fluorescence was inhibited (IC50) was 40 ng/ml.  
 
EGFP fluorescence measured in the cell lysate is linked to the expression of recombinant 
ERβ since both are co-expressed. Based on these fluorescence results three different 
tetracycline concentrations were defined that would result in three ERβ expression levels: (i) 
1000 ng/ml tetracycline where no expression of EGFP was detected and thus no expression of 
recombinant ERβ is expected; (ii) 40 ng/ml tetracycline resulting in 50% expression of EGFP 
and thus of ERβ and (iii) 0 ng/ml tetracycline, leading to full expression of EGFP and ERβ. 
To further confirm that these tetracycline-concentrations result in maximal, 50% and no ERβ 
expression levels the tagged ERβ protein levels at the three tetracycline concentrations were 
characterised using Western blot analysis (Figure 2B). Detection of the tagged ERβ was 
confirmed at 0 ng/ml and 40 ng/ml of tetracycline, whereas no ERβ protein was detected at 
1000 ng/ml. Quantifications of the intensity of the bands by ImageJ corroborated that at 40 
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ng/ml tetracycline expression levels were about 50% of those detected at 0 mg/ml 
tetracycline (Figure 2B).  
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Figure 2: (A) Tetracycline-induced inhibition of ERβ expression in T47D-ERβ cells measured via the 
concurrent expression of Enhanced Green Fluorescence Protein (EGFP) after 48 h of exposure. Fluorescence is 
expressed relative to maximum expression at 0 ng/ml of tetracycline set at 100%. No fluorescence is observed 
above 150 ng of tetracycline per mL. Each data point represents the mean of triplicate exposure ± standard 
deviation. (B) Western blot of T47D-ERβ cells treated with three different concentrations of tetracycline (0, 40 
and 1000 ng/ml) for 48 h. The blotting was done with protein FLAG antibody to detect tagged ERβ. Band 
intensities were determined using ImageJ gel analyzer, available at <http://rsb.info.nih.gov/ij/>. 
 
 
Proliferation of the T47D wild type cells 
Treatment of T47D wild type cells during 48 h with E2, genistein or ascorbate stabilized-
quercetin resulted in a dose-dependent increase in cell proliferation (Figure 3). All 
proliferation data have been normalized to the same reference point, being proliferation levels 
obtained at 1 nM E2, and therefore it can be derived from the data presented in Figure 3 that 
genistein and E2 reached an almost similar maximum proliferation level but at different 
concentrations. The maximum level of proliferation, induced by quercetin was slightly lower 
than that induced by E2 and genistein. The maximum levels of proliferation were reached at 
about 100 pM E2, 500 nM genistein and 1 µM quercetin. The EC50’s for proliferation 
amounted to 8.2 pM E2, 78 nM genistein and 81 nM quercetin (Table 2).  
 
No toxic effects or cell death were observed using optical microscopy at any 
concentration of (phyto)estrogens tested (data not shown). 
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Table 2: Overview of the EC50 and EEF of estradiol, genistein and quercetin using the T47D wild type and 
T47D-ERβ cell lines (np= no proliferation, therefore no EC50 could be calculated).  
 
 
 T47D wild type                                     T47D-ERβ 
 
ERα  
EC50  
ERα  
EEF 
1000 ng/ml 
EC50  
Tet.
EEF 
40 ng/ml 
EC50 
Tet.
EEF 
0 ng/ml  
EC50  
Tet.
EEF 
E2 8.2 ± 2.5  pM 1 30 ± 20  pM 1 28 ± 10 pM 1 np np 
Genistein 78 ± 7   nM 1.05 x 10-4 98 ±  21 nM 3.0 x 10-4  94 ± 18 nM 2.9 x 10- 4 927 ±  346  nM 3 x 10-5 
Quercetin 81 ± 5  nM 1.01 x 10-4 90 nM 3.3 x 10-4  np np np np 
 
(EC50: concentration of the compound at which 50% of the maximum luciferase activity is reached; EEF: 
estradiol equivalent factor calculated as EC50 (E2)/EC50 (test compound)). 
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Figure 3: (A-C) Effect of E2, genistein and ascorbate stabilized quercetin on the proliferation of T47D wild type 
cells. Data are presented normalized with respect to the proliferation of control cells set at 1. Each normalized 
data point represents the mean of triplicate exposure ± standard deviation. * Significantly different from the 
control (DMSO) at p<0.05. 
 
 
Proliferation of the T47D-ERβ cells at three different ERα/ERβ ratios 
The effect of the intracellular ratio of ERα/ERβ on E2 and phytoestrogen-induced cell 
proliferation was tested using the T47D-ERβ recombinant cell line in which the intracellular 
levels of ERβ can be modified. Expression levels of ERβ in the T47D-ERβ cell line are 
tetracycline-dependent, and full expression of the ERβ receptor is observed upon tetracycline 
removal from the medium.  
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Figure 4. Effect of estradiol (A), genistein (B) and ascorbate stabilized quercetin (C), at three different levels of 
ERβ expression, on the proliferation of T47D-ERβ cells. Fully coloured columns represent exposure to the test 
compounds in combination with 1000 ng/ml tetracycline, the shaded columns with 40 ng/ml tetracycline and the 
dotted columns with 0 ng/ml tetracycline.  Proliferation was quantified measuring BrdU incorporation after 48 
hours exposure. Data are presented normalized with respect to the proliferation of control cells in the presence 
of 1000 ng tetracycline/ml set at 1. Each normalized data point represents the mean of triplicate exposure ± 
standard deviation. * Significantly different from the control (proliferation  at 1000 ng/ml Tet.) at p<0.05. 
 
Figure 4 shows the concentration-dependent effect of respectively E2 (Figure 4A), 
genistein (Figure 4B) and ascorbate-stabilized quercetin (Figure 4C) on proliferation of T47D 
cells with varying levels of ERβ expression.  
 
 Exposure of the cells to the test compounds in the presence of 1000 ng/ml tetracycline 
resulted in stimulation of cell proliferation. In the presence of 1000 ng/ml tetracycline the 
recombinant T47D cells do not express ERβ and their response to exposure to the test 
compounds can be compared to that observed for the wild type T47D cells (Figure 3). 
Comparison of the EC50 values obtained in T47D wild type and in T47D-ERβ cells grown in 
the presence of 1000 ng/ml tetracycline inhibiting recombinant ERβ expression (Table 2) 
reveals that in both cell lines genistein and quercetin induce ERα-mediated cell proliferation 
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with lower potency than E2, and that their effect on cell proliferation is similar in both cell 
lines. In E2-treated T47D-ERβ cells proliferation increased until 1.2 nM (Figure 4A) and 
decreased above that concentration (data nor shown). Genistein (Figure 4B) was used in a 
concentration range from 10 nM up to 20 µM, concentrations that were effective for both 
ERα− and ERβ-mediated induction of gene expression in the U2OS-Luc cells. Genistein-
stimulated proliferation reached its maximum at 0.5 µM and decreased in a dose-dependent 
manner at higher concentrations until showing complete inhibition of cell proliferation at 
concentrations above 10 µM. Ascorbate stabilized-quercetin was used in concentrations 
between 5 and 100 µM (Figure 4C). Growth stimulation was observed within a concentration 
range from 5 to 50 µM quercetin. Above 60 µM quercetin cell growth decreased to values 
that were even lower than that of the control cells incubated without quercetin.  
 
In the presence of half of the maximal expression of ERβ, a decrease in the levels of cell 
proliferation induced by E2 and genistein was observed as compared to the cell proliferation 
induced by these compounds in cells with no ERβ expression (Figure 4A and 4B). Moreover, 
the quercetin-induced cell proliferation was completely inhibited when the cellular ERβ 
expression level was at 50%. As a result no EC50 could be derived for quercetin-induced cell 
proliferation of T47D cells with 50% ERβ expression levels. Together these data obtained 
with T47D cells with 50% ERβ expression levels reveal that the growth inhibitory effect of 
ERβ was stronger with quercetin (full inhibition of cell proliferation, no EC50) than with E2 
(EC50 28 pM) and genistein (EC50 94 nM). 
 
Upon complete withdrawal of tetracycline from the medium, resulting in full expression 
of ERβ, E2-, genistein- and quercetin-induced cell proliferation was significantly reduced. 
From the data obtained only those for genistein still allowed definition of an EC50 value for 
genistein-induced cell proliferation of T47D cells with full expression of ERβ amounting to 
927 nM. 
 
In addition, T47D-ERβ cells incubated in the absence of tetracycline and expressing full 
ERβ levels showed a reduced proliferation rate as compared to the cells when incubated in 
the presence of tetracycline, even when not exposed to an estrogen agonist. Furthermore, for 
these cells, cell death was observed based on microscopic examination. Cell death upon 
exposure to phytoestrogens was more pronounced for cells with full expression of ERβ (data 
not shown). 
Discussion 
The present study has investigated the importance of the intracellular ratio of the two 
receptors ERα and ERβ for the ultimate potential of the model phytoestrogens genistein and 
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quercetin to inhibit cancer cell proliferation. This is of importance because (i) ERβ has been 
postulated to play a role in modulating ERα-mediated cell proliferation (24), (ii) the 
phytoestrogen model compounds of the present study, genistein and quercetin, may be 
agonists for both receptor types (1) and (iii) the ratio of ERα to ERβ is known to vary 
between tissues (19, 25). 
 
In this study, it was demonstrated that the binding affinity of phytoestrogens for ERα and 
ERβ is one to three orders of magnitude lower than that of E2. The affinity in favour of ERβ 
is reflected in the ERα EEF/ERβ EEF ratio which is lower for quercetin and genistein (0.069 
and 0.038, respectively) than for E2. The higher transcriptional activity of the phytoestrogens 
compared to E2 resulted in maximal ERα-mediated induction of gene expression by genistein 
and quercetin that was 1.7 times higher than that induced by E2. For ERβ this difference was 
even more pronounced, with a maximal induction that was three and six times higher, 
respectively, for genistein and quercetin than for E2. The relatively higher ERβ affinity and 
the relatively higher level of ERβ receptor-mediated induction of gene expression for the 
phytoestrogen model compounds are in accordance with previously results in other reporter 
gene cell lines (12, 26). Legler et al. suggested that this "superagonism", might be due to 
stimulated receptor and/or cofactor renewal. An enhanced ability of ERβ to recruit 
coactivators in the presence of xenoestrogens has been suggested before. There are 
differences in the positioning of the helix-12 in the ERβ-genistein-bound complex as 
compared with E2-bound ERβ complex  which may allow  the cofactor SRC-3 NR box I to 
bind with a 3-fold greater amount to genistein-bound than E2-bound ERβ (27, 28). It could 
be speculated that this effect might be even more pronounced with quercetin. 
 
The ratio of endogenous ERα to ERβ mRNA in the T47D wild type cell line is 9 to 1 
(19). To investigate whether ERβ plays an important role in inhibiting ERα-mediated 
induction of cell proliferation by the phytoestrogens we used the T47D-ERβ cell line with 
inducible recombinant ERβ expression. E2, genistein and quercetin all stimulated cell 
proliferation in the absence of ERβ expression. The bell-shaped dose-response proliferation 
curve is similar to those previously obtained for genistein-mediated effects on proliferation of 
wild type T47D cells (29, 30). Quercetin exposure of cells with ERβ-inhibited expression 
also resulted in a bell-shaped dose-response curve for cell proliferation. Quercetin was able to 
stimulate cell proliferation in a concentration range between 5 and 50 µM, while inhibition 
was observed at concentrations above 50 µM. These results were in accordance to those 
obtained previously with the wild type T47D cells (12).  
 
Quercetin showed a significantly higher maximum level of activation of gene expression 
in the U2OS-ERβ reporter cells than E2 (i.e. six times higher) and also a relatively higher 
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affinity for ERβ than for ERα. This may explain why the increase in the intracellular level of 
recombinant ERβ had a more pronounced effect on quercetin-induced cell proliferation than 
on E2-induced cell proliferation. With both half and full expression of recombinant ERβ, 
quercetin inhibited cell growth to levels that were even lower than that observed for non-
treated controls. Similar to E2, genistein inhibited growth-stimulatory effects more efficiently 
in cells with full expression of ERβ than in cells with no expression of recombinant ERβ 
exposed to genistein. Surprisingly however, at 20 µM genistein, the highest concentration 
tested, growth of cells at all levels of ERβ expression tested was comparable to that of non-
treated control cells with full expression of ERβ.  This suggests that in the cells exposed to 20 
µM genistein the ERβ-mediated induction of gene expression by genistein is only in part 
responsible for the observed antiproliferative effects.  
 
In contrast to E2 and genistein, with quercetin exposure maximal inhibition of cell 
proliferation was observed already with half expression of the intracellular recombinant ERβ. 
Moreover, in cells with high levels of ERβ expression E2- and flavonoid-induced cell death 
was observed. Since this was not observed upon exposure of the wild type T47D cells and 
also not in the T47D-ERβ cells in which ERβ expression was suppressed by 1000 ng/ml 
tetracycline, cytotoxic effects, as suggested by other authors (31), can be disregarded as the 
cause of this observation. The findings rather suggest, that agonist-mediated activation of 
ERβ not only reduces ERα-mediated gene expression that results in cell proliferation but also 
inhibits cell proliferation by other mechanisms. This would be in line with previous studies 
suggesting an ERβ-mediated induction of apoptosis (32-34). Noteworthy is the fact that 
significant inhibition of cell proliferation was also observed in vehicle treated cells when 
ERβ levels were significantly expressed, suggesting that ERβ can inhibit cell growth in a 
ligand-independent manner, which is consistent with results obtained in MCF7 cells (35). 
Moreover, it has been demonstrated that ERα/ERβ heterodimers and ERα homodimers are 
preferentially formed in intact cells (36). Increasing levels of ERβ expression might enhance 
the ratio of heterodimer formation thereby leading to reduced ERα-homodimer-mediated 
growth stimulation even in the absence of ligand. 
 
Recently Williams et al. reported transcriptome data for E2-exposed T47D-ERβ cells 
with varying levels of recombinant ERβ (37), and concluded that E2-induced ERα-regulated 
genes were involved in cell cycle progression whereas E2-induced ERβ-regulated genes were 
involved in suppression of cell proliferation. The up-regulation of e g Cyclin A (CCNA2), 
CDC20 cell division cycle 20 homolog (CDC20), BUB1 budding uninhibited by 
benzimidazoles 1 homolog (BUB1) and down-regulation of the tumour protein p53 inducible 
nuclear protein (TP53INP1) in T47-ERβ cells in which ERβ expression was inhibited, 
implicates a role of ERα in proliferative processes. In contrast, in T47D cells in which ERβ 
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was expressed, E2 upregulated genes such as quiescin Q6 (QSCN6) and septin (SEPT9), 
involved in negative regulation of cell proliferation, as well as serine/threonine kinase 3 
(STK3), connected to apoptotic processes.  
 
These transcriptomic results are in accordance with our E2-proliferation data and 
corroborate the modulating effect of ERβ reducing the E2-induced ERα-mediated 
proliferation. Similar transcriptional analysis of T47D-ERβ cells with different levels of ERβ 
expression exposed to phytoestrogens should reveal whether the effects induced by the 
phytoestrogens proceed by similar differential gene expression pathways and mechanisms. 
These studies are presently in progress in our laboratory. 
 
In summary, our study shows that activation of ERβ results in a reduction of ERα-
mediated cell proliferation. The results obtained point at the importance of the cellular 
ERα/ERβ ratio for the ultimate effect of (phyto)estrogens on cell proliferation, and this may 
provide a basis to explain the differential effects reported for the influence of 
(phyto)estrogens on cancer incidence.  
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Superinduction
 
Abstract  
 
Several estrogenic compounds including the isoflavonoid genistein, have been reported 
to induce a higher maximal response than the natural estrogen 17β-estradiol in in vitro 
luciferase-based reporter-gene bioassays for testing estrogenicity. The phenomenon has been 
referred to as superinduction. The mechanism underlying this effect and thus also its 
biological relevance remain to be elucidated. In the present study several hypotheses for the 
possible mechanisms underlying this superinduction were investigated using genistein as the 
model compound. These hypotheses included i) a non estrogen receptor (ER)-mediated 
mechanism, ii) a role for an ER  activating genistein metabolite with higher ER inducing 
activity than genistein itself, and iii) a post-transcriptional mechanism that is not biologically 
relevant but specific for the luciferase based reporter gene assays. The data presented in this 
study indicate that induction and also superinduction of the reporter gene is ER-mediated, and 
that superinduction by genistein could be ascribed to stabilization of the firefly luciferase 
reporter enzyme increasing the bioluminescent signal during the cell-based assay. This 
indicates that the phenomenon of superinduction may not be biologically relevant but may 
rather represent a post-transcriptional effect on enzyme stability. 
 
 
 
. 
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Introduction 
Isoflavones represent the most important group of phytoestrogens and have structural 
similarities to endogenous estrogens, suggesting that these compounds might exert their 
estrogenic effects via the estrogen receptor (ER) (1). Several in vitro assays have been used 
over the past years to investigate and define the hormonal, including also estrogenic, activity 
of isoflavones. Indeed, many of these studies have shown that isoflavones exert estrogenic 
and/or anti-estrogenic activities (2). An important model isoflavonoid tested in these studies 
is genistein, which is the main isoflavone present in legumes, particularly soy beans. Diverse 
biological activities have been associated with genistein including its estrogenicity and 
chemopreventive and/or antioxidant potential (3, 4). In vitro, genistein showed a wide range 
of cellular activities including inhibition of tyrosine kinase, inhibition of topoisomerase, 
inhibition of autophosphorylation of the epidermal growth factor receptor, mutagenesis but 
also antimutagenesis, induction of DNA damaging oxidation but also its prevention, and the 
promotion of cell death by apoptosis (5). Some of the estrogenic characteristics of genistein 
may contribute to protective roles in osteoporosis and menopause symptoms (6), but also to 
have positive effects against heart diseases, diabetes or even cancer (7). These proposed 
beneficial health effects of phytoestrogens in general, and of genistein in particular, have led 
to a wide range of isoflavonoid based food supplements.  
 
Numerous in vitro ER assays have been developed to test the agonism or antagonism of a 
given substance. Reporter gene assays have become the most popular technique for 
measuring short-term screening of estrogenic activity. However, a response in an in vitro ER 
agonist or antagonist assay is not sufficient to predict biological or in vivo effects.  
 
Genistein and other isoflavones have been shown to be weakly estrogenic and to have 
relatively low receptor affinity as compared to the natural estrogen receptor ligand 17β-
estradiol (E2). However, in some mammalian cell-based assays, using human U2OS bone or 
Chinese hamster ovarian (CHO) cells, stably transfected to express estrogen receptor (ER) to 
make them responsive to estrogens, or using MCF7 breast cancer cells containing 
endogenous ER, the maximal induction of the luciferase reporter gene by genistein has been 
shown to be substantially  higher than the maximal induction by estradiol (E2) (8-12). In 
contrast, during cell-based estrogen stimulated proliferation assays, cell proliferation rates 
induced by genistein are similar to those induced by E2, although occurring at higher 
concentrations (11, 13, 14). No “superproliferation” effect by genistein or other isoflavones 
has been reported so far.  
 
Superinduction
 
The mechanism underlying the so-called superinduction of estrogen receptor mediated 
gene expression in luciferase based reporter gene assays and also its biological relevance 
remain to be elucidated. The aim of the present study was to investigate possible mechanisms 
underlying  this superinduction in reporter gene assays using genistein as the model 
compound known. Using the ER antagonists ICI 182,780 and RU58668 it was investigated 
whether the superinduction phenomenon was dependent on ER activation. In a T47D cell 
proliferation assay it was investigated whether superinduction was also reflected in 
superproliferation (and thus biologically relevant). Furthermore the possible role for a 
genistein metabolite with higher induction potency than E2 was investigated. And finally, 
using RT-PCR, it was quantified whether the increased luciferase activity was a result of 
increased gene expression and thus mRNA levels or rather a post-transcriptional effect on 
enzyme stability. Together these experiments provided insight in the mechanism underlying 
the observed superinduction, pointing at a post-transcriptional effect on enzyme stability and 
thus an assay artefact rather than at a biologically relevant effect. 
 
Materials and methods: 
Materials: 17β-Estradiol (E2; purity>98%) and genistein (purity>98%), acetonitrile and 
trifluoroacetic acid  were purchased from Sigma (Zwijndrecht, The Netherlands). RU58668 
was a gift from N.V. Organon (Oss, The Netherlands). Orobol was purchased from APIN 
Chemicals LTD (Oxon, UK). ICI 182,780 was provided by Zeneca Pharmaceuticals 
(Cheshire, UK). Dimethyl sulfoxide (DMSO, purity>99%) was purchased from Acros 
Organics (Pittsburgh, PA, USA). Fetal calf serum (FCS, Australian origin, 10099), geneticin, 
G418 and Trizol Reagent were provided by Gibco Invitrogen Life Technologies (Paisley, 
UK). Phosphate-buffered saline (PBS, without Ca2+ and Mg2+), Hank's balanced salt solution 
(HBSS), nonessential amino acids (100×, 11140-035), growth medium 1:1 mixture of Ham's 
nutrient mixture F12 and DMEM (31331-028), Alpha-Modified Eagle's Medium (22561-
021), and exposure medium phenol-free (21041-025) were supplied by Gibco Invitrogen 
(Paisley, UK). Dextran-charcoal-treated FCS (DCC-FCS) was heat inactivated (30 min at 56° 
C) followed by two 45 min DCC-treatments at 45° C (15). Trypsin was obtained from Difco 
(Detroit, USA; 0.25 g/100 ml in phosphate-buffered saline, PBS). Sodium bicarbonate 
(NaHCO3 >99.5%), sodium hydroxide (NaOH) ethylenedinitrotetraacetic acid (EDTA.2H2O; 
Titriplex), magnesium sulfate (MgSO4.7H2O), and 1,4-dithiothreitol (DTT) were  obtained 
from Merck (Darmstadt, Germany). Magnesium carbonate ((MgCO3)4Mg(OH)2.5H2O) was 
obtained from Aldrich (St. Louis, MO, USA). trans-1,2-diaminocyclohexane-N,N,N’,N‘-
tetraacetic acid monohydrate (CDTA) was obtained from Fluka (Buchs, Switzerland). 
Hygromycin and Diferin were obtained from Duchefa (Haarlem, The Netherlands). ATP was 
provided by Roche Diagnostics (Mannheim, Germany) and the BCA Protein Assay Kit by 
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Pierce (Bonn, Germany). RNeasy mini kit and SYBR green were provided by Quiagen 
(Hilden, Germany).  
 
Cell lines: The stably transfected human osteosarcoma (U2OS) cell line (ERα-U2OS-
Luc) expressing the human ERα in addition to 3xERE(GAGCTTAGGTCACTGTGACCT)-
tata-luciferase reporter construct was used as described before (16). T47D human breast 
cancer wild type cells were purchased from the American Type Culture Collection 
(Manassas, VA, USA). The T47D-Luc cell line stably transfected with an estrogen receptor 
mediated luciferase reporter gene construct was described before (17).  
 
Cell culture conditions: ERα-U2OS-Luc cells were cultured in a 1:1 mixture of DMEM 
and F12 (31331-028) buffered with 1260 mg/L NaHCO3, supplemented with 7.5% fetal calf 
serum (FCS) and 0.5% nonessential amino acids. ERα-U2OS-Luc growth medium was 
supplemented with geneticin (200 µg/mL) and hygromycin (50 µg/mL) as selection markers. 
The cells were incubated at 37° C and 7.5% CO2 in a humidified atmosphere. 
The T47D wild type and T47D-Luc cell lines were cultured in a 1:1 mixture of Ham's 
nutrient mixture F12 and DMEM (31331-038) supplemented with 5% FCS. The cells were 
incubated at 37° C and 5% CO2 in a humidified atmosphere. 
 
ERα-U2OS-Luc, T47D-Luc assay: hERα-specific U2OS and T47D luciferase reporter 
gene assays expressing endogenous ERα were carried out as described previously (11).  
 
REA bioassay: The yeast estrogen bioassay, is based on a yeast cell stably expressing 
hERα and stably transfected with a yeast enhanced green fluorescent protein (yEGFP) as a 
reporter gene in response to estrogens. Estrogenic responses using the REA assay were 
measured as described before (18). 
 
YES assay: The yeast estrogen screen (YES) was created by expressing human estrogen 
receptor (hER) and two estrogen response elements (ERE) linked to the β-galactosidase 
(lacZ) reporter gene. The assay was performed according to methods described before (19). 
 
Cell proliferation measurements: After 48 h of exposure, proliferation in the ERα-
U2OS-Luc and T47D cells was determined by measuring incorporation of 5-bromo-2’-
deoxy-uridine (BrdU) into DNA following BrdU Roche’s colorimetric protocol. 
Measurements were performed in a spectrophotometer at 370 nm excitation and 492 nm 
emission wavelengths.  
 
HPLC-DAD analysis: Samples from medium in which T47D and ERα-U2OS-Luc cells 
were exposed for 24 hours under the same conditions described above to different 
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concentrations of genistein, however without DCC treated serum in the medium, were 
collected for HPLC-DAD analysis. The HPLC-DAD system consisted of a Waters (Milford, 
MA, USA) Alliance 2695 separation module connected to a Waters 2996 photodiode array 
detector (DAD), equipped with an Alltech (Breda, The Netherlands) Alltima C18 5-µm 150- 
x 4.6-mm reverse phase column with a 7.5- x 4.6-mm guard column. Before injection, 
samples were centrifuged at 16,000g for 4 min, and 50 µl was injected and eluted at a flow 
rate of 1 ml/min starting at 0% acetonitrile in nanopure water containing 0.1% trifluoroacetic 
acid (TFA), increasing to 10% acetonitrile in 5 min, to 15% in the following 16 min, and to 
50% in the next 16 min all in nanopure with 0.1% TFA. Thereafter, the percentage 
acetonitrile was increased to 80% in 1 min. This condition was kept for 1 min as a cleaning 
step, followed by a decrease to 0% acetonitrile in 1 min, keeping this condition for 10 min, 
allowing the column to re-equilibrate at the initial conditions (total run time, 50 min). DAD 
spectra were detected between 200 and 420 nm, and HPLC chromatograms acquired at 280 
nm were used for quantification and presentation. 
 
LC-MS/MS analysis: Medium of ERα-U2OS-Luc cells exposed to 5 µM genistein under 
the same conditions as described above but without DCC treated serum in the medium was 
collected after 24 h of exposure and analyzed by LC-MS/MS. The medium samples were 
analyzed by injecting 18 µl sample over a 32 x  0.10 mm Prontosil 300-3-C18H pre-
concentration column (Bischoff, Germany) at a flow of 6 µl/min for 10 min. Compounds 
were eluted from the pre-concentration column onto a 200 x 0.10 mm Prontosil 300-3-C18H 
analytical column with an acetonitrile gradient at a flow of 0.5 µl/min. The gradient consisted 
of an increase from 15 to 50% acetonitrile in water containing 1 ml/L formic acid in 16 min. 
Thereafter the percentage acetonitrile was increased to 80% in 3 min as a column cleaning 
step. Downstream of the column, an electrospray potential of 1.8 kV was applied directly to 
the eluent via a solid 0.5 mm platina electrode fitted into a P875 Upchurch microT. Full scan 
positive mode FTMS spectra were measured between an m/z of 200 and 600 at a resolution of 
60.000 on a Thermo electron LTQ-Orbitrap (San Jose, CA, USA). MS/MS scans of the four 
most abundant singly, doubly or triply charged peaks in the FTMS scan were recorded in data 
dependent mode in the linear trap (MS/MS threshold = 10.000). 
 
RT-PCR: RNA was extracted after 6 and 24 h exposure using the TRIzol precipitation 
method and purified using an RNeasy mini kit protocol for second RNA clean up according 
to the manufacturer’s protocol. Integrity and quantity of the extracted RNA was then assessed 
by using the Nanodrop ND-1000 spectrophotometer (Nanodrop Technologies Inc., DE, 
USA). Approximately 1-2 µg of total RNA was collected per sample. Samples were stored at 
−80° C until reverse transcription (RT-)PCR using 1 μg of total RNA. First-strand cDNA 
synthesis was carried out with an oligo(dT)15 primer and Moloney murine leukemia virus 
reverse transcriptase; during synthesis the recombinant ribonuclease inhibitor RNaseOUT™ 
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was present. The amplification reaction was carried out on a LightCycler (Roche 
Diagnostics) with gene-specific primers and used the SYBR Green 1 protocol. The following 
LightCycler protocol was used: 15 min heat start at 95° C; 45 cycles of denaturation at 95° C 
for 30 s, annealing at the optimal annealing temperature for the primer set for 30 s, and 
extension at 72° C for 45 s; and a terminal extension at 72° C for 5 min. Fluorescence 
detection was carried out at 72° C. Luc mRNA levels were expressed as the Luc:β-actin ratio. 
The oligonucleotide sequences for firefly luciferase were reverse primer: 5’-
GCCTCACCTACCTCCTTGCT-3’ and forward primer 5’-CTTCGTGACTTCCCATTTGC-
3’; for β-actine the reverse primer was 5’-CCAGAGGCGTACAGGGATAG-3’ and the 
forward primer was 5’-CACCCCGTGCTGCTGAC-3’. 
  
Calculations and statistics: Luciferase induction by genistein in the ERα-U2OS-Luc, 
T47D-Luc cells, and yEGFP and β-galactosidase induction in yeast cells were compared with 
the induction of the respective activities by the natural ligand E2. The background induction 
by the solvent control was set at 0% induction. The maximum induction of luciferase 
obtained at 12 pM E2 for ERα-U2OS-Luc cells, at 20 pM E2 for the T47D-Luc cells and at 3 
nM and 150 pM E2 for the yEGFP and β-galactosidase induction in yeast cells were set as 
100%. The data obtained for proliferation as quantified by BrdU incorporation were plotted 
as induction of proliferation compared to the solvent control (DMSO). 
Results 
Activation of ERE-mediated gene expression in the ERα-U2OS-Luc reporter gene 
assay: 
Treatment of the human ERα-U2OS-Luc cells with E2 and genistein resulted in dose-
dependent expression of luciferase (Figure 1). Induction of ERα-mediated luciferase 
expression by E2 occurs at concentrations between 1 and 20 pM. Induction by genistein 
appears to be biphasic. Exposure to genistein shows a first phase of dose-related luciferase 
induction at concentrations from 10 to 200 nM and a second phase with a further dose-related 
increased of luciferase induction at concentrations from 1 to 5 µM. The maximum level of 
luciferase induction in the first phase of the genistein induction curve is similar to the 
maximum level of induction by 12 pM E2 and amounts to 104% of the maximum E2 
induction at 100 nM genistein. In the second phase, genistein exposure of the cells  resulted 
in a so-called superinduction of luciferase activity amounting to 188% of the maximum level 
of induction by E2 at 5 µM genistein. When co-exposing cells to E2 with 5 nM of the anti-
estrogen ICI 182,780, the luciferase induction by E2 is completely inhibited (Figure 1). When 
genistein is co-exposed with 5 nM of the anti-estrogen ICI 182,780, luciferase induction in 
the high affinity first phase is inhibited and only the low affinity luciferase induction in the 
second phase remains, as the shape of the curve suggests that only the first part of the 
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genistein dose-response curve was inhibited by ICI 182,780 (Figure 1). However, the 
luciferase induced by genistein was totally inhibited by co-exposure with 100 nM ICI 
182,780 and 180 nM of another pure ER antagonist, RU58668. 
 
 
Figure 1: Induction of ERα-mediated luciferase activity in the ERα-U2OS-Luc cells upon exposure to various 
(anti)estrogens. (Anti)estrogens tested include E2 (■), E2 + 5 nM ICI 182,780 (♦), genistein (●), genistein + 5 
nM ICI 182,780 (○), genistein + 100 nM ICI 182,780 (x), genistein + 180 nM RU58668 (▲). Induction is 
expressed relative to maximal E2 response set at 100%. Data points represent the mean of triplicate exposure ± 
standard deviation. The dashed line indicates from what concentration onwards genistein concentrations 
superinduction is observed. 
 
Activation of ERE-mediated gene expression in the T47D-Luc reporter gene assay: 
Similar experiments were performed with the human breast cancer cell line T47D-Luc 
reporter gene assay in order to investigate whether the above described effects of genistein 
were cell-type specific. The breast cancer derived T47D-Luc cells use the same reporter gene 
construct that is used in the human ERα-U2OS-Luc cell line. The only difference is that the 
T47D cells make use of the endogenous ERα, while the ERα-U2OS-Luc cells contain an 
extra construct to make them express the hERα. The results shown in figure 2 reveal that the 
responses of E2 and genistein are in the same concentration range and similar to those 
obtained with the ERα-U2OS-Luc cells. Also the treatment of the T47D-Luc cells with 
genistein resulted in a biphasic concentration-dependent increase in luciferase activity. 
Genistein shows a first dose-related luciferase induction at concentrations from 10 to 200 nM 
(first curve) and a second dose-related increase in luciferase induction at concentrations from 
1 to 10 µM (Figure 2). The maximum level of luciferase activity reached in the first phase at 
100 nM genistein amounts to 108% of the maximum induction level reached at 20 pM E2. 
Genistein-mediated superinduction of luciferase in the second phase amounts to 227% of the 
maximum level of induction by E2 at 10 µM genistein. When cells were co-exposed to E2 
and 18 nM of the anti-estrogen RU58668, the E2 induced luciferase induction was 
completely inhibited. When cells were co-exposed to genistein and 18 nM of this anti-
estrogen, the luciferase induction was only partly inhibited. Again, the shape of the curve 
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shows that low concentrations of the anti-estrogen inhibit mainly the first part of the 
induction curve. Again, luciferase induction by genistein was completely inhibited by a high 
concentration of RU58668 (180 nM). 
 
Figure 2: Induction of ERα-mediated luciferase activity in the ERα-T47D-Luc cells upon exposure to various 
(anti)estrogens. (Anti)estrogens tested include E2 (■), E2+ 18 nM RU58668 (♦), genistein (●), genistein + 18 
nM RU58668 (○) and genistein + 180 nM RU58668 (x). Induction is expressed relative to maximal E2 response 
set at 100%. Data points represent the mean of triplicate exposure ± standard deviation. The dashed line 
indicates from what concentration onwards genistein concentrations superinduction is observed. 
 
T47D cell proliferation 
In a next series of experiments, it was investigated whether the observed genistein-
mediated superinduction of luciferase activity in reporter gene assays would also be reflected 
in genistein induced ERα-mediated superinduction of cell proliferation, which is a 
biologically relevant endpoint of estrogenic activity. Since the T47D cell line is known to 
express endogenous ERα, and to show estrogen induced ERα mediated cell proliferation, 
cells from the wild type T47D cell line were selected as the model system to investigate the 
possible occurrence of genistein induced ERα-mediated superinduction of cell proliferation.  
 
As shown in figure 3, treatment of T47D wild type cells for 48 h with genistein resulted 
in a dose-dependent increase in cell proliferation. Proliferation data have been normalized to 
the proliferation levels obtained at 1 nM E2, the maximum of E2 induced T47D cell 
proliferation. Figure 3 shows that the maximal proliferative effect elicited by genistein is 
similar to that of 1 nM E2 and is reached at a concentration of 1 µM genistein, which is also 
the genistein concentration inducing the maximum response in the first phase of the 
luciferase induction in the two reporter cell assays. At concentrations of 3-20 µM genistein, 
the range where in both reporter gene assays genistein-mediated superinduction was 
observed,  no genistein induced “superproliferation” of the T47D cells was observed.  
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Figure 3: T47D cell proliferation. Effect of DMSO, estradiol and genistein (black) and DMSO, estradiol and 
genistein + 10 nM ICI 182,780 (grey) on induction of T47D cell proliferation (IP). The horizontal dotted line 
indicates the maximal proliferation by E2 at 1 nM. Proliferation was quantified measuring BrdU incorporation 
after 48 hours exposure. The dashed line indicates from what concentration onwards genistein concentrations 
superinduction is observed. 
 
When cells were co-exposed with the antagonist ICI 182.780 (10 nM), the E2-induced 
proliferation was completely inhibited, and this concentration was able to reduce genistein 
induced cell proliferation at genistein concentrations of 0.1-1 µM, but was not able to inhibit 
the proliferation caused by genistein at 3-20 µM (Figure 3).  
 
Genistein metabolite formation 
One possible explanation for the observed superinduction by genistein, would be the 
formation of a metabolite that is also an active ER agonist by itself. Above 1 µM genistein, at 
which the superinduction occurs, HPLC analysis of the culture medium revealed the 
formation of a genistein metabolite (M1) (Figure 4). The medium from ERα-U2OS-Luc cells 
incubated with 1 and 5 µM genistein was collected upon 24 h exposure.   
 
          
Figures 4: HPLC analysis. Representative sections of the HPLC chromatograms of ERα-U2OS-Luc medium 
samples after 24 h of exposure to A) 1 and B) 5 uM genistein, and the UV spectra belonging to the peaks of M1 
(UVmax 257.6 nm) and genistein (UVmax 262.3 nm). 
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HPLC-DAD chromatograms obtained from medium of genistein-treated cells showed the 
presence of genistein at a retention time of 36.7 min and another compound (M1) at a 
retention time of 31.2 min (Figure 4). Based on the shorter retention time and similarities in 
the UV spectra, M1 is likely to be a polar metabolite of genistein. The formation of this 
unknown metabolite (M1) by the ERα-U2OS-Luc cells was significant at concentrations of 
0.5 µM genistein and higher.  
 
The samples used for the HPLC-DAD analysis, were subsequently analyzed by LC-FT-
MS/MS in positive ion mode. The protonated genistein corresponds to the most abundant ion 
at m/z 271. The MS/MS spectrum (with fragments formed at m/z 271, 253, 243, 225, 215, 187 
and 153) confirmed that the molecular ion [M+H]+ at m/z 271 was indeed genistein (data not 
shown). The M1 metabolite ([M + H]+ ion at m/z 287) was subsequently analysed by LC-
MS/MS. . Fragmentation of the m/z 287 ion yielded product ions at m/z 269, 259, 241, 231 
and 161. The presence of the ion at m/z 161 had only been observed earlier with isoflavones 
as a rearrangement product for a dihydroxylated B-ring fragment (20). The losses at MH+ -18 
(269), MH+ - 28 (259) and MH+ 28 – 28 (231) are typical for hydroxyisoflavones. Taken 
together, the MS/MS data are consistent with a hydroxylation on the ring B for product M1 
identifying the metabolite as 5,7,3’,4’-tetrahydroxyisoflavone, better known as orobol. 
Subsequently, this metabolite, identified as orobol, was also tested in the ERα-U2OS-Luc 
reporter gene assay (Figure 5). Orobol is able to induce reporter gene expression at 
concentrations above 1 µM reaching a superinduction of 187% at 40 µM.  
 
 
Figure 5: Induction of ERα-mediated luciferase activity in the ERα-U2OS-Luc cells upon exposure to genistein 
(●) and orobol (▲). Induction is expressed relative to maximal E2 response set at 100%. Data points represent 
the mean of triplicate exposure ± standard deviation. The dashed line indicates from what concentration 
onwards genistein concentrations superinduction is observed. 
 
Yeast estrogen bioassay 
Two more reporter gene assays were used to test whether the superinduction caused by 
genistein and orobol could also be observed using different reporter genes, namely enhanced 
green fluorescent protein (yEGFP) and β-galactosidase (β-gal). Both of these reporter gene 
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assays are based on yeast cells that have been previously shown to be metabolically inactive 
with regard to natural and synthetic estrogens (21, 22). The yeast cells expressing hERα were 
exposed to genistein and orobol. Figure 6A and figure 6B show that both genistein and orobol 
resulted in the same maximal response as E2. Thus, no superinduction was observed in 
bioassays based on yeast cells and using different reporter genes than firefly luciferase.  
 
A B 
 
Figure 6: Induction of ERE-mediated reporter gene in yeast estrogen bioassays. (A) Induction of ERE-mediated 
yEGFP expression in a yeast estrogen bioassay using yEGFP as reporter gene upon exposure to E2 (●), 
genistein (■) and orobol (▲). Data points represent the mean of triplicate exposure ± standard deviation. (B) 
Induction of ERE-mediated β-galactosidase expression in a yeast estrogen bioassay upon exposure to E2 (●), 
genistein (■) and orobol (▲). Data points represent the mean of triplicate exposure ± standard deviation. (†) 
Represents cytotoxicity. 
 
Genistein and E2 induced luciferase gene expression as detected by RT-PCR 
Additional experiments were performed aiming at studying the effect of genistein on 
luciferase mRNA and/or protein activity and stability. Post-transcriptional activation and 
stabilisation of luciferase mRNA and/or protein might be an alternative explanation for the 
observed superinduction at high concentrations of genistein (>1µM) explaining increased 
luciferase activity without the need for increased transcriptional activity. To actually verify 
whether or not the increased luciferase activity is a true reflection of increased transcriptional 
activity, RT-PCR based quantification of luciferase mRNA formation as a function of 
increasing genistein concentrations was performed and results obtained were compared to the 
level of mRNA formation induced at optimal levels of E2. To this end, ERα-U2OS-Luc cells 
were treated with E2 and genistein during 6 and 24 h. RNA from all the samples was 
extracted, and expression of firefly luciferase gene mRNA was compared with that of the 
housekeeping gene β-actin by RT-PCR. RT-PCR analysis revealed that the firefly luciferase 
gene expression was 23-fold up-regulated by 12 pM E2 (Figure 7). Increasing concentrations 
of genistein resulted in increased expression of luciferase mRNA, but the maximum level of 
mRNA induction reached was 9-fold, and never reached the induction factor observed for E2. 
Moreover, no superinduction of the mRNA level due to genistein treatment at concentration 
above 1 µM genistein was observed.  
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Figure 7: Relative firefly luciferase mRNA expression levels in ERα-U2OS-Luc cells normalized to the 
expression of β-actin after 6 h (black column) and 24 h (grey column). The dashed line indicates from what 
concentration onwards genistein concentrations superinduction is observed. 
 
Genistein at concentrations above 1 µM increased the luciferase activity. Therefore, in 
subsequent experiments we used a cell-free biochemical assay to measure the interaction 
between genistein and the luciferase protein. In  order to investigate whether genistein and 
other compounds causing superinduction may act through interacting with the luciferase 
enzyme thereby ultimately stabilising the enzyme, increasing concentrations of genistein, 
estradiol and resveratrol,  another phytoestrogen that induces superinduction, were incubated 
with a known and constant concentration of pure firefly luciferase protein.  
 BA 
 
Figure 8: Genistein and resveratrol inhibit firefly luciferase activity. A) Firefly luciferase activity  after co-
incubation with increasing concentrations of genistein (■) or resveratrol (●) or B) with estradiol. Data points 
represent the mean of triplicate exposure ± standard deviation. The dashed line indicates from what 
concentration onwards genistein concentrations superinduction is observed. 
 
The firefly luminescence read-out was dose-dependent with an inhibition of the 
enzymatic reaction at concentrations above 1µM for genistein and resveratrol (Figure 8A), 
whereas bioluminescence was unaffected by estradiol (Figure 8B).  
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Discussion 
In recent years, several in vitro assays have been developed to assess estrogenic activity 
of chemicals and naturally occurring compounds. From those, several reporter gene assays 
showed higher transactivation activities, or induction of the reporter gene, for genistein 
compared to E2. This effect was often called superagonism or superinduction, and, although 
the mechanism underlying the phenomenon is still unrevealed, it is often suggested that it 
might be biologically relevant (9). The present study investigated possible mechanisms 
behind this superinduction thereby at the same time addressing its biological importance. 
 
The first hypothesis tested the possibility that the induction of the reporter gene was not 
ER-mediated. Hence, using the ERα-U2OS-Luc cell line, cells were exposed to E2 and 
genistein in the absence and presence of potent ERα antagonists (ICI 182,780 or RU58668). 
Using a concentration of the ERα antagonist that fully blocks luciferase induction mediated 
by E2-ERα (5 nM), the induction of luciferase was only blocked at low genistein 
concentration while at high concentrations, this was only possible with increased antagonist 
concentration (100 nM). The same effect was obtained when using the T47D-Luc cell line, 
another luciferase reporter gene assay based on a cell line that expresses endogenous ERα. 
Therefore, it is concluded that induction of luciferase is ER-mediated. The different 
sensitivity of the two phases of luciferase induction by genistein suggests that both processes, 
although apparently both dependent on ERα mediated luciferase induction, proceed by 
mechanisms that are at least in part dissimilar and displaying different affinities for genistein. 
 
On the other hand, genistein induces superinduction of the reporter gene in the U2OS-
Luc and T47D-Luc cell lines that is not reflected at cell proliferation level. No 
“superproliferation” was observed in the T47D cell line. This shows that the phenomenon of 
superinduction is not reflected in this biologically relevant endpoint.  
 
The next hypothesis tested, was whether the superinduction was not due to genistein but 
to an in vitro formed metabolite. This hypothesis originated from the observation that a 
metabolite was formed at the genistein concentration where superinduction is maximal. The 
biological activities observed in in vitro or in vivo studies are often assumed to originate from 
the parent compounds that are examined, although these may have been subject to 
biotransformation into one or more structurally different compounds (23, 24). A number of 
genistein metabolites have been identified (25-27) but most of them have been shown to be 
less estrogenic than genistein (28, 29). The data presented in this study showed metabolite 
formation at high genistein concentrations, starting at 0.5 µM and strongly increasing at 
concentrations up to 5 µM, in the in vitro tests using U2OS and T47D cells. Orobol, or 
5,7,3',4'-tetrahydroxyisoflavone, was identified as a main oxidative metabolite, which is in 
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agreement with previously reported data that hydroxylated metabolites of genistein are the 
most abundant metabolites in vitro (30) and that the primary oxidative metabolite of genistein 
is orobol (20, 25). 
 
Therefore, genistein and orobol were tested in the ERα-U2OS-Luc cells, but also in a 
metabolically inactive yeast estrogen bioassay which uses another reporter gene than 
luciferase, namely enhanced green fluorescence protein. Additionally, genistein and orobol 
were measured in another yeast estrogen bioassay using β-galactosidase as a reporter gene. 
Both compounds were able to show a dose-response curve in the yeast based estrogen 
bioassays, but neither genistein nor orobol was able to show the superinduction as observed 
in the ERα-U2OS-Luc and T47D-Luc assays. In addition, it was shown that also orobol 
induced superinduction in the ERα-U2OS-Luc. As orobol does not give rise to higher 
maximal induction of the reporter genes than genistein, and especially because orobol is less 
potent than genistein, it can be concluded that orobol is not responsible for the observed 
superinduction by genistein.  
 
Overall, superinduction by genistein and orobol is especially observed in the luciferase 
reporter gene assays, and more importantly reporter gene assays using luciferase from firefly 
as the reporter protein (8-12).  
 
The data obtained can also be used to disregard another hypothesis for the superinduction. 
We show that the superinduction is not likely to be due to the up-regulation of the ER, as 
there was no difference between the ERα-U2OS-Luc and T47D-Luc. The T47D-Luc assay 
uses the endogenous expressed ER which could in theory be upregulated by normal 
physiological mechanisms, while the yeast and U2OS cells use a receptor construct that 
induces a strong and constitutive expression of the human ERα.  
 
Therefore, the next step was to actually verify whether or not the increased firefly 
luciferase activity was a true reflection of increased transciptional activity. Therefore, mRNA 
expression of the firefly luciferase gene was measured in ER-U2OS-Luc cells after 6 and 
24 hours exposures to E2 and genistein. After 6 hours exposure, the maximum induction of 
firefly luciferase at the transcript level was significantly higher for estradiol than for 
genistein-treated cells. At 12 pM E2 luciferase mRNA levels were about 3-fold higher than at 
5 µM genistein, a concentration shown before to result in clear superinduction when 
quantified on the basis of luciferase reporter gene activity. At 24 hours, the time of 
bioluminescent luciferase activity measurements in the ERα-U2OS-Luc reporter gene assay, 
very low induction levels of luciferase transcription were remaining. These data indicated 
that the superinduction detected by measuring luciferase activity is not a reflection of real 
mRNA induction and should more likely be ascribed to a phenomenon that leads to 
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prolonged enzyme activity without the need for increased transcription levels. Therefore, we 
tested the potential of genistein to act as a stabilizer of the luciferase reporter enzyme. 
 
We evaluated the possible direct interaction of genistein with the reporter enzyme 
leading to stabilisation (decreased degradation) of the enzyme. It has been proposed that 
certain compounds directly bind to, and stabilize, the firefly luciferase reporter enzyme 
thereby increasing its half-life (31, 32).  The interaction between the bioactive chemicals and 
the luciferase results in inhibition of the enzyme activity at the same time resulting in 
stabilisation of the enzyme (33, 34). These luciferase-stabilizing compounds are referred to in 
the literature as luciferase inhibitors (34). An accumulation of stabilized luciferase reporter 
enzyme will enhance the observed bioluminescence activity. Superinduction effects have 
been reported for other estrogenic compounds, e.g. the flavonoid resveratrol, and in all cases, 
this was specifically reported in firefly luciferase cell-based assays (9, 35, 36). Thus, in a 
cell-free biochemical assay, the possible interaction between genistein, E2 and resveratrol 
with firefly luciferase was investigated. We observed that resveratrol and genistein but not 
estradiol can specifically inhibit the bioluminescent enzymatic reaction of the firefly 
luciferase. Inhibition of the bioluminescence has been suggested to result from direct 
competitive inhibition of the enzymatic reaction (31). It can be expected that upon rupture of 
the cells the inhibitor will dissociate leading to increased activity of the luciferase enzyme 
due to this stabilising effect. Thus, genistein at concentrations above 1 µM may interact with 
luciferase thereby stabilising the enzyme so that upon lysis of the cells and dissociation of 
genistein from the enzyme due to dilution, increased activity can be measured as compared to 
the situation without an added stabiliser/inhibitor. It has been recently shown, that a series of 
bioactive compounds, that inhibit and thereby stabilise the firefly luciferase enzyme will 
result in an increased luminescence signal (33).  
 
In conclusion, the data presented in this study strongly indicate that the superinduction 
caused by genistein can be ascribed to stabilization of the firefly luciferase reporter enzyme 
increasing the bioluminescent signal during the cell-based assay. This indicates that the 
phenomenon may not be biologically relevant but may rather represent a post-transcriptional 
effect on enzyme stability. 
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Abstract 
The present study addresses, by transcriptomics and quantitative SILAC-based 
proteomics, the estrogen receptor alpha (ERα) and beta (ERβ)-mediated effects on gene and 
protein expression in T47D breast cancer cells exposed to the phytoestrogen genistein. Using 
the T47D human breast cancer cell line with tetracycline-dependent ERβ expression (T47D-
ERβ), the effect of a varying intracellular ERα/ERβ ratio on genistein-induced gene and 
protein expression was characterised. Results obtained reveal that in ERα-expressing T47D-
ERβ-expression cells genistein induces transcriptomics and proteomics signatures pointing at 
rapid cell growth and migration by dynamic activation of cytoskeleton remodeling. The data 
reveal an interplay between integrins, focal adhesion kinase (FAK), CDC42 and actin 
cytoskeleton signaling cascades, occurring upon genistein treatment, in the T47D-ERβ breast 
cancer cells with low levels of ERα and no expression of ERβ. In addition, data from our 
study indicate that ERβ-mediated gene and protein expression counteracts ERα-mediated 
effects, because in T47D-ERβ cells expressing ERβ and exposed to genistein transcriptomics 
and proteomics signatures pointing at a clear downregulation of cell growth and induction of 
cell cycle arrest and apoptosis was demonstrated. These results suggest that ERβ decreases 
cell motility and metastatic potential as well as cell survival of the breast cancer cell line. It is 
concluded that the effects of genistein on proteomics and transcriptomics endpoints in the 
T47D-ERβ cell model are comparable to those reported previously for estradiol, with the 
ultimate estrogenic effect being dependent on the relative affinity for both receptors and on 
the receptor phenotype (ERα/ERβ ratio) in the cells or tissue of interest.  
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Introduction  
At present two main estrogen receptors, ERα and ERβ, have been identified in rats, mice, 
primates and humans (1). Different biological responses may occur when an estrogen binds to 
the different estrogen receptors (ERs). Several studies have shown decreased ERβ expression 
in malignant cancer tissues as compared to benign tumours or normal tissues, where ERα 
expression persists (2-6). Hence ERα and ERβ may have different roles in gene regulation 
and their relative levels or ratios within the tissues may influence cellular responses to 
estrogens. To understand the critical role of estrogens in the regulatory cascade involved in 
the progression of breast cancer, several studies focused on the evaluation of global 
transcriptomics and showed the association of ERα activation with cell proliferation and the 
opposing effects for activation of ERβ (7-9). So far, most of these “omics” studies focused on 
estrogens like estradiol but did not yet widely include so-called phytoestrogens.  
 
Phytoestrogens are a group of plant-derived compounds with estrogenic properties (10). 
The major types of phytoestrogen are isoflavones, flavones, coumestans, lignans and 
stilbenes. Among the most studied flavonoids with respect to anti-tumour functions are 
genistein and quercetin. Phytoestrogens have been considered a natural alternative to the 
hormone replacement therapy since these chemicals are found in the regular diet (11). 
Genistein is mostly present in soybeans. High consumption of phytoestrogen-rich food 
correlates with reduced incidence of breast cancer (12). These two flavonoids, genistein and 
quercetin, have been shown to have potent anti-proliferative effects on tumour cells by 
halting the cell cycle and inducing apoptosis (13-15). However, what effects are induced by 
phytoestrogens and which mechanisms are activated in cells remains to be elucidated. 
Therefore the aim of the present study was to provide “omics” data on the effects of the 
phytoestrogen genistein in cells with variable intracellular ratio of the two estrogen receptors 
ERα and ERβ and to compare these outcomes qualitatively to those reported earlier for 
estradiol (8). 
 
The importance of the intracellular ratio of the two estrogen receptors ERα and ERβ for 
the ultimate potential of estradiol and of the phytoestrogen genistein to stimulate or inhibit 
cell proliferation was demonstrated previously (16, 17). Using the human T47D breast cancer 
cell line with tetracycline-dependent ERβ expression (T47D-ERβ), the effect of a varying 
intracellular ERα/ERβ ratio on estradiol- or genistein-induced cell proliferation was 
characterized (17). With increased expression of ERβ, estrogen-induced ERα-mediated cell 
proliferation was reduced. These results point at the importance of the cellular ERα/ERβ ratio 
for the ultimate effect of (phyto)estrogens on cell proliferation. The results of our previous 
studies also revealed that in this T47D-ERβ model system the effects of genistein on cell 
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proliferation with varying cellular ERα/ ERβ ratios were comparable to the effects induced by 
estradiol itself (17, 18).  
 
In the present study we investigated the consequences of the intracellular ERα/ERβ ratio 
for the effects induced by genistein in more detail using quantitative “omics” technologies, 
characterizing both gene and protein expression patterns and compared the results obtained to 
those previously reported for estradiol in the same model system (8). To this end, state-of-
the-art high-throughput methods for systems-wide gene and protein expression analysis were 
applied. These methods included DNA microarrays, commonly used for global analysis of 
gene expression changes. In addition we applied stable isotope labeling by amino acids in cell 
culture (SILAC) which is a differential and quantitative proteomics technique that uses mass 
spectrometric (MS) analysis (19). The SILAC strategy is based on the metabolic 
incorporation of “light” (normal) and “heavy” (isotope-labeled) amino acids into the cells, 
which is a process shown to occur without adverse effects on cellular physiology (20). Full 
metabolic incorporation of the labeled amino acids into the proteins results in a mass shift of 
the corresponding peptides. This mass shift can be detected by MS. When two samples are 
combined, the ratio of peak intensities in the MS reflects the relative protein abundance. 
Since the metabolic incorporation of the labels does not affect the integrity of genes or 
proteins, the transcriptomics and SILAC proteomics experiments can be performed on the 
same cell samples.  
 
The data obtained from our proteomics and transcriptomics studies indicate that genistein 
induces rapid cell proliferation and migration by dynamic activation of cytoskeleton 
remodeling in the T47D-ERβ cells expressing low levels of ERα and no ERβ. Interaction 
between integrins, focal adhesion kinase (FAK), CDC42 and actin cytoskeleton signaling 
cascades occurs upon genistein treatment supporting the observed cell proliferation. Our 
results also strengthen the concept that ERβ mediated gene and protein expression 
counteracts ERα-mediated effects, because in T47D-ERβ cells expressing ERβ and exposed 
to genistein a clear downregulation of genes and proteins involved in cell growth and 
induction of cell cycle arrest and apoptosis was demonstrated.  
 
Materials and methods 
Cell culture: The stably transfected T47D tetracycline-inducible cell line (T47D-ERβ) 
and the control cell line (T47D-PBI) were made and provided by Ström (16). DMEM SILAC 
medium lacking arginine (Arg) and lysine (Lys), supplemented with 5% of dialyzed fetal 
bovine serum and 1000 ng/ml tetracycline (Tet) was used. Arg and Lys, either “light” or 
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“heavy” depending on the experimental design, were incorporated in the DMEM SILAC 
medium. The final concentrations of Arg and Lys were 21 and 48 mg/L respectively (21). 
 
During the adaptation phase, cells were grown in “light” or “heavy” SILAC media, 
containing respectively 12C614N4-arginine and 12C614N2-lysine or 13C6-15N2-lysine and 
13C6-15N4-arginine, until the cells grown in “heavy” medium had fully incorporated the 
labeled amino acids. Full incorporation of labels into the cells was checked by MS analysis 
(22) of cell samples detecting the time point at which there was no further increase in the 
amount of label incorporated. Full incorporation of labels for the T47D-ERβ cells without 
ERβ expression (Tet containing) was observed after 5 doubling times or 10 days of 
cultivation (data not shown). Preparation of the samples after this adaptation phase, was 
performed as follows. Cells in (SILAC) DMEM medium supplemented with 5% dialyzed-
fetal bovine serum (DFBS) and 1000 ng/ml Tet were seeded in plates for 24 h. After 24 h 
DMEM SILAC medium was replaced by the same medium without phenol red, containing 
the required concentrations of Tet, heavy or light amino acids, and a serum concentration that 
was reduced to 0.5% DFBS. To this, 10 nM ICI 182780 was added for cell synchronization 
(8) and Tet was withdrawn in half of the plates all 12 h before the start of the treatment to 
allow expression of ERβ. The Tet+ and Tet- cultures were incubated with either 10 nM of the 
ERα and ERβ antagonist ICI 182780 (23) or 500 nM of genistein for 24 h according to the 
experimental design (Table 1A) after which all cells were collected simultaneously for RNA 
and protein extraction. Three replicates of each sample were prepared in parallel to minimize 
experimentally induced variability. 
 
Table 1: Experimental design of the present study based on five cellular samples prepared as depicted in Table 
1A) and their  pairwise comparison carried out as presented in Table 1B. 
 
1A) 
 Strain Tetracycline Treatment  
ERβ 
expression  
Compound 
treatment 
No. of samples 
Transcriptomics 
/proteomics 
Label 
A T47D-ERβ yes no ICI 182780 3 / 3 Light 
B T47D-ERβ no yes ICI 182780 3 / 3 Heavy 
C T47D-ERβ yes no genistein 3 / 3 Heavy 
D T47D-ERβ no yes genistein 3 / 3 Light 
E T47D control no no genistein 3 / 3 Heavy 
 
1B)  
Sample Targets 
CA Genistein modulated ERα mediated gene and protein  expression 
DB Genistein modulated ERβ mediated  gene and protein expression 
ED Genistein modulated ERβ mediated gene and protein  expression (second approach) 
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Table 1A summarizes the experimental design applied in order to obtain information on 
the genistein induced levels of gene and protein expression in T47D cells with variable 
ERα/ERβ ratios. Table 1A presents the five different samples prepared, indicating the cell 
line used, the Tet treatment and resulting ERβ expression, exposure to ICI 182780 or 
genistein and the amino acid label (light or heavy) added to the growth medium. In addition 
to genistein, ICI 182780 was used in order to block the receptors thereby suppressing 
receptor-mediated transcription. A control cell line (T47D-PBI) was used to define genistein 
induced non-ERβ mediated gene expression inherent to the cell system used. Table 1B 
presents the pairwise comparisons made using these five samples in order to analyze i) 
genistein induced ERα mediated gene and protein expression (C versus A, referred to as 
sample CA); ii) genistein induced ERβ regulated gene and protein expression in the presence 
of endogenous levels of ERα (D versus B, referred to as sample DB) and iii) a second 
approach to detect genistein induced ERβ mediated gene and protein expression in the 
presence of endogenous levels of ERα (E versus D, referred to as sample ED).  
 
Protein and RNA preparation: Each sample was split in two, one for RNA and one for 
protein preparation. RNA was extracted using the TRIzol precipitation method and purified 
using an RNeasy mini kit protocol for second RNA clean up (RNeasy mini kit, Qiagen). 
Approximately 4 µg of total RNA was collected per replicate. 
 
For protein extraction, cells were washed twice with PBS and lysed in modified RIPA 
buffer [50 mM Tris-HCl (pH 7.4), 1 mM EDTA, 150 mM NaCl, 1% Triton X-100, 0.25% 
sodium deoxycholate] containing a protease inhibitor cocktail (Complete, Mini, Roche) at 4° 
C for 15 min. Samples were sonicated for 1 min and centrifuged at 14000 g for 15 min at 4° 
C, and the supernatant was collected. Equal amounts of protein (BSA Protein Assay Kit, 
Pierce) from each sample were mixed in a ratio of 1:1 according to the experimental design 
presented in table 1A and 1B, and 1 µg of the protein sample thus obtained was separated on 
a 12% Tris-glycine sodium dodecyl sulfate-polyacrylamide gel by electrophoresis (SDS-
PAGE), followed by staining of the SDS gel using colloidal Coomassie blue (Colloidal blue 
staining kit, Invitrogen). Then the resulting 3 gel lanes per replicate (CA, DB and ED) were 
excised and cut horizontally into 8 equal sections per lane. In-gel digestion was performed as 
follows: The SDS gel was destained by two washes with water. Cysteine reduction was 
performed by adding 100 µl 50 mM DTT (dithiotreitol) in 50 mM NH4HCO3. Samples were 
sonicated for 1 min and incubated at 60°C without shaking for 1 h.  Alkylation was 
performed when samples reached room temperature, replacing DDT by 100 µl of 50 mM 
iodoacetamide in 50 mM NH4HCO3. Samples were sonicated for 1 min and alkylated at 
room temperature in the dark for 1 h. The gel pieces were washed three times with 100 µl 50 
mM NH4HCO3 at pH 8. For proteolytic digestion, samples were treated overnight with 100 
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µl trypsin (10 ng/µl in 50 mM NH4HCO3, sequencing grade, Boehringer Mannheim) at room 
temperature. Gel fragments were removed by centrifugation and the proteolytic peptides were 
recovered in the supernatant fraction (25 µl). 10% Trifluoracetic acid  was added to correct 
the pH up to 2 to 4. Finally all extracts were measured by LC-MS/MS. 
 
Data acquisition, Mass Spectrometry: The protein samples were analyzed by injecting 
18 µl sample over a 0.10 *  32 mm Prontosil 300-5-C18H (Bischoff, Germany) pre-
concentration column (prepared in house) at a flow of 6 µl/min for 5 min with a Proxeon 
EASY nLC system. Compounds were eluted from the pre-concentration column onto a 0.10 *  
250 mm Prontosil 300-3-C18H analytical column (prepared in house) with an acetonitril 
gradient at a flow of 0.5 µl/min. The gradient consisted of an increase from 9 to 34% 
acetonitril in water with 1ml/l formic acid in 50 min followed by a fast increase in the 
percentage acetonitril to 80% (with 20% water and 1 ml/l formic acid in both the acetonitril 
and the water) in 3 min as a column cleaning step.  In between the pre-concentration and the 
analytical column, an electrospray potential of 3.5 kV was applied directly to the eluent via a 
solid 0.5 mm platina electrode fitted into a P777 Upchurch microCross. Full scan positive 
mode FT-MS spectra were measured between m/z 380 and 1400 at resolution 60.000 on an 
LTQ-Orbitrap (Thermo electron, San Jose, CA, USA). MSMS scans of the four most 
abundant doubly or triply charged peaks in the FTMS scan were recorded in data dependent 
mode in the linear trap (MSMS threshold = 10.000). Data were acquired using Xcalibur 
software. 
 
Protein identification and quantitation: Mass spectra were analyzed using MaxQuant 
(version 1.0.13.8), which performs e.g. list generation, ratio H/L significance A, ratio H/L 
significance B, SILAC- and extracted ion current (XIC)-based quantification, false positive 
rate and data filtration (24). Data were searched against the human international protein index 
(IPI) database supplemented with frequently observed contaminants and concatenated with 
reversed copies of all sequences (total 148380 sequences) using Mascot v2.2 (Matrix 
Sciences). Spectra determined to result from heavy labeled peptides by pre-search Maxquant 
analysis were searched with the additional fixed modifications Arg10 and Lys8, whereas 
spectra with a SILAC state not defined a priori were searched with Arg10 and Lys8 as 
additional variable modifications. Precursor mass tolerance was set at 10 ppm for the 
complete peptides and 0.5 Da for peptide fragments as observed in the MS2 spectra. 
Trypsin/P cleavage specificity with up to 2 missed cleavage and three labeled amino acids 
(Arg and Lys) were allowed. The required false discovery rate was set to 1% at the protein 
level, and the minimum required peptide length was set to 6 amino acids. Carbamidomethyl 
cysteine was set as a fixed modification and methionine oxidation, deamidation (NQ), and 
acetylation of the N-terminus (protein) were allowed as variable modifications. For protein 
identification, at least two peptides were required, among which at least one peptide was 
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required to be unique in the database. Identified proteins were quantified. Protein ratios 
calculated by MaxQuant were subjected to manual inspection and results obtained compared 
with those from MSQuant software (version 1.5). Further analysis and plotting were 
performed using the R statistical and graphic environments. 
 
Microarray: Integrity and quantity of the extracted RNA was assessed by using an 
Agilent 2100 Bioanalyzer (Agilent, Palo Alto, CA) and the Nanodrop ND-1000 
spectrophotometer (Nanodrop Technologies Inc., DE, USA). cRNA was prepared according 
to the manufacturer’s protocol and hybridized to HG-U133 plus 2.0 GeneChip arrays 
(Affymetrix, Santa Clara, CA, USA). HG-U133 plus 2.0 arrays contain 54.675 sets of 
oligonucleotide probes or probesets. Data were  analyzed based on a mapping to ~17500 
unique human genes with Entrez Gene annotation. 
 
Calculations and statistics: Microarray results were processed in R (http://www.r-
project.org) using gcRMA and filtered using MAS5 calls. Ratios were calculated using limma 
in R, applying moderated t-tests, and were adjusted for multiple testing. The reported ratios 
describing biological effects of interest were calculated as indicated in table 1A and 1B. 
 
Bioinformatics Network Analysis: A cutoff P value ≤ 0.001 (Ratio H/L or L/H) was 
selected for analysis of differentially expressed proteins and a multiple testing adjusted p-
value ≤ 0.05 for differentially regulated genes was used. Ingenuity Pathway Analysis 8.5 
(Ingenuity Systems Inc.) was used to conduct a knowledge-based network analysis, a 
molecular and cellular functions analysis, and a canonical pathway analysis of the proteomics 
and transcriptomics data. Ingenuity Pathway Analysis tools rely on curated functional and 
regulatory interactions extracted from literature. The biological functions across ER-
responsive genes and proteins were identified. Fischer’s exact test was used to calculate a p-
value determining the probability that each biological function assigned to that dataset of ER-
responsive genes/proteins is due to chance alone.  
Results 
Optimization of the experimental protocol and receptor expression. 
T47D cells were previously stably transfected with the ERβ expression plasmid under Tet-
responsive promoter regulation (16). Cells were grown in medium containing light or heavy 
amino acid labels according to the experimental design presented in table 1. After 10 days 
pre-incubation, the MS analysis of cell samples revealed that isotope incorporation did not 
further increase reflecting optimal full metabolic incorporation and indicating that the cells 
were ready for the exposure phase. Cell treatment was performed as indicated by Williams 
and co-workers to be able to compare genistein effects with their results for estradiol in the 
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same cell system and under the same conditions (8). Consequently, after cell synchronization 
by exposure to ICI 182780 cells were exposed to either ICI 182780 or genistein.  
 
ERβ expression in the T47D control cell lines and the T47D-ERβ cell samples pretreated 
in the presence or absence of Tet was checked by fluorescence microscopy (Enhanced Green 
Fluorescence Protein co-expression under control of the same Tet-responsive promoter (16) 
and mRNA quantification (Figure 1). ERβ mRNA levels were undetectable in Tet+ samples 
or the control cell line (no endogenous or exogenous ERβ). LC-MS/MS measurements 
detected high levels of ERβ protein in all Tet- samples (see below). 
 
A                  B 
 
 
 
 
 
 
 
 
 
Figure 1: Estrogen receptor beta (ERβ) expression. A) Mean expression intensities of ERβ at mRNA level based 
on microarray normalized results under five different conditions, Tet+ and ICI (sample A, Table 1A), Tet- and 
ICI (sample B, Table 1A), Tet+ and genistein (sample C, Table 1A), Tet- and genistein (sample D, Table 1A), 
and Tet- in control cell line (T47D-PBI) and genistein (sample E, Table 1A). B) Picture of cells (upper) and 
green fluorescent protein (EGFP) detection (lower) of Tet+ (left) and Tet- (right) cultured cells treated with 
genistein. 
 
Expression of ERα was not found at protein level using LC-MS/MS. However using an 
ERα ELISA (ActiveMotif sandwich ELISA), ERα could be detected in all the experimental 
samples (Figure 2) at expression levels of 6-10% of the levels observed in the wild-type 
T47D cells (not treated with ICI 182780). 
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A                 B 
 
Figure 2: A) ActiveMotif sandwich ERα ELISA. Amounts of intact ERα from SILAC samples were compared 
with the ERα from untreated wild type T47D. Percentage of expression of three measurements of ERα protein 
under five different conditions, Tet+ and ICI (sample A, Table 1A), Tet- and ICI (sample B, Table 1A), Tet+ 
and genistein (sample C, Table 1A), Tet- and genistein (sample D, Table 1A), and Tet- in control cell line 
(T47D-PBI) and genistein (sample E, Table 1A). B) Mean expression intensities of ERα at mRNA probe level 
based on microarray normalized results under  the five different conditions. 
 
Protein identification and quantitation. 
Corresponding light and heavy samples were mixed in a 1 to 1 ratio, according to the 
experimental design providing three data sets (CA, DB and ED, Table 1B). On average, 2600 
proteins were identified per data set (2616 in sample CA, 2543 in DB and 2627 in ED). From 
these, for about 1950 proteins, relative quantification data with at least 2 identified peptides 
per experiment were obtained (1994 in sample CA, 1905 in DB and 1995 in ED). For 
proteins for which corresponding peptides were only detected in the heavy data set but not in 
the light data set, hampering calculation of an H/L ratio, the H/L ratio was set to the largest 
H/L ratio determined in the whole data set. Likewise, for proteins for which corresponding 
peptides were only detected in the light data set but not in the heavy data set, also hampering 
calculation of an H/L ratio, the H/L ratio was set to the smallest H/L ratio in the whole data 
set. This enabled comparison of the proteomic results to results obtained with the microarray 
or to find de novo regulated proteins.  
 
 The ratio distributions obtained from each experiment (CA, DB and ED) are displayed 
in figures 3A, 3B and 3C. The spread of the cloud is lower at high protein abundance (higher 
intensity on Y-axis), which indicates higher precision in the quantification. Notably, higher 
spread of the cloud in the X-direction (ratio (log2)) was observed during ERβ expression 
indicating bigger fold changes in protein expression levels. 
 
Differentially expressed proteins were selected using a cut-off confidence level of ratio 
H/L or L/H Significance B ≤ 0.001. In a next step we used canonical pathways, molecular 
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and cellular function classification from Ingenuity pathway analysis (IPA) to identify 
overrepresented biological themes among these differentially expressed genes and proteins. 
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Figure 3: Proteome-wide accurate quantification significance in A) ERα-mediated proteins expressed as a result 
of genistein treatment (sample CA, table 1B). Normalized protein ratios (H/L) are plotted against summed 
peptide intensities. Left side of the plot shows proteins upregulated in the sample cultured in Light (L) amino 
isotope conditions: ERα(+) ERβ(-) and ICI 182780; Right side of the plot shows proteins upregulated in the 
sample cultured in Heavy (H) amino acid isotope conditions: ERα(+) ERβ(-) and genistein. B) ERβ-mediated 
proteins expressed as a result of genistein treatment (sample DB, Table 1B). Normalized protein ratios (H/L) are 
plotted against summed peptide intensities. Left side of the plot shows proteins upregulated in the sample 
culture in Light (L) amino isotope conditions: ERα(+) ERβ(+) and genistein; Right side of the plot shows 
proteins upregulated in the sample culture in Heavy (H) amino isotope conditions: ERα(+) ERβ(+) and ICI 
182780. C) Second approach to detect ERβ-mediated proteins expressed as a result of genistein treatment 
(sample ED, table 1B). Normalized protein ratios (H/L) are plotted against summed peptide intensities. Left side 
of the plot shows proteins upregulated in the sample culture in Light (L) amino isotope conditions: ERα(+) 
ERβ(+) and genistein; Right side of the plot shows proteins upregulated  in the sample culture in Heavy (H) 
amino isotope conditions: ERα(+) ERβ(-) and genistein in the T47D-PBI cell line. The spread cloud is lower at 
high abundance, indicating that quantification is more precise. The data points are colored by their “significance 
B” (intensity-dependent p-value), with dark blue circles having values > 0.05, light blue circles between 0.05 
and 0.001, yellow circles between 0.001 and 1E-11 and red circles <1E-11. 
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Genistein modulated protein expression in the absence of ERβ (sample CA). 
To determine the genistein induced ERα-mediated effects on protein expression levels, 
cells grown in heavy amino acid isotope containing medium were treated for 24 h with 500 
nM genistein whereas cells grown in light amino acid isotope containing medium were 
treated for 24 h with 10 nM of the ER antagonist ICI 182780, in both cases in the presence of 
Tet therefore without the expression of ERβ (sample CA, table 1A-B). This process resulted 
in the identification of 1994 proteins with at least two unique peptides. The results obtained 
showed small changes for most proteins (Figure 3A). Based on the statistical selection criteria 
(Significance B ≤ 0.001) the data revealed 59 SILAC proteins to be significantly regulated 
(Table 2).  
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Figure 4: Molecular and cellular functional classes affected by genistein induced ERα-mediated effects on 
protein expression (sample CA, Table 1B). IPA was based on molecular and cellular functions of the H/L 
proteins with a P value <0.001. Selected scoring method was based on Fisher’s exact test p-value. The high-
level functional categories that are involved in this analysis are displayed along the x-axis in decreasing order of 
significance. The y-axis displays the -(log) significance. The horizontal line denotes the cutoff for significance 
(p-value of 0.05). 
 
Functional analysis (see materials and methods) of the proteins in this data set revealed 
that the major biological functions that were affected (increased or decreased) by genistein 
included cellular function and maintenance, cell death, cellular assembly and organization, 
cell movement, cell morphology, lipid metabolism or cell cycle (Figure 4). Most of the 
proteins belonging to these functional classes were upregulated, whereas downregulated 
proteins were categorized in the classes representing cell death and lipid metabolism (Table 
2). Notably, five of the most upregulated proteins upon genistein-induced ERα-mediated 
protein expression were myosins (MYH10, MYH14, MYL12B, MYH9 and MYL6). The 
majority of these myosins are actively involved in cell assembly and organization, or 
cytoskeleton reorganization. Among the several significantly downregulated proteins we 
found at least three proteins, S100A8, S100A9 and PIP, of specific interest since their 
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expression is associated with a decrease of cell proliferation and induction of apoptosis (25, 
26). The two S100 EF-hand calcium-binding proteins S100A8/A9 induce apoptosis in various 
cells, especially tumor cells like MCF7 (25).  
 
Table 2: The most significant ERα-mediated proteins as a result of genistein treatment (sample CA, Table 1B), 
only H/L SILAC pairs protein list. 
 
Gene 
Names Protein Names 
Ratio 
 H/L 
Normalized 
Ratio 
Significance 
Ratio 
H/L 
Count 
Sequence 
Coverage 
[%] 
NFAT5 NFAT5 protein 3.9151 8.32E-28 2 1.5 
NBN Nibrin 1.7846 1.02E-06 2 5.3 
TTBK2 Tau-tubulin kinase 1.7012 1.26E-16 2 2.9 
MYH10 Myosin-10 1.5769 2.11E-07 14 15.5 
CCDC25 Coiled-coil domain-containing protein 25 1.5499 0.00013085 2 11.1 
MGP Matrix Gla protein 1.521 1.53E-06 5 23.3 
TMEM120A Transmembrane protein 120A 1.5178 0.00024373 2 3.2 
MYH14 Myosin-14 1.5152 0.00025613 3 4.6 
MRPL20 39S ribosomal protein L20, mitochondrial 1.5095 0.0002857 2 12.8 
KRT18 Keratin, type I cytoskeletal 18 1.4982 2.90E-18 230 91.9 
MYL12B Myosin regulatory light chain MRCL3 variant 1.4819 5.81E-06 8 37.3 
KRT8 Keratin, type II cytoskeletal 8 1.4635 2.30E-16 545 86.1 
KRT19 Keratin, type I cytoskeletal 19 1.4508 1.10E-15 246 95.5 
MYH9 Myosin-9 1.4135 9.37E-14 269 63.9 
MYL6 Myosin light polypeptide 6 1.3405 3.34E-06 22 61.6 
ASNS Asparagine synthetase [glutamine-hydrolyzing] 1.3256 0.00074994 4 8.9 
SLC7A5 Large neutral amino acids transporter small subunit 1 1.2556 0.00024142 6 6.7 
FAM129A Protein Niban 1.2546 0.00025301 6 9.2 
RCN1 Reticulocalbin-1 1.2251 0.00093813 7 18.4 
NPM1 Nucleophosmin 1.2138 3.04E-05 71 64.6 
LOC130773   similar to 60S ribosomal protein L23a 1.1925 0.00014684 5 30.6 
SLC3A2 4F2 cell-surface antigen heavy chain 1.1855 0.00024133 54 28.7 
HIST1H1C Histone H1.2 1.1649 0.00095077 48 39.9 
RPS25 40S ribosomal protein S25 0.85955 0.0001805 24 55.2 
RPS16 40S ribosomal protein S16 0.81669 1.37E-06 41 61 
TPR Nucleoprotein TPR 0.81623 0.00058563 22 9.7 
NPC2 Epididymal secretory protein E1 0.80913 0.00035735 16 35.3 
VAT1 Synaptic vesicle membrane protein VAT-1 homolog 0.80802 0.00032994 16 35.1 
BCKDHA 
cDNA FLJ45695 fis, clone FEBRA2013570, highly similar 
to 2-oxoisovalerate dehydrogenase alpha subunit, 
mitochondrial (EC 1.2.4.4) 
0.80718 0.00031066 8 16.1 
ACTBL2 Beta-actin-like protein 2 0.78565 1.53E-08 9 21.8 
RPS18 40S ribosomal protein S18 0.75035 2.95E-11 40 67.1 
NFS1 Cysteine desulfurase, mitochondrial 0.73481 0.00073737 6 9.4 
- Putative uncharacterized protein ENSP00000384045 (Fragment) 0.73352 0.00069096 2 13.5 
NASP Nuclear autoantigenic sperm protein isoform 2 variant 0.73307 0.00067556 3 7.5 
LMNA Lamin-A/C 0.71605 1.83E-14 102 54.8 
RPS29 40S ribosomal protein S29 0.70426 1.21E-08 5 47.4 
LPP Lipoma-preferred partner 0.6822 3.54E-05 3 8.2 
MAP4 Microtubule-associated protein 4 0.63442 1.02E-06 9 12.7 
THOC2 THO complex subunit 2 0.62342 0.00051663 2 1.4 
NLN Neurolysin, mitochondrial 0.62126 0.00047125 2 3 
CHCHD1 Coiled-coil-helix-coiled-coil-helix domain-containing protein 1 0.61855 0.0004196 2 25.4 
Omics
 
Gene 
Names Protein Names 
Ratio 
 H/L 
Normalized 
Ratio 
Significance 
Ratio H/L 
Count 
Sequence 
Coverage 
[%] 
CHMP2B Charged multivesicular body protein 2b 0.61376 0.00034025 2 4.7 
TOMM40 Mitochondrial import receptor subunit TOM40 homolog 0.61264 3.56E-15 4 10.5 
LMNB1 Lamin-B1 0.56768 1.45E-09 4 12.1 
APLP2 Amyloid-like protein 2 0.56042 2.33E-05 2 4.7 
PIP Prolactin-inducible protein 0.52576 2.73E-06 4 26 
HMGN Non-histone chromosomal protein HMG-14 0.51956 1.79E-06 3 14 
SYAP1 Synapse-associated protein 1 0.51352 1.20E-12 2 7.4 
MOGS Mannosyl-oligosaccharide glucosidase 0.49431 2.80E-07 2 3.8 
HNRNPC Heterogeneous nuclear ribonucleoproteins C1/C2 0.44009 2.22E-09 2 13.4 
SEPHS1 Selenide, water dikinase 1 0.37038 4.08E-56 4 13.3 
POFUT1 GDP-fucose protein O-fucosyltransferase 1 0.35029 1.99E-14 2 4.1 
MYO15A Myosin-XV 0.33393 1.87E-31 2 0.9 
S100A8 Protein S100-A8 0.28004 1.44E-20 2 20.4 
KPRP Keratinocyte proline-rich protein 0.2706 1.29E-21 2 1.6 
FXC1 Mitochondrial import inner membrane translocase subunit Tim9 B 0.15658 4.51E-42 2 24.3 
S100A9 Protein S100-A9 0.15405 5.78E-193 5 26.3 
LGALS7 Galectin-7 0.12058 2.35E-54 2 19.9 
PNKD Probable hydrolase PNKD 0.05602 8.55E-100 3 30.3 
 
Genistein modulated  protein expression in the presence of ERβ (sample DB).  
Proteins induced by genistein in ERα and ERβ expressing cells could be identified 
comparing cells grown in light amino acid isotope containing medium treated with 500 nM 
genistein to cells grown in heavy isotope containing medium exposed to 10 nM of the pure 
ER antagonist ICI 182780, both grown in the absence of Tet thus expressing ERβ (sample 
DB, table 1A-B). This resulted in the identification of 1905 proteins with at least two unique 
peptides. Significant changes observed in protein level after 24 h treatment are depicted in 
Figure 3B. Based on the statistical selection criteria (Significance B ≤ 0.001) the data 
revealed 66 SILAC proteins to be significantly regulated (Table 3). For IPA and further 
analysis inverse ratios were used to allow additional inter-experiment comparisons.  
 
 As reported previously (17), in T47D-ERβ cells grown in the absence of Tet and thus 
expressing both ERα and ERβ, genistein induced cell proliferation was notably reduced as 
compared to genistein induced cell proliferation in T47D cells expressing only ERα. The 
SILAC data of the sample reflect genistein induced upregulation of nine histone related 
proteins (HIST1H4A, HIST1H2AG, H1F0, HIST1H2AB, HIST1H2BN, HIST1H1E, 
HIST1H1B, HIST1H1C and NUMA1) which points at a general downregulation of gene 
transcription (27, 28). In addition, downregulation of TOP2B (Topoisomerase IIβ) was 
significant. Topoisomerases are enzymes that play important roles in transcription, DNA 
synthesis, and chromosome segregation (29). This result is in line with a  previously 
published inhibition of Topoisomerase IIβ by genistein influencing cell growth (30). 
Important proteins belonging to the same signaling network, i.e. interferon signaling 
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pathways (31), were STAT1, MX1, ANXA1, UBE2L6 and ISG15.  Also ANXA3, ANXA1 
and VCL, proteins important for actin cytoskeleton signaling, cell migration and anti-
inflammatory processes (32, 33), were found to be dowregulated by genistein in T47D cells 
expressing both ERα and ERβ. 
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Figure 5: Molecular and cellular functional classes affected by genistein induced ERβ-mediated effects on 
protein expression (sample DB, Table 1B). IPA molecular and cellular functions of the L/H proteins with a P 
value <0.001. Selected scoring method was based on Fisher’s exact test p-value. The high-level functional 
categories that are involved in this analysis are displayed along the x-axis in decreasing order of significance. 
The y-axis displays the -(log) significance. The horizontal line denotes the cutoff for significance (p-value of 
0.05). 
 
 Molecular and cellular function profiling of these data (Figure 5) points at significant 
effects on pathways involved in cell death, cell cycle, cellular assembly and organization, 
DNA replication, recombination and repair, cell growth and proliferation or cellular 
movement. Upregulated proteins by genistein were directly involved in the first three 
categories whereas the downregulated proteins were part of the categories cell movement or 
cell death (Table 3). 
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Table 3: The most significant ERβ-mediated proteins as a result of genistein treatment (sample DB, Table 1B), 
only L/H SILAC pair protein list.  
 
Gene 
Names Protein Names 
Ratio  
L/H  
Normalized 
Ratio 
Significance 
Ratio 
H/L 
Count 
Sequence 
Coverage 
[%] 
FGFR2 Fibroblast growth factor receptor 2 10.47724 1.33E-124 2 2.1 
HIST1H4A Histone H4 7.141837 5.69E-88 7 51.5 
HIST1H2AG Histone H2A 5.420936 8.26E-47 2 27.2 
AD-001 TRM112-like protein 3.275038 5.13E-24 4 32 
SEPHS1 Selenide, water dikinase 1 3.242227 1.22E-23 2 9.2 
ELOVL1 Elongation of very long chain fatty acids protein 1 3.09272 1.72E-12 2 4.3 
PIP Prolactin-inducible protein 2.97274 9.65E-12 4 26 
ARMC10 Armadillo repeat-containing protein 10 2.851521 5.55E-11 2 4.7 
KIAA0753 Uncharacterized protein KIAA0753 2.74198 7.31E-18 2 3.1 
HSD17B8 Estradiol 17-beta-dehydrogenase 8 2.345051 8.49E-08 2 10.7 
HNRNPC Heterogeneous nuclear ribonucleoproteins C1/C2 2.083811 5.49E-14 11 21.9 
PRMT1 Protein arginine N-methyltransferase 1 2.078829 3.24E-10 2 10.8 
MATR3 Putative uncharacterized protein MATR3 2.051366 5.57E-06 2 3 
RNMTL1 RNA methyltransferase-like protein 1 1.955225 2.12E-05 2 2.9 
S100A9 Protein S100-A9 1.939827 2.62E-05 2 13.2 
ESR2 Estrogen receptor beta 1.93304 2.88E-05 3 7.9 
EPHX2 Epoxide hydrolase 2 1.871608 6.24E-08 2 5.2 
RNPEP Putative uncharacterized protein RNPEP 1.750271 0.0003341 2 36.5 
H1F0 Histone H1.0 1.687564 5.23E-06 11 19.6 
HIST1H2AB Histone H2A type 1-B/E 1.686369 1.54E-12 13 35.4 
LAMP2 Lysosomal-associated membrane protein 2C 1.520751 0.0002132 2 1.9 
HIST1H2BN Histone H2B type 1-N 1.518603 1.13E-05 10 25.3 
LMNA Lamin-A/C 1.511624 0.0002583 2 51.2 
ISYNA1 Inositol-3-phosphate synthase 1 1.504959 1.68E-05 14 24.2 
HNRNPUL2 Heterogeneous nuclear ribonucleoprotein U-like 
protein 2 
1.49997 0.0003293 3 3.1 
SLC9A3R1 Na(+)/H(+) exchange regulatory cofactor NHE-RF1 1.497253 2.11E-05 18 34.9 
MUC1 cDNA FLJ60927, highly similar to Mucin-1 1.496468 2.16E-05 16 19.1 
CD9 CD9 antigen 1.494098 0.0003718 3 14.5 
NUMA1 Nuclear mitotic apparatus protein 1 1.491402 3.76E-08 71 35.5 
HIST1H1E Histone H1.4 1.45588 6.87E-05 11 39.7 
TFRC Transferrin receptor protein 1 1.386155 4.75E-06 62 37.2 
HIST1H1B Histone H1.5 1.385003 5.00E-06 40 38.1 
HIST1H1C Histone H1.2 1.314389 9.28E-05 45 45.1 
PYGB Glycogen phosphorylase, brain form 1.298937 0.0001691 24 21.9 
HNRNPA2B1 Heterogeneous nuclear ribonucleoproteins A2/B1 1.272961 0.000447 97 74.5 
ACLY ATP-citrate synthase 0.820075 0.0007347 65 35.6 
COTL1 Coactosin-like protein 0.818666 0.0006644 22 55.6 
EIF4G1 Eukaryotic translation initiation factor 4 gamma 1 0.811886 0.0003983 60 29.8 
CNN2 cDNA FLJ52765, highly similar to Calponin-2 0.808211 0.0002993 27 36.7 
TNKS1BP1 Tankyrase 1 binding protein 1, 182kDa 0.798276 0.0001335 63 31.9 
VCL Vinculin 0.792896 8.39E-05 98 61 
REEP5 Receptor expression-enhancing protein 5 0.786225 4.62E-05 25 34.4 
CYB5A Cytochrome b5 0.770594 0.0006788 10 47 
FLNA Filamin-A 0.768285 8.22E-06 239 53.9 
PPL Periplakin 0.761325 0.0003987 34 17.3 
NFKB2 Nuclear factor NF-kappa-B p100 subunit 0.753977 0.0009489 5 5.1 
MAP4 Microtubule-associated protein 4 0.742666 0.0005389 4 6 
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Names Protein Names 
Ratio  
L/H  
Normalized 
Ratio 
Significance 
Ratio 
H/L 
Count 
Sequence 
Coverage 
[%] 
ADSL Adenylosuccinate lyase 0.720305 0.0001592 2 5.6 
UBTF Nucleolar transcription factor 1 0.717051 0.0001318 4 4.6 
CSRP1 Cysteine and glycine-rich protein 1 0.709673 6.73E-09 30 67.9 
DDRGK1 DDRGK domain-containing protein 1 0.701361 5.04E-05 2 8.6 
ANXA1 Annexin A1 0.691324 2.67E-06 9 20.2 
GPS1 COP9 signalosome complex subunit 1 0.654407 1.75E-06 2 6.8 
ANXA3 Annexin A3 0.647249 1.76E-13 22 37.8 
TOP2B DNA topoisomerase 2-beta 0.643791 0.0004078 4 2.1 
SLK STE20-like serine/threonine-protein kinase 0.62692 0.0001979 2 1.9 
DNPEP Aspartyl aminopeptidase 0.621157 9.79E-08 2 4.9 
UBE2L6 Ubiquitin/ISG15-conjugating enzyme E2 L6 0.534416 1.20E-06 2 11.8 
STAT1 Signal transducer and activator of transcription 1-
alpha/beta 
0.511326 5.44E-17 9 15.1 
TTC9C Tetratricopeptide repeat protein 9C (TPR repeat protein 
9C) 
0.474518 2.35E-16 3 6.5 
BAG5 cDNA FLJ77290, highly similar to Homo sapiens 
BCL2-associated athanogene 5 (BAG5), mRNA 
0.470389 7.84E-09 2 6.6 
MX1 Interferon-induced GTP-binding protein Mx1 0.221029 2.22E-78 4 11.9 
ISG15 Interferon-induced 17 kDa protein 0.181045 3.92E-77 4 29.7 
PRAF2 PRA1 family protein 2 0.106702 9.82E-170 2 16.9 
 
Genistein modulated protein expression in the presence of ERβ (sample ED). 
Genistein modulated ERβ-regulated proteins could also be identified comparing T47D-
ERβ cells grown in light amino acid isotope containing medium treated with 500 nM 
genistein to mock transfected T47D-control cells grown in heavy isotope containing medium 
treated with 500 nM genistein, both grown in the absence of Tet with the T47D-ERβ cells 
expressing ERβ (sample ED, table 1A-B). Significant changes observed in protein levels after 
24 h treatment are depicted in Figure 3C. The mock control cell line do not express ERβ. This 
comparison resulted in the identification of 1995 proteins with at least two unique peptides 
that were differentially expressed upon genistein exposure in the presence of ERβ. 
 
Based on the statistical selection criteria (Significance B ≤ 0.001) the data revealed 58 
SILAC proteins that appeared to be significantly regulated (Figure 3C and table 4). Genistein 
induced ERβ-mediated protein expression causes the most significant changes in proteins 
involved in processes like cell death (ERβ, FHL2, LMNA or CYB5A), lipid metabolism 
(ERβ, ACOX1, COLT1, CYB5A), gene expression (ERβ, HIST1H2AG, HIST1H4A, 
H2AFZ or HNRNCP), and cell cycle (LMNA, ITGAV or ERβ) (Figure 6, Table 4).  
 
Both ERβ-target approaches (samples DB and ED) found comparable results. In both 
experiments, genistein-mediated ERβ activation regulated molecular functions including cell 
death, cell cycle, cell movements and lipid metabolism. Among the most significant ERβ-
targets identified were proteins mediating gene transcription, like HNRNCP and Histones 
related proteins. 
Omics
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Figure 6: Molecular and cellular functional classes affected in a second approach to detect genistein induced 
ERβ-mediated effects on protein expression (sample ED, Table 1B). IPA molecular and cellular functions of the 
H/L proteins with a P value <0.001. Selected scoring method was based on Fisher’s exact test p-value. The high-
level functional categories that are involved in this analysis are displayed along the x-axis in decreasing order of 
significance. The y-axis displays the -(log) significance. The horizontal line denotes the cutoff for significance 
(p-value of 0.05). 
 
Table 4: The most significant ERβ-mediated proteins as a result of genistein treatment (sample HD, Table 1B), 
only L/H SILAC pair protein list. 
 
Gene Names Protein Names 
Ratio 
H/L 
Normalized 
Ratio 
Significance 
Ratio 
H/L 
Count 
Sequence 
Coverage 
[%] 
ANKRD36B UPF0634 protein C 5.594 1.04E-17 2 1.5 
MGP Matrix Gla protein 3.1457 1.26E-09 7 23.3 
KRT18 Keratin, type I cytoskeletal 18 2.4136 8.26E-09 215 94.4 
GIPC1 PDZ domain-containing protein GIPC1 2.2777 1.76E-05 2 9.3 
TP53I3 Putative quinone oxidoreductase 2.245 1.11E-07 21 40.4 
CLDN1 Claudin-1 2.2442 1.38E-06 5 19 
EFHD1 EF-hand domain-containing protein D1 2.1675 3.63E-06 8 18.4 
KIAA1107 Uncharacterized protein KIAA1107 2.1623 3.87E-06 2 2.1 
REEP5 Receptor expression-enhancing protein 5 2.1537 4.50E-07 32 34.9 
GOT2 Aspartate aminotransferase, mitochondrial 2.0696 1.61E-06 36 41.6 
KRT8 Keratin, type II cytoskeletal 8 2.0237 3.21E-06 535 85.7 
COMTD1 
cDNA FLJ52132, highly similar to Catechol-O-
methyltransferasedomain-containing protein 1 (EC 
2.1.1.-) 
1.89 0.00061374 2 2.8 
CRIP1 Cysteine-rich protein 1 1.8892 2.35E-05 7 79.2 
VPS24 
cDNA FLJ58988, highly similar to Charged 
multivesicular body protein 3 
 1.8736 0.00071107 2 4.8 
METTL7A Methyltransferase-like protein 7A 1.8288 0.00023505 6 17.2 
RAB18 Ras-related protein Rab-18 1.8235 0.00025018 12 34.5 
CNPY2 Protein canopy homolog 2 1.8106 0.00094353 14 37.9 
KRT19 Keratin, type I cytoskeletal 19 1.8021 8.29E-05 240 93.8 
LYRM7 Putative uncharacterized protein LYRM7 1.7869 0.00038649 4 24 
NPM1 Nucleophosmin 1.7869 0.00010282 68 71.4 
APRT Adenine phosphoribosyltransferase 1.7725 0.00012622 36 78.3 
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Gene Names Protein Names 
Ratio 
    H/L 
Normalized 
Ratio  
Significance 
Ratio 
H/L 
Count 
Sequence 
Coverage 
[%] 
HSPA9 Stress-70 protein, mitochondrial 1.7722 0.00012673 142 60.8 
PTGR2 Prostaglandin reductase 2 1.7713 0.00046415 3 15.7 
CANX Calnexin 1.7616 0.0001473 31 28.2 
CBX5 Chromobox protein homolog 5 1.7157 0.00088702 5 19.4 
ACY1 Aminoacylase-1 1.7126 0.00091913 6 10.6 
FLNA Filamin-A 0.60289 0.00070352 269 51.8 
ISYNA1 Inositol-3-phosphate synthase 1 0.60177 0.00067576 17 23.8 
COTL1 Coactosin-like protein 0.56046 0.00013071 22 54.2 
PRSS8 Prostasin 0.54848 0.00087159 2 12.8 
CYB5A Cytochrome b5 0.52474 0.00012112 13 56 
COX7A2L Putative uncharacterized protein COX7A2L 0.51931 0.00031952 3 34.8 
S100A16 Protein S100-A16 0.5155 8.08E-05 9 68 
RPL38 60S ribosomal protein L38 0.51546 0.00027718 5 50 
HIST1H2AG Histone H2A 0.5063 9.01E-06 15 27.2 
FHL2 Four and a half LIM-domain protein 2 0.48592 8.52E-05 6 26 
ACOX1 Peroxisomal acyl-coenzyme A oxidase 1 0.48194 1.59E-05 14 20 
SRPR Signal recognition particle receptor subunit alpha 0.47482 5.24E-05 2 3.3 
ANXA3 Annexin A3 0.47299 9.83E-06 14 33.7 
LMNA Lamin-A/C 0.47133 1.09E-06 113 61.1 
ITGAV Integrin alpha-V 0.46812 3.86E-05 5 4.8 
S100A8 Protein S100-A8 0.46418 0.00078094 2 32.3 
ARMCX3 Armadillo repeat-containing X-linked protein 3 0.45982 0.00067904 3 12.1 
PREX1 Phosphatidylinositol 3,4,5-trisphosphate-dependent Rac exchanger 1 protein 0.45533 2.10E-05 11 7.1 
SDHB Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial 0.42786 0.00022185 2 7.1 
HIST1H4A Histone H4 0.39614 2.83E-09 9 44.7 
HNRNPC Heterogeneous nuclear ribonucleoproteins C1/C2 0.37985 1.58E-08 11 25.2 
H2AFZ Histone H2A.Z 0.35593 8.43E-06 2 20.3 
ABAT 4-aminobutyrate aminotransferase, mitochondrial 0.35076 1.04E-09 9 13 
LMNB2 Lamin-B2 0.31103 5.26E-07 2 4.5 
ISG15 Interferon-induced 17 kDa protein 0.22984 3.20E-10 5 29.7 
UGDH UDP-glucose 6-dehydrogenase 0.21775 7.17E-11 2 6.1 
MX1 Interferon-induced GTP-binding protein Mx1 0.17993 3.85E-23 12 17.1 
MATR3 Putative uncharacterized protein MATR3 0.17222 5.90E-14 2 3.6 
ESR2 Estrogen receptor beta 0.15132 7.65E-16 2 5.7 
DMD Dystrophin 0.14177 1.63E-24 4 0.3 
LDHB L-lactate dehydrogenase B chain 0.099128 1.64E-40 6 33.2 
 
Transcriptomics data. 
In addition to the proteomics also transcriptomics was performed. Using the same 
samples as for the SILAC protein analysis, differentially expressed genes for each experiment 
(CA, DB and ED) were obtained. The comparison of gene expression levels between 
genistein and ICI induced T47D-ERβ cells in the absence of ERβ (sample CA) did not 
identify  significant differentially expressed genes. This is different from the study of 
Williams et al. (8). It is however in agreement with the relatively low levels of ERα present. 
The presence of more subtle gene regulations which could indeed be ERα-mediated was 
investigated. A functional analysis of the top 30 genes as ranked by p-value (Figure 7A) 
showed that these genes are involved in biological processes that match ERα-mediated 
Omics
 
effects. Cellular function and maintenance, cell-to-cell signaling and interaction, cellular 
movement, cell death, cellular assembly and organization, were enhanced at the mRNA level 
as already seen at the protein level. The majority of the top 30 geneset were upregulated as a 
result of genistein treatment, resulting in stimulation of pathways for cellular growth and 
proliferation, cell death and cellular development.  
 
The results of the genistein treatment effects in the presence of ERβ (sample DB), 
contained a set of 73 differentially regulated genes (p ≤ 0.05). Functional analysis of this 
gene set showed upregulation of cell death and downregulation of cellular growth and 
proliferation, and cell cycle regulation. These effects (Figure 7B) were similar to those 
observed at protein level, pointing at increases in expression of genes and proteins involved 
in for example: cellular growth and proliferation, cell cycle, cellular assembly and 
organisation. 
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Figure 7: Most significant molecular and cellular functional classes affected as a result of A) genistein induced 
ERα-mediated effects on gene expression (sample CA, Table 1B), B) genistein induced ERβ-mediated effects 
on gene expression (sample DB, Table 1B), C) a second approach to detect genistein induced ERβ-mediated 
effects on gene expression (sample ED, Table 1B). IPA molecular and cellular functions of the genes with a P 
value <0.05. Selected scoring method was based on Fisher’s exact test p-value. The high-level functional 
categories that are involved in this analysis are displayed along the x-axis in decreasing order of significance. 
The y-axis displays the -(log) significance. The horizontal line denotes the cutoff for significance (p-value of 
0.05). 
 
The second approach detecting genistein modulated ERβ mediated gene expression 
(sample ED) revealed 1011 differentially regulated genes (p ≤ 0.05). Genistein modulated 
ERβ-mediated effects (Figure 7C) were related to RNA post-transcriptional modification, 
cellular growth and proliferation, cell-to-cell signaling and interaction, cell death, cellular 
function and maintenance. 
 
Furthermore, hierarchical cluster analysis of the gene expression of the 73 differentially 
regulated genes by ERβ was used to identify three main clusters in this gene set (Figure 8). 
Genes present in the upper part of the dendrogram correspond to those genes downregulated 
in genistein exposed T47D-ERβ cells with ERβ expression. Pathway and functional analysis 
shows the involvement of these genes with cellular growth, proliferation and cell cycle. 
Genes clustered in the lower part of the dendrogram correspond to those genes upregulated in 
genistein exposed T47D-ERβ cells expressing ERβ, and belong to the functional group of cell 
death. APOD, RBP4, IL29, NRIP3 and LRRC15 genes were found to be clearly upregulated 
by genistein-ERβ (Figure 9). It is also observed that negative regulators of ERα transcription 
are clustered together with ERβ and progesterone receptor (PGR). In addition, 
downregulation of genes involved in cellular growth and proliferation was seen in the last 
cluster of genes, in the center of the dendrogram. Most of the genes belonging to this group 
are negative regulators of colony formation of cancer cell lines. 
Omics
 
 
 
Figure 8: Hierarchical cluster analysis of the 73 differentially regulated genes. Using complete linkage and 
Pearson correlation similarity. Gene symbols and Entrez gene ID are shown. 
 
 
 
 
 
 
109 
Chapter 5
 
110 
A 
 
B 
 
C 
 
 
 
 
Omics
 
D 
 
Figure 9: Mean expression intensities of A) APOD, B) RBP4, C) NRIP and D) LRRC15 at mRNA level based 
on microarray normalized results under five different conditions, Tet+ and ICI (sample A, Table 1A), Tet- and 
ICI (sample B, Table 1A), Tet+ and genistein (sample C, Table 1A), Tet- and genistein (sample D, Table 1A), 
and Tet- in control cell line (T47D-PBI) and genistein (sample E, Table 1A) and their corresponding fold 
changes. 
 
In summary, both at the gene and protein level, genistein induced signatures of cell 
proliferation and negative regulation of cell death in the absence of ERβ (sample CA), 
whereas signatures of upregulation of cell death, negative regulation of cell cycle and cell 
proliferation was observed during genistein treatment in the presence of ERβ (contrast DB 
and ED).  
 
 
Discussion 
 
Various molecular profiling technologies have been developed recently in order to 
identify and quantify proteins and/or genes in biological samples. From these studies it was 
observed that mRNA levels are only a partial reflection of the functional state of an organism 
and that a comprehensive understanding of the genomic information will require means of 
analyzing quantitative differences in protein expression on a proteome-wide scale (34-37). In 
general, an overall positive correlation between protein and mRNA abundance has been 
observed in many organisms, but simple correlations are insufficient to assess regulatory 
patterns  of gene and protein expression (37).  Therefore, in this paper, we combined SILAC-
based proteomics and microarray analysis of identical samples to address the signaling effects 
of estrogen receptor subtypes in the T47D-ERβ breast cancer cells exposed to the 
phytoestrogen genistein.  
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 In ERα-positive breast cancer cells, growth and proliferation is preserved by active 
transcription of ER targets (38, 39), whereas ERβ expression results in a significant decrease 
in cell proliferation (16, 18). In previous studies we observed that genistein, a phytoestrogen 
with relatively higher affinity for ERβ (10, 40) than for ERα, increased cell-proliferation in 
ERα-positive cells at physiologically relevant concentrations (17). Furthermore, genistein did 
not induce cell-proliferation in ER-negative breast cancer cells like MDA-MB-231 (15, 41).  
 
In the present study, ERα expression levels in the ICI synchronized T47D-ERβ cell line 
were 6-10% compared to the wild type T47D cells as measured by ELISA (Figure 2A). 
However, ERα mRNA was detected in all samples (Figure 2B) albeit at levels 30 fold lower 
than the maximum ERβ mRNA levels detected in the T47D-ERβ cells in absence of 
tetracycline. The low levels of ERα protein observed are in accordance with previous studies 
where it was shown that i) the ERα protein displays a shorter half-life after ligand binding 
(42), ii) that ERα is subject to degradation induced by its antagonist ICI 182780 (43) and, iii) 
that ERα may be downregulated by the genistein treatment . It has been proposed that 
proteasomal degradation of ERα protein is increased in the presence of the co-regulated 
proteins KRT18 and KRT8 (44, 45). Upregulation of these cytokeratins (Table 2, Table 4)  
attract the receptor into close proximity to nuclear matrix-associated proteasomes for 
degradation as has been described after treatment with ICI 182780 (46).  In the samples 
treated with genistein expression of ERα, after  ICI withdrawal, could return to low basal 
levels (42, 44, 45), because genistein influences the expression of ERα. This observation is 
supported by the co-regulation of ERα and c-MYC proteins. The proto-oncogene c-MYC is 
normally upregulated by ERα in response to the presence of estradiol (47, 48). On the other 
hand ERβ is able to repress c-MYC expression (4, 8, 46). In our proteome dataset, the 
differential regulation of most of the ERα-regulated proteins appeared to be similar to that of 
c-MYC (49), including upregulation of KRT18, MYH10, HNRPC, MYH9 or MYL6.  
 
It has been proposed that epigenetic mechanisms including DNA methylation and 
histone modifications might contribute to ERβ-mediated ERα silencing (50, 51)(44, 45). 
Furthermore, genistein has been shown to alter DNA methylation patters in mice (52). A 
possible increase of DNA and protein methylation is supported by regulation of 
methyltransferases, histones and histone deacetylases as observed in our SILAC studies. 
Additional studies investigating epigenetic mechanisms in the presence of genistein would be 
of interest. 
 
Our transcriptomics results showed some overlap with those reported by Williams and 
coworkers (8) for the effect of estradiol on ERβ regulated genes. We used the same 
experimental conditions but with a different ligand (genistein instead of estradiol) and a 
different technology platform (affymetrix gene-chip versus operon’s oligomer spotted array). 
Omics
 
Comparing expression data, similar ERβ targets are induced in both studies, e.g. LRRC15, 
APOD, HMGCL and NRIP3. Expression of APOD is absent in proliferating cells and 
induced in cells that undergo growth arrest and senescence (53). APOD protein levels were 
only detected in one SILAC experiment, namely in cells co-expressing both receptors during 
genistein treatment. Both studies confirmed that estradiol and genistein induce changes at 
gene and protein expression level that point at stimulation of cell proliferation in the absence 
of ERβ expression, whereas expression of ERβ drives the cell to protein and gene expression 
leading to negative regulation of cell cycle and induction of apoptosis.  
 
Functional analysis of the genistein induced ERα-activated proteome data revealed that 
genistein was able to induce growth of the breast epithelial cells as indicated by the activation 
of cellular reorganization and maintenance. Cytoskeletal rearrangement, which is organized 
by microtubules, actin containing microfilaments and mechanochemical molecules, is a 
sensitive indicator of cell growth. Expression of myosins is important for proliferation and 
migration of breast cancer cells controlled by Rho and ERK signaling (54, 55). 
 
ERβ decreases the cell motility and cell proliferation, two of the most common 
components of breast cancer progression. This was observed during functional analysis of the 
genistein-induced ERβ activated proteome (samples DB and ED). Cellular organization and 
cell movement (migration) were downregulated processes by ERβ expression. More 
importantly and in accordance with gene expression experiments, ERβ activity induces 
negative regulation of cell proliferation and induction of cell death. An increase of histone 
related proteins is thought to result in a general repression of ERα transcription (27, 28) and 
is associated with breast cancer disease progression (48). Repression of transcription was also 
observed by the downregulation of TOP2B after genistein treatment (30, 45). 
 
Finally, enrichment of canonical pathways (Figure 10) comparing genistein exposed cells 
expressing ERβ to those not containing ERβ, agreed with similar findings in genistein 
exposed epithelial cells (55) indicating that cells not containing ERβ loose their cell–cell 
interactions and cell polarity, and undergo a major change in their actin cytoskeleton, 
enabling them to acquire an increased motility and invasiveness. Expression of ERβ halts 
genistein induced cell migration and cytoskeleton reorganization by inactivating the same 
signaling pathways.  
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Figure 10: The top IPA canonical pathways regulated by ERα-mediated effects (dark columns) and ERβ-
mediated effects (light columns) as based on Fisher’s exact test p-value using bigger protein data set (P< 0.05).  
The horizontal line denotes the cutoff for significance (p-value of 0.05). 
 
 
 In summary, we have demonstrated by using proteomics and transcriptomics that even 
in presence of low ERα levels genistein induces effects on gene and protein expression in the 
T47D-ERβ cells comparable to those previously reported for estradiol. It is concluded that 
genistein can act as an estrogen and that its ultimate estrogenic effect on cells and tissues are 
dependent on the receptor phenotype and the ratio between the receptor subtypes within these 
cells or tissues a phenotype that may potentially be modified upon genistein exposure. 
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Abstract 
The present study presents a protein-network based analysis of the quantitative SILAC-
based proteome of T47D-ERβ breast cancer cells with tetracycline-dependent varying 
intracellular ERα/ERβ ratio exposed to the isoflavone genistein. Genistein is a phytoestrogen 
found in high levels in soy products, the intake of which has been frequently associated with 
various beneficial health effects including reduced risk on breast cancer and osteoporosis in 
menopausal women. In our study protein networks involved in cell proliferation and 
apoptosis appear to be affected upon genistein exposure of the T47D-ERβ breast cancer cells. 
In addition the data point at genistein-induced ERβ mediated immune suppression. Genistein 
induced ERβ-mediated downregulation of the expression of the transcription factors NF-κB 
and STAT3 as well as down regulation of a variety of cytokines including IL-1β, IL-18, IFN-
γ, and TNF-α. On the other hand, a considerable increase of TGF-β induction was found in 
genistein treated T47D-ERβ cells expressing ERβ compared with cells with no expression of 
ERβ, further corroborating the genistein induced ERβ mediated  downregulation of immune 
signaling. Altogether, the results of the present study reveal that in addition to cell 
proliferation and apoptosis, immune signaling appears to be another major estrogen target 
influenced by phytoestrogen exposure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
121 
Chapter 6
 
122 
Introduction 
Epidemiological studies have concluded that Asian women consuming a diet rich in soy 
products have a low incidence of breast cancer (1, 2). This finding has initiated numerous 
studies carried out in in vivo and in vitro models trying to unravel the underlying mechanisms 
(3, 4). Genistein, a major isoflavone in soy and soy-based products, has been reported to exert 
its effects mainly through the two estrogen receptors (ERs), ERα and ERβ, and also by non 
ER mediated-mechanisms (5). Preferential binding of genistein to ERβ relative to ERα has 
led to the suggestion that genistein signaling via ERβ is of important for its biological effects 
(6-8).  
 
In our previous studies using the human T47D breast cancer cell line with tetracycline-
dependent ERβ expression (T47D-ERβ), the effect of a varying intracellular ERα/ERβ ratio 
on genistein-induced cell proliferation was characterized. Genistein-induced cell proliferation 
of cells in which ERβ expression was inhibited, whereas this genistein-induced cell 
proliferation was no longer observed when ERβ expression was increased (8). These results 
pointed at the importance of the cellular ERα/ERβ ratio for the ultimate effect of genistein on 
cell proliferation. In a subsequent study this ultimate biological end point, cell proliferation, 
was linked to both transcriptomics and proteomics analysis data in order to unravel the 
mechanisms underlying observed effect (Chapter 5). Based on molecular function analysis, in 
the genistein exposed T47D-ERβ cells with no ERβ expression, changes in gene and protein 
levels pointed at genistein induced cell proliferation, growth and migration by dynamic 
activation of cytoskeleton remodeling. Moreover, in the genistein exposed T47D-ERβ cells 
expressing high levels of ERβ, a clear downregulation of genes and proteins involved in cell 
growth, and an upregulation of genes and proteins involved in cell cycle arrest and apoptosis 
was demonstrated. These effects of genistein on gene and protein expression were in 
agreement with our previous in vitro results on cell proliferation obtained using the same 
T47D-ERβ cell model with variable ERβ expression levels (8). 
 
 The aim of the present study was to investigate a global analysis at the protein level 
of genistein-induced ERβ dependent biological effects in addition to its dualistic, ERβ 
expression-dependent effects on cell proliferation and apoptosis. To this end, we applied a 
protein-network-based approach to identify subnetworks instead of individual proteins that 
were affected upon genistein exposure of the T47D-ERβ cells expressing variable levels of 
ERβ. This protein-network-based approach proved able to provide new insights into cellular 
processes affected upon genistein exposure.  
Networks
 
Materials and methods: 
Cell culture: The stably transfected T47D tetracycline-inducible cell line (T47D-ERβ) 
and the mock control cell line (T47D-PBI) were made and provided by Ström (9, 10). 
DMEM SILAC medium lacking arginine (Arg) and lysine (Lys), supplemented with 5% of 
dialyzed fetal bovine serum and 1000 ng/ml tetracycline (Tet) was used. Arg and Lys, either 
“light” or “heavy” depending on the experimental design, were incorporated in the DMEM 
SILAC medium. The final concentrations of Arg and Lys were 21 and 48 mg/L respectively 
(11). 
 
During the adaptation phase, cells were grown in “light” or “heavy” SILAC media, 
containing respectively 12C614N4-arginine and 12C614N2-lysine or 13C6-15N2-lysine and 
13C6-15N4-arginine, until the cells grown in “heavy” medium had fully incorporated the 
labeled amino acids. Full incorporation of labels into the cells was checked by MS analysis 
(12) of cell samples detecting the time point at which there was no further increase in the 
amount of label incorporated. Full incorporation of labels for the T47D-ERβ cells (Tet 
containing) was observed after 5 doubling times or 10 days of cultivation (data not shown). 
Preparation of the samples after the adaptation phase, was performed as follows. Cells in 
DMEM SILAC medium supplemented with 5% dialyzed-fetal bovine serum (DFBS) and 
1000 ng/ml Tet were seeded at 105 cells/ml in plates for 24 h. After 24 h DMEM SILAC 
medium was replaced by the same medium without phenol red, containing the required 
concentrations of Tet, heavy or light amino acids, and a serum concentration that was reduced 
to 0.5% DFBS. To this, 10 nM ICI 182780 was added for cell synchronization (10). Tet was 
withdrawn in half of the plates 12 h before the start of the treatment to allow expression of 
ERβ. The Tet+ and Tet- cultures were incubated with either 10 nM of the ERα and ERβ 
antagonist ICI 182780 (13) or 500 nM of the ER ligand genistein for 24 h according to the 
experimental design (Table 1) after which all cells were collected simultaneously for RNA 
and protein extraction. Three replicates of each sample were prepared in parallel to minimize 
experimentally induced variability. 
 
Table 1 summarizes the experimental design applied in order to obtain information on 
the genistein induced levels of protein expression in T47D- ERβ cells with variable ERα/ERβ 
ratios. Table 1 presents the five different samples prepared, indicating the cell lines used, the 
Tet treatment and the resulting ERβ expression as well as the compound and the amino acid 
label (light or heavy) added to the growth medium. In addition to genistein the ER antagonist 
ICI 182780 was used in order to block the receptors thereby suppressing receptor-mediated 
transcription. A mock control cell line (T47D-PBI) was used to define genistein mediated 
non-ERβ protein expression inherent to the cell system used. Pairwise comparisons made 
using these five samples in order to analyze i) genistein induced ERα mediated protein 
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expression in the absence of ERβ (C versus A, referred to as sample CA); ii) genistein 
induced ERβ regulated protein expression in the presence of low endogenous amounts of 
ERα (D versus B, referred to as sample DB) and iii) a second approach to detect genistein 
induced ERβ mediated protein expression in the presence of low endogenous levels of ERα 
(E versus D, referred to as sample ED).   
 
Table 1: Experimental design of the present study based on four cellular samples prepared. 
 
 Strain Tetracycline Treatment  
ERβ 
expression  
Compound 
treatment No. of samples Label 
A T47D-ERβ yes no ICI 182780 3 / 3 Light 
B T47D-ERβ no yes ICI 182780 3 / 3 Heavy 
C T47D-ERβ yes no genistein 3 / 3 Heavy 
D T47D-ERβ no yes genistein 3 / 3 Light 
E T47D control no no genistein 3 / 3 Heavy 
 
 
Protein preparation: For protein extraction, cells were washed twice with PBS and lysed 
in modified RIPA buffer [50 mM Tris-HCl (pH 7.4), 1 mM EDTA, 150 mM NaCl, 1% Triton 
X-100, 0.25% sodium deoxycholate] containing a protease inhibitor cocktail (Complete, 
Mini, Roche) at 4° C for 15 min. Samples were sonicated for 1 min and centrifuged at 14000 
g for 15 min at 4° C, and the supernatant was collected. Equal amounts of protein (BSA 
Protein Assay Kit, Pierce) from each sample were mixed in a ratio of 1:1 according to the 
experimental design presented in table 1, and 1 µg of the protein sample thus obtained was 
separated on a 12% Tris-glycine sodium dodecyl sulfate-polyacrylamide (SDS-PAGE) gel by 
electrophoresis, followed by staining of the SDS gel  using colloidal Coomassie blue 
(Colloidal blue staining kit, Invitrogen). Then the resulting 3 gel lanes per replicate (CA, DB 
and ED) were excised and cut horizontally into 8 equal sections per lane. In-gel digestion was 
performed as follows: The SDS gel was destained by two washes with water. Cysteine 
reduction was performed by adding 100 µl 50 mM DTT (dithiotreitol) in 50 mM NH4HCO3. 
Samples were sonicated for 1 min and incubated at 60°C without shaking for 1 h.  Alkylation 
was performed when samples reached room temperature, replacing DDT by 100 µl of 50 mM 
iodoacetamide in 50 mM NH4HCO3. Samples were sonicated for 1 min and alkylated at room 
temperature in the dark for 1 h. The gel pieces were washed three times with 100 µl 50 mM 
NH4HCO3 at pH 8. For proteolytic digestion, samples were treated overnight with 100 µl 
trypsin (10 ng/µl in 50 mM NH4HCO3, sequencing grade, Boehringer Mannheim) at room 
temperature. Gel fragments were removed by centrifugation and the proteolytic peptides were 
recovered in the supernatant fraction (25 µl). 10% TFA was added to correct the pH up to 2 
to 4. Finally all extracts were measured by LC-MS/MS. 
 
Networks
 
Data acquisition, Mass Spectrometry: The protein samples were analyzed by injecting 
18 µl sample over a 0.10 * 32 mm Prontosil 300-5-C18H (Bischoff, Germany) pre-
concentration column (prepared in house) at a flow of 6 µl/min for 5 min with a Proxeon 
EASY nLC system. Compounds were eluted from the pre-concentration column onto a 0.10 *  
250 mm Prontosil 300-3-C18H analytical column (prepared in house) with an acetonitril 
gradient at a flow of 0.5 µl/min. The gradient consisted of an increase from 9 to 34% 
acetonitril in water with 1ml/l formic acid in 50 min followed by a fast increase in the 
percentage acetonitril to 80% (with 20% water and 1 ml/l formic acid in both the acetonitril 
and the water) in 3 min as a column cleaning step.  In between the pre-concentration and the 
analytical column, an electrospray potential of 3.5 kV was applied directly to the eluent via a 
solid 0.5 mm platina electrode fitted into a P777 Upchurch microCross. Full scan positive 
mode FTMS spectra were measured between m/z 380 and 1400 at resolution 60.000 on an 
LTQ-Orbitrap (Thermo electron, San Jose, CA, USA). MSMS scans of the four most 
abundant doubly or triply charged peaks in the FTMS scan were recorded in data dependent 
mode in the linear trap (MSMS threshold = 10.000). Data were acquired using Xcalibur 
software. 
 
Protein identification and quantitation: Mass spectra were analyzed using MaxQuant 
(version 1.0.13.8), which performs e.g. list generation, ratio H/L significance A, ratio H/L 
significance B, SILAC- and XIC-based quantification, false positive rate and data filtration 
(14). Data were searched against the human IPI human protein database supplemented with 
frequently observed contaminants and concatenated with reversed copies of all sequences 
(total 148380 sequences) using Mascot v2.2 (Matrix Sciences). Spectra determined to result 
from heavy labeled peptides by pre-search Maxquant analysis were searched with the 
additional fixed modifications Arg10 and Lys8, whereas spectra with a SILAC state not 
defined a priori were searched with Arg10 and Lys8 as additional variable modifications. 
Precursor mass tolerance was set at 10 ppm for the complete peptides and 0.5 Da for peptide 
fragments as observed in the MS2 spectra. Trypsin/P cleavage specificity with up to 2 missed 
cleavage and three labeled amino acids (Arg and Lys) were allowed. The required false 
discovery rate was set to 1% at the protein level, and the minimum required peptide length 
was set to 6 amino acids. Carbamidomethyl cysteine was set as a fixed modification and 
methionine oxidation, deamidation (NQ), and acetylation of the N-terminus (protein) were 
allowed as variable modifications. For protein identification, at least two peptides were 
required, among which at least one peptide was required to be unique in the database. 
Identified proteins were quantified. Protein ratios calculated by MaxQuant were subjected to 
manual inspection. 
 
Bioinformatics Network Analysis: A cutoff P value ≤ 0.05 (Ratio H/L Significance B) 
was selected for analysis of differentially expressed proteins. Ingenuity Pathway Analysis 
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(IPA) version 8.5 (Ingenuity Systems Inc.) was used to conduct a knowledge-based network 
analysis. IPA tool relies on curated functional and regulatory interactions extracted from 
literature. The biological functions across ER-responsive proteins networks were identified. 
IPA calculates a significance score for each network. The network score is based on the 
hypergeometric distribution and is calculated with the right-tailed Fisher's Exact Test. This 
score indicates the likelihood that the assembly of a set of focus ER-genes or gene products in 
a network could be explained by random chance alone. Networks were ranked according to 
their degree of relevance to the network eligible molecules in our dataset. 
 
Cytokine detection: The exposure medium from treated cells was used for detection and 
quantification of selected cytokines, including interleukins 1β, 6, 8, 10 and 12 (IL-1β, IL-6, 
IL-8, IL-10 and IL-12), interferon- γ (IFN-γ), tumor necrosis factor α (TNF-α) and tumor 
growth factor β (TGF-β).  Detection and quantification of these cytokines was performed by 
Cytometric Bead Array Flex sets (BD Biosciences, San Diego, USA)  as previously described 
(15). 
 
Results 
Human breast T47D cancer cells were previously stably transfected with the ERβ 
expression plasmid under Tet-responsive promoter regulation (9). This cell line expresses 
endogenous ERα, and variable levels of ERβ depending on the concentration of Tet in the 
culture medium, with ERβ expression being maximal after complete removal of Tet from the 
medium (8, 16) (chapter 5). 
 
Based on the presented SILAC experimental design (Table 1), five different proteomes 
were obtained. Following our SILAC comparisons, three protein datasets were obtained: one 
dataset that determined genistein-mediated proteins in cells not expressing ERβ (sample CA), 
a second dataset that determined genistein-mediated protein induction in cells expressing 
high levels of ERβ (sample DB) and a third data set also able to detect genistein-induced ERβ 
mediated protein expression (sample ED). Differential protein expression in the three datasets 
was defined using a cutoff P value ≤ 0.05, and the protein lists thus obtained were uploaded 
into Ingenuity pathway analysis (IPA) and contained respectively 219 proteins (sample CA), 
229 proteins (sample DB) and 253 proteins (sample ED). 
 
We applied a protein-network-based approach to analyze the expression profiles of the 
three different datasets. In addition, IPA software included in the SILAC derived protein-
networks additional proteins that are associated with the related functions. The resulting 
networks were in turn ranked by the software according to their significance (scores). Table 
Networks
 
2, 3 and 4 present the results of the IPA network analysis of the three different samples. The 
tables reveal a total of 18, 20 and 22 networks that were identified in respectively genistein 
exposed cells expressing no ERβ (sample CA), genistein exposed cells expressing high levels 
of ERβ (samples BD and ED). Protein networks presented in Table 2,3 and 4 were found 
significantly enriched with scores ranging from 58 to 2, reflecting high respectively low 
significance. 
 
Table 2: IPA network analysis in cells expressing endogenous ERα and inhibited ERβ. Bold protein names and 
underlined italic indicate up- and down-regulated expression, respectively. Regular black colour indicates 
intermediate molecules incorporated through relationships with other molecules. 
 
ID Molecules in Network Score Focus 
Molecules 
Top Functions 
Genistein-ERα 
 1  Actin, ACTR1A, AKR1B1, BANF1, Caspase, DHX9, 
DLAT, DSP, HIST1H1B, HIST1H1C, HNRNPC, ILF3, 
ILF2 (includes EG:3608), KIAA1967, KRT8, KRT18, 
KRT19, Lamin b, LMNA, LMNB1, NASP, NFkB 
(complex), NLRP2, PCM1, PKP3, PLEC1, PNKD 
(includes EG:25953), PUF60, Raf, RPS25, SF3A3, 
SUGT1, TFAM, TMPO, UGP2 
 58  30  Infection Mechanism, Cellular 
Assembly and Organization, 
Hair and Skin Development 
and Function 
 2  ACTN1, Akt, ANXA1, ANXA2, CaMKII, CAPN2, CBX5, 
Ck2, DHCR7, E2f, EBP, FSH, HMGN1, IgG, JUP, LDL, 
Mlc, MUC1, MYH9, MYH10, MYH14, MYL6, MYL12B, 
Myosin, NBN, NPC2, PAFAH1B1, PPL, RNA 
polymerase II, RPL22, RPL34, RPS16, RPS18, 
TUBB2A, Vegf 
 38  24  Drug Metabolism, Small 
Molecule Biochemistry, Cellular 
Function and Maintenance 
 3  ACTN4, ALCAM, Alpha Actinin, Alpha catenin, Calpain, 
CAPZB, CNN2, Collagen(s), CSRP1, DIAPH1, ERK, F 
Actin, FAK, Fibrinogen, HADHB, Integrin, Integrin&beta;, 
ITGAV, LAMP1, LGALS1, LPP, MRPL20, Pkg, PSAT1, 
PTK2, Rac, Ras homolog, RHOG, SLC3A2, SLC7A5, 
SLC9A3R1, TAF15, TCR, VASP, VCL 
 35  21  Cell Morphology, Connective 
Tissue Development and 
Function, Amino Acid 
Metabolism 
 4  Ant, ASNS, C20ORF72, CECR5, CHORDC1, CHTF18, 
FAM129A, FBXO2, FXC1, GDI1, HSP90AA1, MAP4, 
MARS, MMS19, MYC, NOC2L, NOP58, NPM1 (includes 
EG:18148), NPM1 (includes EG:4869), PPID, PPP1CA, 
PPP1R13B, PTGES2, RPL22, RPL5 (includes 
EG:6125), SF3B3, SFXN1, SLC25A13, SMG5, SNCG, 
SNRPN, TERT, TP53I3, TSPO, XPOT 
 28  18  Molecular Transport, Cell 
Cycle, Connective Tissue 
Development and Function 
 5  ACAT1, AKR1A1, BLZF1, CIRBP, DAD1, DDX42, 
DHPS, EEF1B2, GCDH, GH1, GNMT, GOT1, GSTM2, 
GSTM3 (includes EG:2947), HEBP1, HNRNPK, IVD, 
MGST1, MGST3, MOGS, NIF3L1, NPEPPS, PRDX3, 
PSPH, RALB, RBMX, retinoic acid, RPS19, RPS20, 
RRBP1, SDF2L1, SEPHS1, TMEM120A, TPR, XBP1 
 22  15  Skeletal and Muscular System 
Development and Function, 
Digestive System Development 
and Function, Hepatic System 
Development and Function 
 6  ACTBL2, ADAM23, ALDH16A1, ALDH6A1, ARRB2, 
ATP5I, ATP6V1B2, ATP6V1D, ATP6V1F, C2CD2L, 
CCNY, CLINT1, COX4I1, EIF4E, ERI3, FAM82A2, 
GARS, GGCT, LARP1, MIR205 (includes EG:406988), 
MRPL44, NOP10, PDS5B, PFKFB2, PRNP, 
progesterone, RAB11FIP1, RASSF8, RPS17 (includes 
EG:6218), SLC2A4, SRGAP2, TBC1D1, YWHAD, 
YWHAG, YWHAH 
 20  14  Reproductive System 
Development and Function, 
Amino Acid Metabolism, 
Cardiovascular System 
Development and Function 
 7  Ap1, APLP2, ASB3, BAG2, ERK1/2, FLNA, gamma-
linolenic acid, GSS, Histone h3, Ikb, IL18, Insulin, Jnk, 
Mapk, MAT2A, MSK1/2, Nrp-PlexinA, P38 MAPK, 
PDGF BB, PI3K, Pkc(s), PSMD4, Ras, RASAL1, 
S100A8, S100A9, SFRS7, SHC4, SHP2-PI3K-GAB2, 
SLC25A5, SLC25A11, TNFRSF4, TXN, UGDH, WDR5 
 20  14  Inflammatory Response, Lipid 
Metabolism, Molecular 
Transport 
 8  ABCC6, AGA, AGT, ANK3, APEH, BAT1, CLPX, DDX1, 
DDX39, HNF4A, HNRNPA0, MIPEP, MME, MRPL44, 
MRPS25, NDUFB1, NDUFB3, NDUFB4, NDUFB5, NLN, 
PEPD, S100A9, SARNP, SPAST, SUCLA2, SYNJ2BP, 
THOC2, THOC3, UBA52, UCHL3, USP5, USP15, 
VDAC2, VPS29, XPNPEP3 
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 9  ARL1, C11ORF73, C6ORF211, CCDC25, CDK5RAP3 
(includes EG:80279), CYTH2, DDRGK1, EED, FLAD1 
(includes EG:80308), FZD1, GABPA, GSTK1, HNF4A, 
INTS3, KIAA0664, MAT2A, MIR135B (includes 
EG:442891), MRPS28, MTHFS, PCNP, PDK2, PPCS, 
PPIL2, PPP1R12B, PRDM5, PTGES3 (includes 
EG:10728), PTPN13, RASSF5, SAP18, SGSH, SRPRB, 
TRIM23, UBE2D3, UBL7, UFM1 
 18  13  Post-Translational 
Modification, Carbohydrate 
Metabolism, Genetic Disorder 
 10  ALAD, B4GALT1, Bvr, FGF18, GPD2, HIPK1, 
HNRNPD, HNRNPM, HSP90AB1, HYOU1, IARS2, 
INSR, KHSRP, LDHA, LDHAL6B, LDHB, MGP, NFAT5, 
NFS1, NLRP12, OGN, PCBP2, PIP, PPAP2A, PSPC1, 
RPSA, SAMD4A, SCYL1, SF1, SFPQ, SGK1, TIAL1, 
TNF, TOMM40, TUB 
 18  13  Molecular Transport, Cell 
Death, Hematological Disease 
 11  ADI1, AIFM3, AKR1C14, ALDH16A1, ANXA9, 
COX6B1, COX6C, CPNE3, CYB5R1, DHCR24, 
DNASE2, ETFDH, F7, GPNMB, HSDL1, IL13, IL15, 
IL1B, MIR124, MYO15A (includes EG:51168), NAGLU, 
NARG1, NDOR1, NDUFB10, Oxidoreductase, POFUT1, 
PTGR2, RDH12, RDH13, SMPDL3B, Sos, SYAP1, 
TRPS1, YARS, ZAP70 
 18  13  Gene Expression, 
Carbohydrate Metabolism, 
Drug Metabolism 
 12  ACER1, AK3L1, BAG3, Ca2+, CACNA2D2, Calcineurin 
B, CARS, CASP3, CLIC4, CNN3, D-sphingosine, 
DIDO1, EIF4H, ETFA, FNTA, HEXB, HSD17B10, IDI1, 
KLF16, LSS, MDH2, MIA3, MRPL23, PITPNM1, PLS3, 
PPT1, PRSS3 (includes EG:5646), RCN1, RDH11, 
S100A9, S100A11, SREBF1, TGFB1, VAT1, VEGFA 
 16  12  Lipid Metabolism, Small 
Molecule Biochemistry, 
Carbohydrate Metabolism 
 13  ANXA3, ASNS, ASS1, BCKDHA, COPS5, 
dihydrotestosterone, GLRX, GPI, GSR, HINT1, HUWE1, 
IGH@, MCAM, NEBL, PADI4, PARK7, PHGDH, PLAC8, 
PLXNB2, PMEPA1, PPOX, PPP1R13L, PSIP1, 
RECQL4, RPS29, SEL1L, SHISA5, SLC19A2, SP1, 
SUB1, TMED7, TP53, TXNRD1, UBA6, ZYX 
 16  12  Cell Death, Gene Expression, 
Cancer 
 14  ARF6, CHMP2B, CISH, CUL1, CUL2, CUL5, E3 RING, 
EEF1A1, EIF5, EIF3G, EIF3K, EPAS1, EPO, GSPT1, 
HBB (includes EG:3043), MRPL14, NEDD8, PCBP1 
(includes EG:5093), PRKCI, QPRT, RBX1 (includes 
EG:56438), RBX1 (includes EG:9978), RCC2, RPS6, 
SART1, SOCS2, TARS, TCEB1, TCEB2, UBXN7, 
USP33, VHL, VHL-Cul2-Elongin-RBX1, XIAP 
 8  7  Post-Translational 
Modification, Protein Synthesis, 
Hematological Disease 
 15  CCDC56, RYR1 (includes EG:6261)  2  1  Genetic Disorder, Skeletal and 
Muscular Disorders, Cell 
Signaling 
 16  ERGIC1, ERGIC3  2  1  Molecular Transport, Protein 
Trafficking 
 17  AARS2, Alanine-tRNA ligase  2  1   
 18  DNAJC, DNAJC9, Hsp22/Hsp40/Hsp90  2  1   
 
Networks identified as a result of genistein treatment of cells not expressing ERβ 
(sample CA) included (Table 2) functions associated with infection mechanism, cellular 
assembly and organization, cellular function and maintenance, cell cycle, cancer, cell death, 
lipid and drug metabolism, inflammatory response, molecular transport and connective tissue 
development and function. The most significant networks in genistein exposed T47D-ERβ 
cells expressing ERβ (sample DB)(Table 3), included functional categories such as infection 
mechanism, lipid metabolism, gene expression, cell cycle, cell-mediated immune response, 
cell death and immunological diseases. The results obtained for the second sample analyzing 
genistein induced ERβ-mediated effects (sample ED) are presented in table 4 and indicate 
networks affected to be involved in infection mechanism, lipid metabolism, vitamin and 
mineral metabolism, antigen presentation, cancer, cellular growth and proliferation, and cell 
death. 
Networks
 
Table 3: IPA network analysis in cells expressing ERα and ERβ. Bold protein names and underlined italic  
indicate up- and down-regulated expression, respectively. Regular black colour indicates intermediate molecules 
incorporated through relationships with other molecules. 
 
ID Molecules in Network Score Focus 
Molecules 
Top Functions 
Genistein-ERα/ERβ 
 1  AK2, Caspase, CLIC4, Cytochrome c, DHX9, DLAT, 
DLD, ELOVL1, GSTM2, GSTM3 (includes EG:2947), 
HNRNPC, HNRNPM, HNRNPU, Hsp90, ILF3, ILF2 
(includes EG:3608), IQGAP1, KIAA1967, KTN1, 
MIR124, MYL12B, NARG1, NFKB2, NUMA1, P38 
MAPK, PAK2, PGRMC2, PRMT1, ROCK1, S100A9, 
SERPINB6, STAU1, TRIP11, TWF2, Vegf 
 53  29  Infection Mechanism, Lipid 
Metabolism, Nucleic Acid 
Metabolism 
 2  Actin, ACTN4, ALCAM, Alpha actin, Alpha Actinin, 
Alpha catenin, ANXA1, ANXA2, Cadherin, Calpain, 
CAPN2, CAPNS1, CFL2, CNN2, Cofilin, CSRP1, 
DCTN2, DSTN, ERK, F Actin, FAK, FAU, FLNA, MAEA, 
MAP4, MAPK13, MARCKSL1, MATR3, PCYT1A, 
RPS18, S100A11, SFPQ, SSH3, TLN1, VCL 
 44  25  Cellular Assembly and 
Organization, Antigen 
Presentation, Cell 
Morphology 
 3  ACAT2, ACLY, Akt, APOE, BAG5, BCAM, BCR, CD3, 
CD9, CRK, DNAJA2, EIF4A, EIF4G1, EIF4G2, FGR, 
G6PD, HNRNPR, Hsp70, Jnk, LAMA5, Laminin, LMNA, 
MUC1, NAT1, Pdgf, PDGF BB, Pdgfr, PGR, PI3K, Ras 
homolog, S100A6, SRC, TCR, Tgf beta, UNC45A 
 32  20  Gene Expression, Cell-To-
Cell Signaling and 
Interaction, Renal and 
Urological System 
Development and Function 
 4  B2M, CYB5R3, DSP, ECSIT, ESR2, FDFT1, Growth 
hormone, HSP90B1, Ifn, IFN Beta, Ifn gamma, IFN 
TYPE 1, Ige, IgG, IL18, IL12 (complex), Interferon 
alpha, ISG15, LDL, MHC Class I (complex), MX1, NFkB 
(complex), NPC2, PLS3, PPL, PPP4C, PRSS8, Rab11, 
RAB11A, STAT1, STAT3, STAT5a/b, TFRC, TMEM43, 
Tnf receptor 
 32  20  Cell-To-Cell Signaling and 
Interaction, Cell-mediated 
Immune Response, 
Hematological System 
Development and Function 
 5  26s Proteasome, ACADM, ADRM1, Ap1, ASNS, 
CDK5RAP3 (includes EG:80279), Ck2, CTSD, Cyclin A, 
DDRGK1, E2f, HIST1H1B, HIST1H2AB, Histone h3, 
HK1, HNRNPA2B1, HNRNPL, IL1, Insulin, JUP, 
KIAA0776, LAP3, Mapk, MGMT, peptidase, Pkc(s), 
PP2A, Rac, Ras, Sapk, TIMM13, TOP2B, Ubiquitin, 
UBTF, UFD1L 
 30  19  Cancer, Cell Cycle, 
Immunological Disease 
 6  ADSL, C11ORF79, C17ORF81, CCDC45, CLDN1, 
CLDN3, DNAJB4, DUSP3, EEF1A1, FGF5, FGF6, 
FGF7, FGF9, FGF16, FGF17, FGF18, FGF20, FGF21, 
FGF22, FGF23, FGFR2, GFM1, HNF4A, HSPC152, 
ISOC1, LRSAM1, LSM3, MRPL32, MUTYH, PABPN1, 
PRAF2, RAB1B (includes EG:81876), RMND1, 
RNMTL1, SULT1A1 
 22  15  Cell-To-Cell Signaling and 
Interaction, Carbohydrate 
Metabolism, Lipid 
Metabolism 
 7  ALDH1B1, ATAD3A, BCL2L1, COMMD3, CRIP2, 
CYTSB, DDX1, EDC4, EPCAM, EPHX2, FOXJ1, GAA, 
GCDH, GMFB, GOSR1, GRB2, H1F0, HMGN2, LEP, 
LRRC47, MRPL12, MYC, NFKB1, OPLAH, RPL27, 
RPL38 (includes EG:6169), RPS18, RPS23, RPS15A, 
SHMT2, SLK, SNCA, UGP2, ZFP36, ZNF274 
 20  14  Cellular Compromise, 
Cancer, Skeletal and 
Muscular Disorders 
 8  ABCF1, ADI1, AIFM3, AKR1C14, ARMC10, beta-
estradiol, BLVRB, CBR3, CDKN2C, CNN2, COX6B1, 
CYB5R1, DNPEP, ENO1, ERO1L, GALE, Histone h4, 
HSDL1, IDH3B, IL6, MME, NAGLU, NDOR1, 
NDUFA12, NDUFB10, NHP2L1, OSTF1, 
Oxidoreductase, PMM2, RBL1, RDH11, RDH12, 
RDH13, SLC9A3R1, TGFB1 
 20  14  Cell Cycle, Cancer, 
Cardiovascular System 
Development and Function 
 9  AARS, ACOT2, ANXA3, C14ORF166, COX4I1, DDX1, 
EEF1B2, EIF3M, EIF4A2, EIF4E, EIF4G3, FAM62A, 
GH1, GIGYF2, GLG1, GLUD1, GPS1 (includes 
EG:2873), HNRNPUL2, HSD17B8, HSD17B10, 
HSP90AB1, MAN2B1, MDH1, NANS, NPEPPS, PPT1, 
PRDX3, REEP6, RPL19 (includes EG:6143), RPS29, 
SLC2A4, SSBP1, TKT, UBA7, YWHAZ 
 18  13  RNA Post-Transcriptional 
Modification, Gene 
Expression, RNA Trafficking 
 10  ARF3, ARF4, CECR5, COTL1, CPSF1, CTSC, 
CUGBP1, EHD1, EIF2A, FOS, GLB1, HAS1, HIPK1, 
HNRNPC, HOXB6, KHSRP, LAMP2, LSS, MFGE8, 
MGP, MIR1, MKL1, MMD, OPTN, PIP, RASA3, RBM7, 
RBP1, RPS6KA4, Rxr, SF3B2, SGK1, TAGLN2, TERT, 
TNF 
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 11  AK1, AK3L1, BANP, BZW2, C19ORF10, CYB5A, 
DNASE2, DUT (includes EG:1854), EI24, ETFA, FDXR, 
GART, GBP1 (includes EG:2633), GSDMD, HEXB, 
HLX, HNRNPA3, hydrogen peroxide, IFNG, IL13, 
LETMD1, MIR298 (includes EG:723832), MOBKL1A, 
OSGIN1, PIP4K2C, PPA1, RCN1, REEP5, RNF144B, 
SCGB3A1, SESN1, TP53, UBE2L6, UBE2V1, VEGFA 
 17  13  Lipid Metabolism, Small 
Molecule Biochemistry, 
Skeletal and Muscular 
Disorders 
 12  ABCC6, ACTBL2, AFG3L1, AFG3L2, ARRB2, ATP6, 
ATP8, ATP5H (includes EG:10476), ATP6V1G1, 
ATP6V1G2, ATPase, BAT1, CA12, CGN, CLPX, 
DDX1, DDX39, DHX16, ENTPD2, FN3K, HBB (includes 
EG:3043), HIST1H1C, KIF20B, MYO9A, RNA 
polymerase II, S100A16, SFN, SMARCA4, SPAST, 
TCOF1, TNKS1BP1, TOB1, TOMM34, VCP, VPS4B 
 16  12  Carbohydrate Metabolism, 
Small Molecule 
Biochemistry, DNA 
Replication, Recombination, 
and Repair 
 13  APBB2, ATXN10, BLZF1, CRAT, DNAJC3, EGFR, 
Egfr dimer, EIF5B, FKBP2, FKBP7, HIST1H1E, HM13, 
HTT, LDHB, NDUFA8, NDUFA12, NDUFA13, 
NDUFB10, NDUFV1, NDUFV2, PDXK, PPP1CC, 
RAB3D, retinoic acid, RNF40, SEC22B, SEPHS1, 
SLC25A3, SP110, SRP9, STX1A, STXBP2, TPR, 
VAPB, XBP1 
 16  12  Skeletal and Muscular 
System Development and 
Function, Cellular 
Compromise, Cancer 
 14  ACPP, AKAP11, Androgen-AR, Calmodulin, Cbp/p300, 
CRB3, DLG1, EDF1, ERK1/2, FSH, FZD4, GLYCOGEN 
PHOSPHORYLASE, hCG, HIST1H1D (includes 
EG:3007), HNRNPAB, ISYNA1, KCNK3, KIDINS220, 
LIN7C, MGMT, MOCS2, MPP2, MPP5, MPP7, 
PPP1R3C, PPP2CA, PPP2R3A (includes EG:5523), 
PRKCE, Proteasome, PTPN7, PYGB, PYGM, 
S100A10, STK25, UPP1 
 9  8  Carbohydrate Metabolism, 
Cell-To-Cell Signaling and 
Interaction, Cellular 
Assembly and Organization 
 15  MIRN349, TTC9C  2  1   
 16  BCCIP, HIST1H2BN  2  1  Cell Signaling, Cancer, 
Cellular Growth and 
Proliferation 
 17  Cl--transporting ATPase, PCYOX1  2  1  Amino Acid Metabolism, 
Small Molecule 
Biochemistry, Cell-To-Cell 
Signaling and Interaction 
 18  CLIC3, MAPK15  2  1  Molecular Transport, Post-
Translational Modification, 
Cancer 
 19  ARPM1, KIF21A, MIB1  2  1  Genetic Disorder, 
Ophthalmic Disease, 
Skeletal and Muscular 
Disorders 
 20  KIAA1324, MIR128-1 (includes EG:406915), MIR128-2 
(includes EG:406916) 
 2  1  Cardiac Arteriopathy, 
Cardiovascular Disease, 
Genetic Disorder 
 
Expected networks overlap between datasets was found. In depth analysis of these 
overlapping networks based on protein expression values (Tables 2, 3 and 4), showed that 
proteins belonging to overlapping networks were regulated in opposite directions (i.e. up- 
respectively downregulated). Proteins listed in functions like cell cycle, cellular assembly and 
organization, apoptosis or cellular growth and proliferation showed opposite expression 
profiles with high scores when comparing all datasets. Networks involved in cell proliferation 
and growth were shown to be regulated in both genistein exposed cells expressing ERβ and in 
genistein exposed cells not expressing ERβ albeit in opposite directions. These biological 
effects elucidated by the present protein-network based approach were in line with our 
previous results obtained on the basis of analysis of modification of individual proteins also 
demonstrating that in genistein exposed T47D-ERβ cells not expressing ERβ processes of 
cell proliferation and cell growth were stimulated, whereas in genistein exposed T47D-ERβ 
cells expressing high levels of ERβ proteins involved in cell proliferation and cell death were 
Networks
 
downregulated and proteins involved in apoptosis and cell death were upregulated (chapter 
5). The results are also in line with our previous data on genistein mediated effects on cell 
proliferation as a biological endpoint, showing genistein induced cell proliferation in cells in 
which ERβ expression was absent whereas genistein induced cell proliferation was inhibited 
upon increased ERβ expression in the T47D-ERβ breast cancer cells (8).  
 
Table 4: IPA network analysis of second approach for ERβ taget proteins. Bold protein names and underlined 
italic  indicate up- and down-regulated expression, respectively. Regular black colour indicates intermediate 
molecules incorporated through relationships with other molecules. 
 
ID Molecules in Network Score Focus 
Molecules 
Top Functions 
 1  ACY1, ANXA6, Caspase, CAT, Cytochrome c, DCD, 
EIF2AK2, EIF2B1, ERK, GANAB, GDI1, GIPC1, GOT2, 
Hdac, Hsp70, Hsp90, HSP90B1, HSPA4, HSPA9, 
HSPA1A, IFN Beta, ILF3, ILF2 (includes EG:3608), Lamin 
b, LMNA, LMNB1, LMNB2, MVD, MYO6, PA2G4, PPIB, 
PTGES3 (includes EG:10728), TOR1AIP1, TTC1, 
VDAC1 
 48  27  Infection Mechanism, Cell 
Morphology, Cellular 
Assembly and Organization 
 2  ACP2, Akt, Alpha actin, Alpha catenin, ANP32A, ANXA2, 
ATPIF1, BLVRB, CIRBP, CLU, COX7A2L, ERK1/2, 
ERO1L, ESR2, ETFDH, FDFT1, FSH, hCG, HYOU1, 
LASP1, LDL, MAP4, MUC1, MVK, MX1, NPC2, 
Oxidoreductase, PP2A, PPP1R2, PTGR2, RBMX, RPL22, 
Tgf beta, VCL, Vegf 
 40  24  Lipid Metabolism, Small 
Molecule Biochemistry, 
Vitamin and Mineral 
Metabolism 
 3  ANXA1, CA12, CBX5, CORO1B, COTL1, DIAPH1, 
Dynamin, F Actin, FLNA, GAPDH (includes EG:2597), 
GFPT1, GSTM2, HK1, Ifn, Insulin, Jnk, LNPEP, Mapk, 
MED20, NAE1, OGT, PDGF BB, PI3K, Pkc(s), PREX1, 
Rab5, Rac, Ras, RBBP4, RNA polymerase II, S100A6, 
S100A8, TAF9, UGDH, VPS45 
 36  22  Carbohydrate Metabolism, 
Molecular Transport, Nucleic 
Acid Metabolism 
 4  Ap1, APOE, Arf, ASS1, BID, CD59, Ck2, CRABP2, 
DHX9, EIF4B, FKBP2, GBF1, HADH, HNRNPC, IFIT1, 
IFN TYPE 1, IgG, IL1, IL12 (complex), Interferon alpha, 
ISG15, MIR124, NPM1 (includes EG:4869), NUMA1, 
P38 MAPK, Pdgf, PRSS8, SCARB2, SMC1A, STOM, 
SWAP70, TACSTD2, TWF2, WARS, ZMPSTE24 
 36  24  Genetic Disorder, 
Ophthalmic Disease, 
Cellular Assembly and 
Organization 
 5  ALDH7A1, Alpha Actinin, Calpain, CD3, CD9, 
Collagen(s), DBNL, DMD, DSP, FAK, FGR, FHL2, 
Fibrinogen, Integrin, Integrin alpha 3 beta 1, Integrin alpha 
6 beta 1, Integrin&alpha;, Integrin&beta;, ITGA2, ITGAV, 
ITGB1, ITGB5, KPNA4, KRT8, KRT18, KRT19, Laminin, 
NFkB (complex), NME3, PEBP1, Raf, Ras homolog, 
RRAS, TCR, TPMT 
 29  19  Tissue Development, Cell-
To-Cell Signaling and 
Interaction, Endocrine 
System Development and 
Function 
 6  ACSS1, ALAD, ANKHD1-EIF4EBP3, butyric acid, 
CNPY2, COTL1, DAK, DCXR, DEK, EHD1, FAM49B, 
GBP1 (includes EG:14468), GMPS, HNRNPAB, IFIH1, 
IFIT1, IFNA5 (includes EG:3442), IFNB1, IKBKE, ISG15, 
ITGAD, KLF15, NFKBIE, PHGDH, PURA, RIG1, RPL38 
(includes EG:6169), SLK, SP1, TALDO1, TBCB, TNF, 
TP53I3, TPR, YARS 
 25  17  Infection Mechanism, 
Infectious Disease, Antigen 
Presentation 
 7  2-hydroxyestradiol, AARS, ABAT, ACOX1, AHSA1, 
AIMP2, ANXA3, AP1B1, beta-estradiol, C8ORF55, CFTR, 
CLCN3, CRK, CSTB, CTPS, CYB5A, 
dehydroepiandrosterone sulfate, FADS2, Glutathione 
peroxidase, GMFB, GPX2, GPX3, GPX7, GPX8, GSTZ1 
(includes EG:2954), KARS, LGALS4, MB, MGP, 
MGST3, PTP4A2, RAB15, RARS, THOC2, WFS1 
 20  15  Gene Expression, Lipid 
Metabolism, Small Molecule 
Biochemistry 
 8  ACLY, AGR3, APOA1, APOA4, APOC1, APOC2, 
CLYBL, CRIP1, CSK, DAG1, DHX38, EPPK1, FGA, 
GALM, GPT, GSTK1, HNF4A, HSDL2, ISOC1, LBP, 
LIPC, PCMT1, PHB2, PNPO, PON1, PSAT1, QDPR, 
RAB18, SCARB1, SERTAD3, SRPR, SSR2, TBC1D15, 
TOMM20, TTR 
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 9  ALDH18A1, CCT2, CCT3, CCT4, CCT5, CCT8, CCT6A, 
CSDA, FAM118B, FAM129A, GAMT, GCN1L1, HDDC3, 
HIGD1A, IFI16, IFI202B, IMPACT, MAPKAP1, MYC, 
NDUFA5, NDUFA8, NDUFAF2, NDUFS1, NDUFS2, 
NDUFS3, NMI, PCBP2, PHB (includes EG:5245), 
PTBP1, RPS27, SHMT1, SHMT2, TCP1, TKT, TP53I3 
 19  14  Amino Acid Metabolism, 
Small Molecule 
Biochemistry, Cancer 
 10  APP, ARL2, BLMH, CLDN1, CRAT, CTNNB1, DCI, 
DNM1L, EHHADH, FRUCTOSE 1,6 BIPHOSPHATASE, 
HYOU1, IDE, INS1, ISYNA1, KCNJ11, KYNU, Ldh, 
LDHB, LGALS9, NCSTN, PECI, Pka, PPME1, PPP1R2, 
PPP1R1A, PPP2CA, PTGFRN, RAF1, SLC1A5, TBCD, 
THOP1, UBE2D2, UBE2E2, WBP2, ZNRF1 
 17  14  Lipid Metabolism, Small 
Molecule Biochemistry, Cell 
Cycle 
 11  AHNAK, AK3, AP3B1, ARMCX3, ATP6V1G1, CLIC4, 
CLTC, CLTCL1, CMPK1, CSRP1, DDX1, DNASE2, 
EHD1, EIF3A, ETF1, IL9R, KPNA1, LARP1, MIR16-1, 
MIR206 (includes EG:406989), MYOF, NUFIP1, PFN1, 
RP11-529I10.4, RUVBL1, RUVBL2, SEC24A, SH3BP4, 
SNX5, TNFSF11, TRAP1, UTRN, WIBG, WWC2, 
YWHAZ 
 17  13  Antigen Presentation, Cell 
Death, Cell Morphology 
 12  ANXA11, ARF4, ASPM, CCAR1, DDX19A, EGFR, 
FDXR, H2AFZ, HARS, HINT2, KCNJ4, LETMD1, LMCD1, 
LRRFIP1, MBNL2, NCAPG (includes EG:64151), NEDD8, 
P4HA1, PMM1, REEP5, RNH1, RPS7, RPS15A, RYR1 
(includes EG:6261), S100A11, SCAMP1, SHISA5, 
SMURF2, SNX2, SPG20, SRM, TGFB1, TP53, UBE4B, 
VPS24 
 17  13  Cancer, Cell Cycle, Tumor 
Morphology 
 13  AK3L1, ALDOC, B2m-Mhc1a, BCAT2, C11ORF79, 
CANX, CBR3, COX6B1, CPSF7, DECR1, EFHD1, ELP2, 
ELP5, ERBB2, Histone h3, Histone h4, HLA-A, 
HSD17B12, HYOU1, IKBKAP, KIAA1107, LSR, ME2, 
NOC2L, PHYH, PIP, RPL17, SDHB, SDHD, SGK1, 
SNUPN, TUFM, VEGFA, WBP5, WWOX 
 16  12  Cancer, Hematological 
Disease, Reproductive 
System Disease 
 14  ACTBL2, Actin, AKT1, AP3B1, AP3D1, ARRB1, ARRB2, 
BOLA2, CMBL, DGKE, DGKZ, DMD, EEF1A2, GMPPB, 
GRHPR, H1FX, HIST1H1C, HIST1H2BO, HNRNPA0, 
IKBKB, KTN1, MATR3, NOP10, RBM10, RPL7A, RPS8, 
RPS17 (includes EG:6218), S100A16, SCYL2, SLC9A5, 
TCOF1, TPM3, TUBA1C, UBA52, XPOT 
 15  12  Cellular Development, Cell 
Signaling, DNA Replication, 
Recombination, and Repair 
 15  4-phenylbutyric acid, AIF1, APRT, BCL2L1, BNIP3 
(includes EG:664), CA9, CAPG, CAPN1, CCND1, CDV3, 
FAF2, GBE1, GPI, GTPBP4, HIF1A, HIF1AN, HIF3A, 
HINT1, HISTONE, HUWE1, LYPLA1, PEBP1, PGAM5, 
PITPNB, PLEC1, PRDX5, PRKCA, QPRT, S100A11, 
TPT1 (includes EG:7178), Ube3, UBR2, VHL, VHL-Cul2-
Elongin-RBX1, ZNF197 
 12  11  Cellular Growth and 
Proliferation, Cancer, Cell 
Death 
 16  ACAD8, ACAD9, ACAD10, ACADL, ACADS, ACADSB, 
ACADVL, ACOT8, ACOT9, ACP2, Acyl-CoA 
dehydrogenase, CRIP1, HNF4A, IL4, IVD, KPTN, LTA4H, 
MED23, MIR1, NDFIP1, NP, OTC, PAH, PPARA, 
PPM1G, RAB25, RAB11A, RAB11B, RAB11FIP1, 
RAB11FIP2, SRM, TAGLN2, TRAPPC3, UCHL5, 
XPNPEP3 
 12  10  Lipid Metabolism, Small 
Molecule Biochemistry, 
Amino Acid Metabolism 
 17  METTL7A, MME  2  1  Cancer, Cell Death, 
Neurological Disease 
 18  Cob(I)alamin adenosyltransferase, MMAB  2  1  Genetic Disorder, Metabolic 
Disease 
 19  Cl--transporting ATPase, PCYOX1  2  1  Amino Acid Metabolism, 
Small Molecule 
Biochemistry, Cell-To-Cell 
Signaling and Interaction 
 20  AMDHD2, N-acetylglucosamine-6-phosphate 
deacetylase 
 2  1  Dermatological Diseases 
and Conditions, Infectious 
Disease, Embryonic 
Development 
 21  GLTP, MIR373  2  1  Lipid Metabolism, Molecular 
Transport, Small Molecule 
Biochemistry 
 22  ACTL6B, ANO8, COQ9  2  1   
 
 
Networks
 
Subnetwork markers corresponding to the hallmarks of immune/inflammatory system 
deregulation. 
When comparing the IPA network-based classification from all the datasets (Table 2, 3 
and 4), other protein networks than those involved in cell proliferation and apoptosis also 
appeared to be affected upon genistein treatment. Especially evident was a marked 
enrichment of molecular mechanisms correlated with immune system regulation or 
inflammatory response apparently affected upon genistein treatment of the cells.  
 
Infection mechanism was the most significant function (scores 58, 53 and 48) shared 
between the three datasets (sample CA, DB and ED). This immune function was affected, 
reflected by downregulation of ILF2, ILF3, DLAT, DHX9, HNRNPC and KIAA1967, upon 
genistein exposure of T47D-ERβ cells without ERβ  (sample CA, table 2), and by 
upregulation upon genistein exposure of T47D- ERβ cells that do express ERβ  (sample DB, 
table 3 and sample ED table 4), the latter reflected by downregulation of ILF2, ILF3, LMNA 
and LMNB1 proteins in the inhibited-ERβ dataset.  
 
In table 3, presenting the results for genistein exposed T47D-ERβ cells expressing high 
levels of ERβ (sample DB), network IDs 1, 2, 4 and 5 indicated also additional effects of 
genistein on immune response mechanisms. Functions related with immune responses such 
us antigen presentation (CNN2, ANXA1 and DCTN2)(score 44), cell-mediated immune 
response (STAT1, STAT3, NF-κB, IL18, B2M, MHC class I and HSP90B1) (score 32), and 
immunological disease (MGMT and TOP2B) (score 30) were found to be downregulated in 
genistein exposed ERβ expressing T47D-ERβ cells.  
 
This type of immune regulation processes were not found as functional terms in the 
genistein exposed cells not expressing ERβ (sample CA, table 2), only inflammatory response 
(score 20) was found regulated (IL18, TXN, S100A8 and S100A9). Enrichment of additional  
immune-related terms were also found in the second sample reflecting genistein induced 
ERβ-mediated effects (sample ED, table 4) and included molecular functions such as 
infection mechanism, infectious disease and antigen presentation.  
 
Immune-response differences between genistein exposed ERβ and non-ERβ expressing 
T47D-ERβ cells 
In addition of the protein-network based analysis presented above, the SILAC datasets 
were also analyzed using a protein interaction network based approach. Using this approach, 
it becomes possible to select all the associated proteins from a specific term and construct a 
unique merged protein interaction network. Initially the four main immune system related 
networks regulated by the expression of ERβ (Network IDs 1, 2, 4 and 5 from sample DB) 
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were merged using the IPA tool into one. Expression values and protein relationships could 
be visualized in the connectivity map (Figure 1).  
 
 
 
Figure 1: Connectivity map of the responses by Ingenuity Pathway assistant analysis. Merged networks 1, 2, 4 
and 5 from genistein-ERα/ERβ regulated proteins experiment. Red colored proteins indicates upregulated, green 
indicates dowregulated proteins, white represents not detected proteins whereas grey indicates detected proteins 
that do not pass our statistical cut off. A more detailed legend to the connectivity map in figure 1 can be found in 
Supplementary Fig. S1, explaining the symbols. 
 
Networks
 
Consistent with other systems biology methodologies, and based on the results above 
(Figure 1), we conducted a thorough functional study of the highly scored nodes from our 
merged  immune-related protein expression using functional analysis in Ingenuity. For this, 
IPA analyses of the original dataset was done without extra molecules added by ingenuity 
that might decrease the p-value of the networks and become more meaningful. The molecular 
function and disease analysis inquired into the functions of all significantly affected proteins, 
regardless of their mutual interaction, confirmed the implication of the selected proteins in 
immune-related processes (Table 5), terms such as infection mechanism, inflammatory 
response or immune trafficking were found confirmed. 
 
Table 5: IPA Top molecular functions and diseases from ERβ-merged  network.   
 
Relative function & disease  p‐value  Molecules  
Cellular assembly and organization  6.69E‐05  25 
Cardiovascular disease  1.52E‐04  12 
Genetic disorder  1.52E‐04  20 
Gene expression  5.54E‐04  9 
Infection mechanism  5.54E‐04  7 
Cell‐to‐cell signaling and interaction  7.79E‐04  16 
Hematological system development 
and function 
7.79E‐04  15 
Immune trafficking  7.79E‐04  13 
Inflammatory response  7.79E‐04  12 
Cancer  2.26E‐03  16 
Reproductive system disease   2.26E‐03  12 
Antigen presentation  2.70E‐03  9 
 
In a next step, the highly complex network obtained, was reduced to give the data-model 
presented in Figure 2 by selecting significant ER-mediated immune protein relationships. 
 
The molecular pathways in normal and tumor cells that control immune responses 
include transcription factors, such as nuclear factor kappa B (NF-κB), and signal transducer 
and activator of transcription 3 (STAT3), which, in turn, control the production of other 
chemokines and inflammatory mediators (cytokines). These two significant transcription 
factors appear to be significantly regulated in both datasets (CA and DB), being both 
downregulated in genistein exposed T47D-ERβ cells that express ERβ (Figure 2B), whereas 
in non-ERβ-expressing cells, only NF-κB was dowregulated (Figure 2A). 
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A 
 
B 
 
Figure 2: Connectivity map of the responses by Ingenuity Pathway assistant analysis. A) Cells expressing only 
low levels of ERα. Green indicates dowregulated, red indicates upregulated, pink indicates low expression and 
white not detected. B) Cell coexpressing ERα and ERβ. A more detailed legend to the connectivity map in 
figure 2 can be found in Supplementary Fig. S1, explaining the symbols. 
 
Figure 2B (sample DB) also shows that in genistein exposed T47D-ERβ cells that 
express ERβ , complete dowregulation of the immune system network is observed. Since the 
expression of ERβ in this experiment was found to be much higher than ERα (chapter 5), it is 
likely that genistein mediated ERβ activation downregulated the production of cytokines (IL1 
and IL18) by inhibition of NF-κB or STAT3. The protein interaction network analysis also 
revealed that gensitein exposure of T47D-ERβ cells expressing ERβ also resulted in direct 
inhibition of STAT1 and NF-κB activation (Table 3), and therefore downregulated the 
production of an array of inflammatory mediators, finally resulting in downregulation of 
interferon-stimulated proteins like MX1, ISG15, B2M. 
Networks
 
Upregulation of cytokines IL1 and IL18 and further increased expression of interferon 
related proteins was found. Thus, in the absence of ERβ expression, genistein induced 
immunosuppression was no longer observed (Figure 2A). 
 
 
Cytokine production 
To validate the predicted genistein-induced ERβ mediated immune suppression, 
exposure medium from treated cells (samples A, B, C, D and E) was used to measure 
cytokine production. Specifically the cytokines that might be influenced by the genistein 
induced downregulation of the transcription factors NF-κB and/or STAT-1 (Figure 2) were 
analysed, being interleukines 1β and 8 (IL-1β, IL-8), interferon γ (IFN-γ), and tumor necrosis 
factor a (TNF-α). In addition tumor growth factor β (TGF-β) known to be upregulated when 
IFN-γ levels go down was quantified as breast cancer patients have increased levels of 
regulatory T-cells that are profoundly able to inhibit T-cell dependent production of IFN-γ 
(17) In line with the fact that genistein exposure of ERβ expressing T47D-ERβ cells resulted 
in down regulation of NF-κB and/or STAT-1, expression of the related cytokines IL-1β, IL-8, 
IFN-γ, and TNF-α could not be detected in the medium. Only the production of TGF-β was 
detected (Figure 3) showing small differences between samples. Genistein was able to induce 
the production of TGF-β, and this production was higher in ERβ expressing samples than in 
non-ERβ expressing cells. Upregulation of TGF-β was more pronounced in genistein exposed 
T47D-ERβ cells expressing ERβ than cells not expressing ERβ. 
      
Figure 3: Cytokine TGF-β production. Ratios of cytokine production were calculated. 
 Discussion: 
The present study presents a protein-network based analysis of the quantitative SILAC-
based proteome of T47D-ERβ breast cancer cells with tetracycline-dependent varying 
intracellular ERα/ERβ ratio exposed to genistein. Genistein is a phytoestrogen found in high 
levels in soy products the intake of which has been frequently associated with various 
beneficial health effects including reduced risk on breast cancer and osteoporosis in 
menopausal women (18-20). 
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 Using the T47D-ERβ cell line, three different protein datasets were obtained using the 
SILAC approach, and signaling effects of estrogen receptor subtypes exposed to the 
phytoestrogen genistein were addressed based on single protein expression level analysis in a 
previous paper (Chapter 5). Functional analysis of the genistein induced proteome data in 
genistein exposed T47D-ERβ cells not expressing ERβ, revealed that genistein was able to 
induce growth of the breast epithelial cells as indicated by the activation of cellular 
reorganization and maintenance, whereas gensitein exposure of ERβ expressing T47D-ERβ 
cells decreased the cell motility and cell proliferation. Analysis of the data by a protein 
network approach as presented in the present paper corroborates that pathways of cell 
proliferation, cell death, cell cycle and lipid metabolism are significantly affected in opposite 
ways in cells that do not express ERβ on one hand and cells that do express higher levels of 
ERβ (Tables 2, 3 and 4). Networks found to be upregulated in the gensitein exposed T47D-
ERβ cells not expressing ERβ belonged to processes such us cellular assembly and 
organization, cellular function and maintenance, and cell cycle among others, whereas 
networks upregulated in the genistein exposed T47D-ERβ cells expressing high levels of ERβ 
showed a clear implication in cell cycle, gene expression and cell death.   
 
 Furthermore, comparing network analysis between samples expressing or not ERβ, we 
detected clear differences in regulatory networks among differentially expressed proteins 
related to immune responses. Genistein, in the presence of ERβ, downregulated cellular 
processed and proteins implicated  in antigen presentation, cell-mediated immune response, 
and immunological disease. Whereas, in absence of ERβ, these processes were not regulated, 
instead, parameters such as inflammatory response or infection mechanism were found to be 
affected. It is well established that estrogens and phytoestrogens can affect the development 
and regulation of the immune system in vivo and in vitro, but how the biological function of 
this estrogenic compounds are mediated is still not fully understood (3, 21, 22).  
 
During the past few years implications of ERs on inflammation and immune diseases 
have been proposed but not further elucidated (23, 24). It is well established that sex 
hormones can have a substantial impact on the immune system (25). Immune tissues and 
cells expressing ERs respond to estrogens (22). Several studies have reported increased 
activity of several immune function parameters, such as interferons and interleukins 
production, or T and NK cell activity after exposure to the isoflavones, daidzein and genistein 
(22, 26). Moreover, genistein attenuates cytokine-stimulated proliferation of both normal and 
cancer cells supporting its contribution to the inflammatory/immune responses as its possible 
mechanism of action (27, 28). Recently it has been suggested that genistein may exhibit anti-
tumour activity via a cellular immune mechanism (4, 21). Therefore, estrogens and estrogen-
like compounds may modulate immunological responses and the mechanisms underlying 
these effects remain unclear (29). 
Networks
 
It has been shown, that ERα and ERβ have an important role in immune organ 
development. Knock out ERα, ERβ and double knock out (ERα and ERβ) mice show thymus 
and spleen atrophy (3, 30). Moreover, recent data suggested the immunosuppressive and 
thymic atrophy effects as a result of genistein treatment in mice (21).  
 
 Our results are in line with the hypothesis that the immune system is a major estrogen 
target (29). In addition to the protein-network based analysis, in a next step a regulatory 
protein network model was used in order to elucidate if the immune modulating effects of 
genistein were ER- or non-ER-mediated. Figure 2 shows how ERs are able to directly 
downregulate NF-κB after genistein binding. Moreover, genistein is able to downregulate 
STAT1 and NF-κB directly and indirectly (Figure 2). These two transcription factors are the 
main regulators for iNOS, through an array of inflammatory mediators. Other flavonoids such 
us kaempferol, quercetin and daidzein have shown this anti-inflammatory property in 
previous studies (31). Since the downregulation of STAT1 and NF-κB was common in cells 
expressing or not ERβ, the possible downregulation of the immune system protein network in 
ERβ-expressing cells could not be explain by the regulation of this two transcription factors.  
 
 Pathways different from those regulated by STAT1 and NF-κB could be identified in  
the presented model (Figure 2) as the main mechanism for the regulation of the immune 
suppression in breast cancer cells. Among all STAT family members, STAT3 is most often 
correlated to tumorigenesis, and is considered as an oncogene (32). Many indications suggest 
a role for STAT3 in regulating cell movement, mainly by contributing to cytoskeleton 
reorganization and controlling cell adhesion properties (33). Expression of STAT3 was found 
to be upregulated in genistein treated cells in which ERβ was inhibited, supporting the 
implication of genistein-activated ERα in cell proliferation by cytoskeleton reorganization 
and cell movement. Moreover, STAT3 also regulates in tumor cells the molecular pathways 
that control cancer-related immunity (34) which, in turn, controls the production of other 
cytokines. Cytokines are also expressed in breast cancer cells (35). IL-18 produced by cancer 
cells seems to have pro-cancer activity, promoting cell proliferation and migration, more 
importantly is reported to be an important marker for breast cancer progression (36, 37). IL-1 
and IL-18 are pro-inflammatory cytokines and activate immune responses (38). Both 
cytokines were upregulated upon gensitein treatment of T47D-ERβ cells that did not 
expressed ERβ. As a consequence of this upregulation of pro-inflammatory cytokines, 
upregulation of interferon gamma related proteins was also found (B2M, MHC Class I and 
HSP90B1). 
 
 Downregulation of STAT3, IL-18 and IL-1 in genistein treated cells expressing ERβ 
resulted in further downregulation of the overall immune protein-network. In addition, other 
interferon gamma stimulated proteins were detected as a result of the treatment (ISG15 and 
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MX1). These proteins were also found to be secreted from both non-immune and immune 
cell (39) in addition, MX1 present a putative steroid receptor binding site for ER and PR (40).  
 
 Furthermore, the merged  immune-related network (Figure 1), also pointed at the 
downregulation of p38 MAP Kinase in genistein treated cells expressing ERβ (an effect not 
observed in genistein treated cells that did not express ERβ (sample CA). This is in 
agreement with the previously reported inhibition of p38 MAP Kinase by genistein (41).   
 
 Finally in an attempt to validate the predicted genistein-induced ERβ mediated immune 
suppression, cytokines involved in immune/inflammatory responses were analyzed. Exposure 
medium (supernatant) from SILAC samples were used to measure an array of different 
cytokines not detected by LC-MS/MS analysis. No formation of IL-1β, IL-6, IL-8, IL-10, IL-
12, IFN-γ and TNF-α could be detected. These cytokines were not detected in any of the 
treatment conditions. These results were in agreement with the negative regulation of 
interferon gamma by NF-κB. 
 
 On the other hand, production of transforming growth factor β  (TGF-β) was detected 
in all the samples (A, B, C, D and E). In breast cancer TGF-β presents an important 
immunosuppressive role (42, 43). From the independent measurements of treated samples 
with genistein and ICI 182780 (A, B, C, D and E) slightly different levels of TGF-β were 
detected (data not shown). This is in accordance with the direct antagonist effects of 
antiestrogens in TGF-β production. Previous studies shown that ICI 182780 (or fulvestrant) is 
able to induce this cytokine secretion and activation in breast cancer (44-46). TGF-β is an 
prognostic indicator associated with relapse in breast cancer patients supporting its important 
role in modulating disease activity(47). TGF-β induces MAPK and MAPK/ERK kinase 
dependent signal transduction in addition to the NF-κB pathway. TGF-β signaling is highly 
regulated via interaction with inhibitory SMAD’s or binding of the E3-ubiquitin ligases and 
coreceptors. TGF-β is able to cause inhibition of NF-κB transactivation and therefore 
proinflammatory cytokine production, including IFN-γ,  mainly through p38 MAPK (48). In 
addition, TGF-β, an inhibitor of epithelial cell growth, has both increased expression and 
production in the presence of genistein in normal and transformed breast epithelial cells (27, 
28). Therefore, when calculating resulting ratios, as in SILAC comparison, genistein treated 
cells expressing ERβ showed higher induction of cytokine production than those not 
expressing ERβ.  
 
  Altogether the results of the present study reveal that in addition to cell proliferation 
and apoptosis, immune signaling appears to be another major estrogen target influenced by 
phytoestrogen exposure resulting in genistein induced ERβ-mediated downregulation of 
immune signaling networks. 
Networks
 
Supplemental Material 
Figure S1: Legends from Ingenuity pathway analysis. 
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Summary and concluding remarks
 
Summary 
The multiple actions of estradiol and other estrogenic compounds in mammalian 
physiology are brought about, on a molecular level, as a result of complex signalling 
pathways, and mediated by at least two receptors namely estrogen receptor (ER) α and ERβ.  
 
The aim of the work presented in this thesis was to obtain insight in the role of ERα, ERβ 
and the ratio of ERα/ERβ present within a cell, in the cellular response to estrogen-like 
compounds. To this end, this thesis addressed the transcriptional activity at both the gene and 
protein level and effects on cell proliferation under the influence of specifically-acting 
estrogen-like molecules when varying the ratio of ERα/ERβ present in the cells under study. 
The ultimate aim was to link the data on cell proliferation as the biological end-point to the 
transcriptomics and proteomics data.  
 
Chapter 1 of this thesis gives an introduction describing the molecular basis of ERs, 
their tissue distribution and their dualistic role in cancer cell proliferation.  
 
Several studies demonstrated that estrogens stimulate the growth of a large proportion of 
ERα positive breast cancers (1-4) or reported a decreased ERβ expression in cancer tissues as 
compared to benign tumors or normal tissues, whereas ERα expression persists (5, 6). This 
led to the hypothesis that ERβ may modulate the proliferative effect of ERα. To further 
investigate this possible ERβ mediated modulation of the proliferative effect of ERα we 
investigated in Chapter 2 how variable cellular expression ratios of the ERα and ERβ 
modulate the effects on cell proliferation induced by ERα or ERβ agonists, respectively. 
Using human osteosarcoma (U2OS) ERα or ERβ reporter cells, propyl-pyrazole-triol (PPT) 
was shown to be a selective ERα and diarylpropionitrile (DPN) a preferential ERβ modulator. 
The effects of these selective estrogen receptor modulators (SERMs) and of the model 
compound estradiol (E2) on the proliferation of T47D human breast cancer cells with 
tetracycline-dependent expression of ERβ (T47D-ERβ) were characterized. E2-induced  
proliferation of cells in which ERβ expression was inhibited was similar to that of the T47D 
wild-type cells, whereas this E2-induced cell proliferation was no longer observed when ERβ 
expression in the T47D-ERβ cells was increased. In the T47D-ERβ cell line, DPN also 
appeared to be able to suppress cell proliferation when levels of ERβ expression were high. In 
the T47D-ERβ cell line, PPT was unable to suppress cell proliferation at all ratios of 
ERα/ERβ expression, reflecting its ability to activate only ERα and not ERβ. It was 
concluded that effects of estrogen-like compounds on cell proliferation are dependent on the 
actual ERα/ERβ expression levels in these cells or tissues and the potential of the estrogen 
agonists to activate ERα and/or ERβ. 
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In further studies described in the present thesis attention was focussed on food-born 
estrogens, genistein and quercetin. The ubiquitous and unavoidable presence of estrogenic 
substances in our western diet may pose a significant health concern, although others have 
claimed beneficial effects related to for example intake of phytoestrogens from soy (7-9). The 
human diet contains several plant-derived, nonsteroidal weakly estrogenic compounds (10). 
Moreover, phytoestrogens have been considered a natural alternative to hormone replacement 
therapy (HRT) since these chemicals are found in the regular diet (11). A hypothesis put 
forward to explain the seemingly contradictory health effects of estrogens and phytoestrogens 
relates to the potentially different ultimate cellular effect of activation of ERα, promoting cell 
proliferation and possible adverse health effects on  the one hand, and ERβ, promoting 
apoptosis and beneficial health effects on the other hand, with phytoestrogens activating 
especially ERβ but estradiol activating preferentially ERα. This hypothesis was investigated 
to a further extent in Chapter 3 of the thesis. In Chapter 3, the importance of the intracellular 
ratio of the two estrogen receptors ERα and ERβ for the ultimate potential of the 
phytoestrogens genistein and quercetin to stimulate or inhibit cancer cell proliferation was 
investigated. This is of importance because i) ERβ was shown to play a role in modulating 
ERα-mediated cell proliferation (Chapter 2), ii) genistein and quercetin may be agonists for 
both receptor types and iii) the ratio of ERα to ERβ is known to vary between tissues. Using 
human osteosarcoma (U2OS) ERα or ERβ reporter cells it was shown that, compared to 
estradiol (E2), genistein and quercetin have not only a relatively greater preference for ERβ 
but also a higher maximal potential for activating ERβ-mediated gene expression. Using the 
human  T47D breast cancer cell line with tetracycline-dependent ERβ expression (T47D-
ERβ), the effect of a varying intracellular ERα/ERβ ratio on E2- or pythoestrogen-induced 
cell proliferation was characterised. Similar to the results obtained in Chapter 2 the data in 
Chapter 3 reveal that E2-induced cell proliferation of cells in which ERβ expression was 
inhibited was similar to that of the T47D wild type cells, whereas this E2-induced cell 
proliferation was no longer observed when ERβ expression was increased. With increased 
expression of ERβ the phytoestrogen-induced cell proliferation was also reduced. These 
results pointed at the importance of the cellular ERα/ERβ ratio for the ultimate effect of 
phytoestrogens on cell proliferation. 
 
A remarkable observation reported in Chapter 3 was that in the U2OS ERα and ERβ 
reporter cells genistein and quercetin resulted in a higher maximal induction of ERα or ERβ-
mediated luciferase activity than the maximal luciferase activity induced by E2. This 
phenomenon has been observed also in other studies (12, 13) and has been referred to as 
superinduction. This effect was consistently measured in our lab, but so far, the mechanism 
underlying this effect and thus also its biological relevance remained to be elucidated. 
Therefore, in Chapter 4, several hypotheses for the possible mechanisms underlying this 
Summary and concluding remarks
 
superinduction were investigated using genistein as the model compound known to induce 
the effect. These hypotheses included i) a non ER-mediated mechanism, ii) a role for an ERα 
and/or ERβ activating genistein metabolite with higher ER-inducing activity than genistein 
itself, and iii) an artefact that is not biologically relevant but specific for the luciferase based 
reporter gene assays. The data presented in Chapter 4 indicate that induction and also 
superinduction of the reporter gene is ER-mediated, and that superinduction by genistein 
could be ascribed to stabilization (decreased degradation) of the firefly luciferase reporter 
enzyme increasing the bioluminescent signal during the cell-based assay at genistein 
concentrations above 1 µM. This indicated that the phenomenon of superinduction may not 
be biologically relevant but may rather represent a post-transcriptional effect on protein 
stability. 
 
In order to elucidate the mechanisms underlying the genistein induced effects on cell 
proliferation in T47D-ERβ cells with variable cellular ERα/ERβ ratio as reported in Chapter 
3, Chapter 5 addressed by transcriptomics and quantitative SILAC-based proteomics, the 
ERα and ERβ-mediated effects on gene and protein expression in T47D-ERβ breast cancer 
cells exposed to the phytoestrogen genistein. Using the T47D-ERβ human breast cancer cell 
line with tetracycline-dependent ERβ expression, the effect of a varying intracellular 
ERα/ERβ ratio on genistein-induced gene and protein expression was characterised. Results 
obtained revealed that in ERα-expressing T47D-ERβ cells genistein induced transcriptomics 
and proteomics signatures pointing at rapid cell growth and migration by dynamic activation 
of cytoskeleton remodeling. The data revealed an interplay between integrins, focal adhesion 
kinase (FAK), CDC42 and actin cytoskeleton signalling cascades, occurring upon genistein 
treatment, in the T47D-ERβ breast cancer cells with low levels of ERα and no expression of 
ERβ. In addition, data presented in Chapter 5 indicated that ERβ-mediated gene and protein 
expression counteract ERα-mediated effects, because in T47D-ERβ cells expressing ERβ and 
exposed to genistein a clear downregulation of genes and proteins involved in cell growth and 
induction of genes and proteins involved in cell cycle arrest and apoptosis was demonstrated. 
Thus, genistein induced ERβ mediated effects resulted in decreased expression of genes and 
proteins involved in cell motility and metastatic potential as well as of genes and proteins 
involved in cell survival of the breast cancer cell line. It was concluded that the effects of 
genistein on proteomics and transcriptomics endpoints in the T47D-ERβ cell model were 
comparable to those reported previously for estradiol, and that the ultimate estrogenic effect 
will be dependent on the receptor phenotype (ERα/ERβ ratio) in the cells or tissue of interest.  
 
In a subsequent study of the proteomics results, data analysis was performed based on a 
protein-network approach. Results from this protein-network analysis revealed additional 
protein networks to those involved in cell proliferation and apoptosis to be affected upon 
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genistein exposure of the T47D-ERβ breast cancer cells. These results are described in 
Chapter 6.  
 
Chapter 6, presents a protein-network based analysis of the quantitative SILAC-based 
proteome of T47D-ERβ breast cancer cells with tetracycline-dependent varying intracellular 
ERα/ERβ ratio exposed to the isoflavone genistein. Genistein is a phytoestrogen found in 
high levels in soy products, the intake of which has been frequently associated with various 
beneficial health effects including reduced risk on breast cancer and osteoporosis in 
menopausal women. In our study protein networks involved in cell proliferation and 
apoptosis appear to be affected upon genistein exposure of the T47D-ERβ breast cancer cells. 
In addition the data point at genistein-induced ERβ mediated immune suppression. Genistein 
induced ERβ-mediated downregulation of the expression of the transcription factors NF-κB 
and STAT3 as well as down regulation of a variety of cytokines including IL-1β, IL-18, IFN-
γ, and TNF-α. On the other hand, a considerable increase of TGF-β induction was found in 
genistein treated T47D-ERβ cells expressing ERβ compared with cells with no expression of 
ERβ, further corroborating the genistein induced ERβ mediated  downregulation of immune 
signaling. Altogether, the results of the present study reveal that in addition to cell 
proliferation and apoptosis, immune signaling appears to be another major estrogen target 
influenced by phytoestrogen exposure. 
 
Concluding remarks and future perspectives 
After more than ten years since the discovery of the second estrogen receptor, named 
ERβ, the importance of the complex balance in estrogen signalling through the two receptors 
ERα and ERβ for the regulation of human development and reproduction becomes more 
evident. It has been demonstrated that ERβ is an anti-proliferative transcription factor in ERα 
positive breast cancer cells. Hence, estrogen signalling is dependent on the balance between 
two opposing receptors (ERα and ERβ). With our studies, we provided some insight into the 
mechanism of differential biological responses induced by food-borne, xeno- and phyto-
estrogenic compounds using the latest state-of-the-art techniques. In the present thesis 
emphasis was on especially the nature of the estrogen, activating preferably ERα (PPT), ERβ 
(DPN, quercetin and genistein) and/or both receptors (E2), as well as on the importance of 
the ratio between the two receptors. It is however, important to note that the overall ultimate 
biological effects of estrogenic compounds in cancer cells will be the result of an even more 
complex interplay between various mechanisms, which may depend on the cellular context, 
balance between ER subtypes, but also on coactivators and corepresors present in the cell, 
and splice variants of the two receptors present in the cells. All these factors taken together 
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enable accurate and targeted responses to hormones or antiestrogens. Given these 
considerations it seems logic that future research should be directed at the following topics: 
 
i) the role of coactivators and corepressors that may vary with the cells or tissues of 
interest, 
ii) the role of splice variants of the two receptors ERα and ERβ, which may vary 
within the cells or tissue of interest, 
iii) a comparison of the actual ERα/ERβ ratio in the T47D-ERβ model system 
compared to ERα/ERβ ratios actually observed in in vivo tissues, 
iv) integration of the knowledge obtained into the risk assessment of phytoestrogen 
preparations already sold on the market. 
 
ERs can associate with distinct subsets of coactivators and corepressors depending on 
binding affinities and relative abundance of these factors (14, 15). Several ER coactivators 
and corepressors have been described (16). Differences between ERα and ERβ in coactivators 
and corepressors recruitment have also been reported (17, 18), and therefore this preferential 
binding of certain coactivators and corepressors to one of the ERs will have consequences for 
specific ligand signalling and the ultimate biological effect elicited by ligand binding.  
 
NCoR and SMRT corepressors and the p160 family coactivators are widely expressed 
(19-21). Low levels of SRC-3 have been demonstrated for human proliferating endometrium 
with increased expression in the late secretory phase (22) while overexpression of SRC-3 is 
frequently observed in breast, ovarian, and prostate cancers (23-25). Similar expression levels 
of CBP, p300, AIB1, GRIP1, p300, NCoR, and SMRT have been measured for Ishikawa 
uterine and MCF-7 breast cancer cells (26). High levels of SRC-1 expression is found in the 
Ishikawa cells, and this might correlate with the agonist activity of tamoxifen in this cell line 
(26). We have seen in our studies (Chapter 4), that the T47D breast cancer cells express the 
ER coactivator PRMT1. Recruitment of this coactivator is accompanied by histone 
methylation (27, 28). Recently, PRMT1 gene expression has been used as a marker of 
unfavourable prognosis for colon cancer patients (29).  
 
Thus, other signalling events within the cell may affect nuclear receptor transcriptional 
responses via alteration in the expression of certain coregulators, and therefore it is predicted 
that significant differences in coactivator and corepressor expression found in various cell 
and tissue types would be important determinants of specific receptor modulator activity.  
 
In addition, distribution of particular splicing variants of both ERs should be taken into 
account when considering tissue response to estrogens and cofactor recruitment as they have 
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differential and sometimes antagonistic properties and their relative abundance might 
significantly influence biological responses to hormones. The main physiological role of ER 
splice variants in breast cancer development is however far from clear and might be a crucial 
determinant for clinical parameters. 
 
Full length ERα and ERβ proteins are approximately 66 and 59 kDa respectively (30, 
31), although as a result of alternative splicing both receptors can form different isoforms. 
ERα has been shown to form over 20 alternative splice variants in breast cancer and other 
tumors (32), three of them with relevant functionality, while at least five ERβ variants have 
been reported in human (33). The two most referenced ERα isoforms that seem to be of 
particular significance are ERα46 and ERα36 as they were reported to oppose genomic 
actions of full length ERα66 (Figure 1).  
 
  
 
Figure 1: Schematic comparison between full length ERα and its most referenced truncated isoforms. 
 
The ERα46 isoform has been identified in the MCF7 breast cancer cell line (34) in 
which it is coexpressed with full length ERα66. The presence of ERα46 has also been 
confirmed in osteoblasts (35) and endothelial cells (36). This isoform is devoid of AF-1  
(ligand independent transactivation domain) activity. In contrast with full length ERα66, 
truncated isoform ERα46 does not mediate E2 dependent cell proliferation and high levels of 
this isoform have been shown to be associated with cell cycle arrest in the G0/G1 phase. 
Similarly to ERβ, ERα46 is a potent ligand-dependent transcription factor in promoter and 
cell context sensitive to AF-2 (ligand dependent transactivation domain) and a powerful 
inhibitor of AF-1 dependent transcription (36). Coexpression of ERα46 with ERα66 in a 
SaOs osteoblast cell line results in receptor-concentration dependent inhibition of E2 
stimulated cell proliferation (37). 
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The second truncated ERα isoform, ERα36, was described recently (35), and it has been 
shown to lack both the AF-1 and AF-2 transactivation functions of full length ERα. However 
it has functional DNA binding and ligand binding domains (DBD and LBD). ERα36 contains 
an exon coding for myristoylation sites, hence suggesting an interaction with the plasma 
membrane. With no functional AF-1 and AF-2, ERα36 does not have any direct 
transcriptional activity. However, it is a powerful inhibitor of full length ERα and ERβ 
dependent transactivation (38). Even though it lacks transcriptional activity it can activate 
non genomic ER pathways such as MAPK/ERK signaling in response to E2 which is of 
particular significance in response to antiestrogens such as tamoxifen, 4OH-tamoxifen and 
ICI-182.780 (38).  
 
The ERα80 isoform was detected in the MCF7:2A cell line, which is a subclone of the 
MCF7 cell line  derived from long term growth in the absence of E2. This ERα80 isoform 
was produced by duplication of exons 6 and 7 (39). No evident functionality has been 
described so far. A list of selected ERα splice variants and their expression in various breast 
tissues (normal and tumor) and breast cancer cell lines is given in Table 1. 
 
Table 1: List of selected ERα splice variants and their expression in various breast tissues (normal and tumour) 
and breast cancer cell lines. 
 
Splice 
variant 
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47
D
 
M
D
A
-M
B
-2
31
 
M
D
A
-M
B
-4
35
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B
T
20
 
Z
R
-7
5 
References 
ERα36 +   +     (40, 38, 41) 
ERα46 (or 
ERα∆1) 
 +       (34) 
ERα∆2 + + +  +    (42, 43, 44, 45, 46, 32) 
ERα∆3 + + + +     (42, 45, 44, 43, 47, 48, 46, 49) 
ERα∆4  +   +   + (50, 43, 44, 32, 45) 
ERα∆5 + + + + + + + + (51, 43, 44, 45, 43, 52, 53) 
ERα∆6 +        (45, 44) 
ERα∆7 + + + +     (42, 54, 45, 44, 54, 46) 
ERα∆5,7 +        (43) 
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The presence of ERβ isoforms has been confirmed in various human cell lines as well as 
in a broad range of tissues at different levels (55, 56). At present their functional significance 
is poorly understood. The only fully functional ERβ isoform is ERβ1, which is a full length 
protein with LBD and active AF-2 domain (Figure 2). ERβ2, 4 and 5 have a shortened Helix 
11 and a full length Helix 12 is present only in ER-β1 and β2. Although in ERβ2 it has a 
different orientation than in ERβ1 due to the shorter Helix 11. It has been reported that 
displaced Helix 12 in ERβ2 limits ligand access to the binding pocket. As a consequence of 
this altered structure, ERβ2, 4 and 5 cannot form homodimers and have no transcriptional 
activity on their own, although they have been shown to heterodimerize with ERβ1 upon E2 
binding and enhance its AF-2 mediated transcriptional activity (56). Studies of interactions 
between different ERβ isoforms with ERα are very limited. However ERβ2 (also named 
ERβcx) was shown to limit DNA binding of ERα66 and inhibit its transcriptional activity in 
a manner similar to that described for ERβ1 (57). 
 
     
Figure 2: Comparison between full length ERβ and its most referenced truncated isoforms.  
 
Two new exon-deleted variants were detected in the cancer cell line MDA-MB-231, 
ERβΔ1,2,5  and  ERβΔ1,2,5,6  of approximately 35 and 28 kDa (58). Both proteins are 
predicted not to contain AF-1, and be the result of deletions in the DBD and LBD. Therefore, 
these two variants are expected to be devoid of or have significantly reduced ligand-
dependent and ligand independent activities, and their expression did not affect growth of 
cancer cell lines tested (Table 2). A list of selected ERβ splice variants and their expression in 
various breast tissues (normal and tumour) and breast cancer cell lines is given in Table 2. 
 
All together it can be concluded that more in depth analysis of the mechanisms of 
estrogen receptor splicing variants and corepressors/coactivators is needed because they 
provide possible additional mechanisms underlying the tissue-dependent modulation of the 
ER response. 
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In future research, it might be possible that knowing the nature of the ER subtype by 
specific receptor isoform transfection, and by using technologies such as chromatin 
immuneprecipitation studies (Chip), the expression and the association of coactivators and 
repressors in a specific given cell type might provide further insight about the mechanism 
whereby estrogens and estrogen like compounds produce tissue-specific effects. 
 
Moreover, literature data reveal that physiological levels of ERα to ERβ may vary in 
such a way that either one of the two receptors is dominant. It remains to be established in 
what way the range of ERα to ERβ ratios in the T47D-ERβ line with increasing 
concentrations of tetracycline reflect physiologically relevant variations in the receptor ratio 
compared to in vivo tissues.  
 
Table 2: List of selected ER splice variants and their expression in various breast tissues (normal and tumour) 
and breast cancer cell lines. 
 
Splice 
variant 
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References 
ERβ2 + + + +  + (59, 60, 61, 62, 7, 56) 
ERβ3 +      (61) 
ERβ4 +  +  +  (55, 61, 63) 
ERβ5 + + + + + + (59, 61, 55, 30, 56, 7) 
ERβ∆2 +   +   (64) 
ERβ∆3 +      (64, 65) 
ERβ∆4 +      (64, 65) 
ERβ∆5 + +  +   (64, 66, 67) 
ERβ∆6 +      (64, 67) 
ERβ∆1,2,5  +  +   (58) 
ERβ∆1,2,5,6  +  +   (58) 
 
 
Various studies reveal that physiologically levels of ERα and ERβ may vary depending 
on the cell or tissue type, with for example ERα being dominant in the liver or within the 
ovary in the thecal and interstitial cells and ERβ being dominant in isolated granulosa cells 
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(68), in cells from human umbilical vein endothelium, prostate tumours (69) as well as in 
colon, epithelium of prostate cells or granulose cells within the ovary (68) in normal 
secretory luminal prostate cells (70) or human testis in the developing spermatids (71). 
 
Since the T47D-ERβ cell line is derived from a human breast tumor (T47D) the levels of 
ERα and ERβ in the cell line when grown in the presence of 1000 ng/ml tetracycline (no 
additional ERβ expressed) are expected to reflect the physiological levels in this tumour 
tissue. Expression of ERβ in the T47D wild type cells appeared to be below the detection 
limit (72). These low levels of ERβ expression in breast tumour tissue is in line with the loss 
of ERβ expression in malignant cancer tissues as compared to benign tumours or normal 
tissues, where the ratio of ERα/ERβ expression is higher than in normal tissues (6, 67, 73, 
74). Information on the levels of ERα and ERβ in the T47D cells when grown in the absence 
of tetracycline (full ERβ expression) can be derived from data reported in a previous paper 
(72), where it was demonstrated that, based on mRNA levels, the T47D-ERβ cell line at 0 
ng/ml of tetracycline (full expression of ERβ) expresses only 4 times more ERβ than ERα. 
Such a 4-fold difference in the level of the two receptors does appear physiologically relevant 
when compared to literature data on other tissues. Quantification of the levels of both 
receptor types in the T47D-ERβ cells grown in the presence of varying levels of tetracycline 
and comparing them to the levels quantified by the same technique in the same study in 
relevant tissues would validate and optimise the model system used in the present study to a 
further extent. 
 
Finally, one may question whether the results obtained in the present thesis provide some 
clues to the presently ongoing discussion on the risk-benefit of phytoestrogen preparations 
already sold on the market. At present the consumer tends to believe that just because a 
product can be bought from the health food store, it is healthy and that "natural" equals 
“safe”. Nothing could be further from the truth. Although several health claims are connected 
to phytoestrogen preparations, such as lowering the risks of developing breast cancer or 
decreasing menopause symptoms, there is also evidence that suggests that phytoestrogens 
may stimulate cancer progression and other undesired side effects concerning the central 
nerve system and immune system among others. The results of the present thesis clearly 
indicate that the differences between phytoestrogens on the one hand and estradiol on the 
other hand may be smaller than generally suggested, and that the ultimate biological effect of 
these estrogens strongly depends on the tissue of interest and could even be similar. The 
results obtained argue against the general idea that phytoestrogens are beneficial because they 
activate ERβ, while estradiol may be adverse because it activates ERα. The ultimate 
biological effect is influenced by a complex interplay between the agonist characteristics but 
also characteristics of the cells and tissues of interest, including their ratio of the two 
receptors, receptor splice variants and coactivators and corepressors being present. Thus it 
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seems likely that the effects of phytoestrogens will vary with the tissue of interest and can be 
beneficial for one tissue and biological endpoint but at the same dose adverse for another 
tissue and biological endpoint. Furthermore, there is a need for a better understanding of the 
health implications of the dose, bioavailability and long-term effects of these phytoestrogen 
based food supplements, and as a consequence, a need for a better and more detailed 
evaluation of their risks and benefits.  
 
Results of the present thesis have elucidated possible similarities between E2 and the 
phytoestrogen genistein pointing at not only beneficial health effects of phytoestrogens and 
this should not be ignored in the safety assessment of phytoestrogen supplements. 
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Samenvatting 
De verscheidene acties van estradiol en andere oestrogene stoffen in de 
zoogdierfysiologie worden bewerkstelligd, op een moleculair niveau, via complexe routes, en 
de werking van ten minste twee oestrogeenreceptoren ERα en ERβ. 
  
Het doel van het onderzoek beschreven in dit proefschrift was om meer inzicht te krijgen 
in de invloed van ERα en ERβ en de intracellulaire ERα/ERβ-ratio op de cellulaire reactie op 
oestrogeenachtige stoffen. Dit proefschrift beschrijft de invloed van oestrogenen op de 
transcriptionele activiteit op zowel het gen- als het eiwitniveau en op de celproliferatie 
wanneer de intracellulaire verhouding van ERα/ERβ wordt gevarieerd. Het uiteindelijke doel 
was de gegevens over celproliferatie als biologisch eindpunt te correleren met de 
transcriptomics- en proteomicsgegevens.  
 
Hoofdstuk 1 van dit proefschrift beschrijft de moleculaire basis van ERs, hun 
weefseldistributie en hun dualistische rol in kankercelproliferatie.  
 
Verscheidene studies tonen aan dat oestrogenen de groei van een groot aantal ERα- 
positieve borstkankers bevorderen (1-4), of zij rapporteren een verminderde expressie van 
ERβ in kankerweefsels in vergelijking met goedaardige tumoren of normale weefsels, terwijl 
de expressie van ERα in die weefsels hetzelfde blijft (5, 6). Dit leidde tot de hypothese dat 
ERβ het stimulerende effect van ERα op de celproliferatie zou kunnen moduleren. Om deze 
mogelijke ERβ-gemedieerde modulatie van het proliferatieve effect van ERα verder te 
onderzoeken, wordt in Hoofdstuk 2 bestudeerd hoe een variabele intracellulaire ERα/ERβ-
ratio de door respectievelijk ERα- en ERβ-agonisten geïnduceerde celproliferatie beïnvloedt. 
Met behulp van humane osteosarcoom ERα- of ERβ-reportercellijnen werd allereerst 
aangetoond dat propyl-pyrazole-triol (PPT) een ERα-selectieve agonist en diarylpropionitrile 
(DPN) een preferentiële ERβ-agonist is. Vervolgens werden de effecten gekarakteriseerd van 
deze selectieve oestrogeenreceptormodulatoren (SERMs) en van de modelstof estradiol (E2) 
op de proliferatie van cellen van de T47D menselijke borstkankercellijn met tetracycline-
afhankelijke expressie van ERβ (T47D-ERβ). De E2-geïnduceerde proliferatie van T47D-
ERβ-cellen waarin ERβ-expressie was geblokkeerd, was vergelijkbaar met die van de T47D 
wild type cellen, terwijl deze E2-geïnduceerde celproliferatie niet langer werd waargenomen 
als ERβ in de T47D-ERβ-cellen tot expressie kwam. In de T47D-ERβ-cellijn was ook DPN 
in staat om celproliferatie te onderdrukken wanneer de ERβ-expressieniveaus hoog waren. In 
de T47D-ERβ-cellijn was PPT, ongeacht de intracellulaire ERα/ERβ- ratio, niet in staat om 
celproliferatie te onderdrukken, en dit is in lijn met de waarneming dat  PPT alleen in staat is 
ERα te activeren en niet ERβ. Geconcludeerd kon worden dat de effecten van 
oestrogeenachtige stoffen op celproliferatie afhankelijk zijn van de intracellulaire ERα/ERβ-
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expressieniveaus in de betreffende cellen of weefsels en de potentiële activatie van ERα en/of 
ERβ door de oestrogene agonist. 
 
In verdere studies die in dit proefschrift staan beschreven, wordt de aandacht gevestigd 
op de voedingsgeassocieerde oestrogenen, genisteïne en quercetine. De alomtegenwoordige 
en onvermijdelijke aanwezigheid van oestrogene stoffen in ons westerse dieet. brengt een 
significante zorg met zich mee rond de mogelijke gezondheidseffecten die dat teweeg kan 
brengen, hoewel sommige studies juist een gunstig effect claimen voor bijvoorbeeld de in de 
voeding aanwezige phyto-oestrogenen van soja (7-9). Het humane dieet bevat verscheidene 
plantgerelateerde zwak oestrogene stoffen (10). Deze phyto-oestrogenen worden wel gezien 
als een mogelijk natuurlijk alternatief voor hormoonvervangingstherapie aangezien deze 
stoffen ook van nature in ons dieet worden aangetroffen (11). Een hypothese om de 
schijnbaar tegenstrijdige gezondheidseffecten van oestrogenen en phyto-oestrogenen te 
verklaren stelt, dat er verschillende uiteindelijke cellulaire effecten zijn van enerzijds ERα-
activatie, wat zou leiden tot promotie van celproliferatie en mogelijke nadelige 
gezondheidseffecten, en van anderzijds ERβ-activatie, wat apoptose en gunstige 
gezondheidseffecten zou bevorderen. Phyto-oestrogenen die speficifiek ERβ activeren 
hebben dan een positief effect en stoffen die preferentieel ERα activeren hebben een nadelig 
effect. Deze hypothese is verder onderzocht in hoofdstuk 3 van dit proefschrift. In hoofdstuk 
3 werd het belang van de intracellulaire verhoudingen onderzocht van de twee oestrogene 
receptoren ERα en ERβ voor het uiteindelijke vermogen van de phyto-oestrogenen genisteïne 
en quercetine om celproliferatie te stimuleren of te remmen. Dit is van belang omdat i) ERβ 
een rol blijkt te spelen in de modulatie van middels ERα-activatie gestimuleerde 
celproliferatie (hoofdstuk 2), ii) genisteïne en quercetine agonisten kunnen zijn voor beide 
receptortypes en iii) de verhouding van ERα en ERβ tussen weefsels kan variëren. Door 
humane osteosarcoom (U2OS) ERα- of ERβ-reportercellen te gebruiken, werd aangetoond 
dat, vergeleken met estradiol (E2), genisteïne en quercetine niet alleen een relatief grotere 
voorkeur hebben voor ERβ, maar ook een hogere maximale inductie van de 
reportergenrespons tot stand brengen dan E2.  Door gebruik te maken van de menselijke 
T47D borstkankercellen met tetracycline-afhankelijke expressie van ERβ (T47D-ERβ), werd 
het effect van een variërende intracellulaire ERα/ERβ-ratio op door E2- of pytho-oestrogen  
veroorzaakte celproliferatie gekarakteriseerd. Voor de modelstof E2 komen de data van 
hoofdstuk 3  overeen met de resultaten van hoofdstuk 2, en laten zien dat E2-geïnduceerde 
ERα-afhankelijke celproliferatie in cellen zonder ERβ-expressie gelijk is aan de E2-
geïnduceerde celproliferatie van T47D wildtype-cellen, terwijl de E2-geïnduceerde 
celproliferatie geremd wordt in cellen waarin behalve ERα ook ERβ tot expressie wordt 
gebracht. Met verhoogde ERβ-expressie werd de phyto-oestrogen geïnduceerde ERα-
afhankelijke celproliferatie ook verminderd. Deze resultaten wijzen op het belang van de 
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cellulaire verhouding ERα/ERβ voor het uiteindelijke effect van phyto-oestrogens op de 
celproliferatie. 
 
Een opmerkelijke observatie, beschreven in Hoofdstuk 3, was dat in de U2OS ERα- en 
ERβ-reportercellen door genisteïne en quercetine een hogere maximale ERα- of ERβ-
gemedieerde inductie van luciferaseactiviteit wordt gemeten, dan de maximale 
luciferaseactiviteit die door E2 wordt geïnduceerd. Dit fenomeen is ook in andere studies 
waargenomen (12, 13) en word superinductie genoemd. Dit effect werd in ons laboratorium 
al meerdere malen waargenomen in reportergenbioassays, maar het mechanisme dat aan dit 
effect ten grondslag ligt, evenals de biologische relevantie van het effect, was nog 
onduidelijk. Daarom werden in Hoofdstuk 4 de verscheidene hypothesen voor de mogelijke 
mechanismen die aan deze superinductie ten grondslag liggen onderzocht met gebruik van 
genisteïne als modelstof. Deze hypothesen omvatten i) een niet ER-gemedieerd mechanisme, 
ii) een rol voor een ERα- en/of ERβ-activerende genisteïne metaboliet met hogere activiteit 
dan genisteïne zelf, en iii) een artefact dat niet biologisch relevant is, en specifiek is voor de 
op luciferasereportergenactiviteit gebaseerde assays. De gegevens die in Hoofdstuk 4 worden 
gepresenteerd, wijzen erop dat ER betrokken is bij de inductie en ook de superinductie van de 
luciferase reportergenactiviteit, en dat de superinductie door genisteïne kan worden 
toegeschreven aan stabilisatie (verminderde degradatie) van het luciferase reporterenzym, 
waarbij deze stabilisatie en dus ook de extra verhoging in de luciferaseactiviteit in de 
bioassays optreedt bij genisteïneconcentraties boven 1 µM. De resultaten wijzen erop dat het 
fenomeen van superinductie niet biologisch relevant is, maar eerder het gevolg van een 
posttranscriptioneel effect op de eiwitstabiliteit. 
 
Om de mechanismen die ten grondslag liggen aan de door genisteïne geïnduceerde 
effecten op de celproliferatie van T47D-ERβ-cellen met variabele cellulaire ERα/ERβ-ratio, 
zoals beschreven in Hoofdstuk 3, nader op te helderen wordt in Hoofdstuk 5 gebruik 
gemaakt van transcriptomics en van kwantitatieve op SILAC-gebaseerde proteomics. 
Daarmee werden de via ERα en ERβ veroorzaakte gevolgen op gen- en eiwitexpressie in 
T47D-ERβ-borstkankercellen, die aan het phyto-oestrogen genisteine werden blootgesteld, 
geanalysereerd. Gebruik makend van de humane kankercellijn T47D-ERβ met tetracycline-
afhankelijke expressie van ERβ, werd het effect van een variërende intracellulaire ERα/ERβ-
ratio op genisteïne-geïnduceerde gen- en eiwitexpressie gekarakteriseerd. De verkregen data 
laten zien dat in T47D-ERβ-cellen die alleen ERα tot expressie brengen, transcriptomics- en 
proteomics- data aangeven dat genisteïne vooral genen en eiwitten beïnvloedt die betrokken 
zijn bij snelle celgroei en bij celmigratie door dynamische activering van cytoskelet-
remodellering. De gegevens openbaarden een interactie tussen integrins, focal adhesion 
kinase (FAK), CDC42 en actin cytoskeleton signalling cascades, dit als gevolg van 
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blootstelling aan genisteïne van de T47D-ERβ-cellen met alleen ERα- en geen ERβ-
expressie. Bovendien wezen de gegevens die in Hoofdstuk 5 worden beschreven erop dat via 
ERβ-beïnvloede gen- en eiwitexpressie de via ERα-geïnduceerde effecten tegengaan. Dit 
omdat in T47D-ERβ-cellen die ERβ tot expressie brengen en die aan genisteïne werden 
blootgesteld, een duidelijke downregulering werd aangetoond van genen en eiwitten die 
betrokken zijn bij de celgroei en een inductie van genen en eiwitten die betrokken zijn bij het 
afbreken van de celdeling en apoptosis. Op deze wijze leidt de door genisteïne gemedieerde 
activering van ERβ tot een verminderde expressie van genen en eiwitten betrokken bij 
celmotiliteit en het vermogen tot metastase evenals van genen en eiwitten betrokken bij 
celoverleving. Uiteindelijk kan worden geconcludeerd dat de gevolgen van genisteïne voor 
proteomics en transcriptomics eindpunten in het T47D-ERβ celmodel vergelijkbaar waren 
met eerder vermelde data voor estradiol, en dat het uiteindelijke estrogene effect afhankelijk 
zal zijn van het receptorfenotype (de verhouding ERα/ERβ) in de bestudeerde cellen of 
weefsels.  
 
In een verdere studie van de proteomicsresultaten, werd de gegevensanalyse uitgevoerd 
op basis van een eiwitnetwerkbenadering. De resultaten van deze eiwitnetwerkanalyse 
openbaarden extra eiwitnetwerken, behalve diegenen die betrokken zijn bij celproliferatie en 
apoptosis, welke werden beïnvloed door blootstelling van de T47D-ERβ-borstkankercellen 
aan genisteïne. Deze resultaten worden beschreven in Hoofdstuk 6.  
 
Hoofdstuk 6, beschrijft een op eiwitnetwerk gebaseerde analyse van het kwantitatieve 
SILAC-gebaseerde proteome van T47D-ERβ-cellen met tetracycline-afhankelijke variërende 
intracellulaire ERα/ERβ-ratio blootgesteld  aan genisteïne. Genisteïne is een phyto-oestrogen 
dat in hoge concentraties wordt gevonden in sojaproducten. Blootstelling aan genisteïne 
wordt vaak geassocieerd met diverse gunstige gevolgen voor de gezondheid, met inbegrip 
van verminderd risico voor borstkanker en osteoporose bij vrouwen tijdens de menopauze. 
Ook in de netwerkanalyse van de proteomicsdata, beschreven in Hoofdstuk 6, bleken de 
eiwitnetwerken, betrokken bij celproliferatie en apoptosis, beïnvloed te worden door 
blootstelling van de T47D-ERβ-cellen aan genisteïne. Daarnaast wijzen de data op  een 
genisteïne-geïnduceerde ERβ-gemedieerde immuunsuppressie. Genisteïne geïnduceerde ERβ 
activering resulteerde in downregulering van de expressie van de transcriptiefactoren NF-κB 
en STAT3, evenals in downregulatie van een verscheidenheid aan cytokines met inbegrip van 
IL-1β, IL-18, IFN-γ, en TNF-α. Ook werd een aanzienlijke verhoging van TGF-β-inductie 
gevonden in genisteïne- behandelde T47D-ERβ-cellen die ERβ tot expressie brachten in 
vergelijking met cellen zonder ERβ-expressie, en dit was een verdere aanwijzing dat 
genisteïne geïnduceerde ERβ-gemedieerde eiwitexpressie leidt tot downregulering van de 
immuunsignalering. Alles bij elkaar laten de resultaten van deze studie zien dat naast 
Samenvatting
 
celproliferatie en apoptosis, de immuunsignalering een ander belangrijk oestrogeen eindpunt 
lijkt te zijn dat door blootstelling aan phytoestrogenen wordt beïnvloed. 
 
Concluderende opmerkingen en toekomstige perspectieven 
Meer dan tien jaar, sinds de ontdekking van de tweede oestrogeenreceptor, ERβ, wordt 
het belang van de complexe balans in oestrogeensignalering door de twee receptoren ERα en 
ERβ voor de regulering van de menselijke ontwikkeling en reproductie steeds duidelijker. 
Het is aangetoond dat ERβ een antiproliferatie transcriptiefactor in ERα-positieve 
borstkankercellen is. Vandaar dat oestrogeensignalering afhankelijk is van het evenwicht 
tussen twee verschillende receptoren (ERα en ERβ). Met de studies, beschreven in het 
huidige proefschrift, is extra inzicht verkregen in het mechanisme van differentiële 
biologische reacties die door voedingsgeassocieerde, xeno- en fyto-oestrogene stoffen 
geïnduceerd worden. Hiervoor gebruikten wij de meest recente state-of-the-art technieken. In 
de huidige thesis werd de nadruk vooral gelegd op de aard van het oestrogeen, dat bij 
voorkeur ERα (PPT), ERβ (DPN, quercetine en genisteïne) en/of beide receptoren (E2) 
activeert, evenals op het belang van de verhouding tussen de twee receptoren. Het is nochtans 
belangrijk om op te merken dat de algemene uiteindelijke biologische gevolgen van 
oestrogene stoffen in (kanker)cellen het resultaat zullen zijn van een complexe interactie 
tussen diverse mechanismen, die afhangen van de cellulaire context, de ratio tussen de ER-
subtypes, maar ook van coactivatoren en corepressoren in de cel, evenals van splicing 
varianten van de twee receptoren in de cellen. Al deze factoren samen maken nauwkeurige en 
gerichte reacties op hormonen of anti-oestrogenen mogelijk. Gezien deze overwegingen is het 
belangrijk dat toekomstig onderzoek ook aandacht besteedt aan de volgende aspecten: 
 
I)      de rol van coactivatoren en corepressoren die kunnen variëren in de relevante cellen 
of de weefsels, 
II)  de rol van splicing varianten van de twee receptoren ERα en ERβ die kunnen 
variëren binnen de relevante cellen of het weefsel,  
III) een vergelijking van de daadwerkelijke ERα/ERβ-verhouding in het T47D-ERβ-
modelsysteem in vergelijking met de ERα/ERβ-verhoudingen die in  in vivo 
weefsels worden waargenomen,  
IV) integratie van de reeds verkregen kennis in de risicobeoordeling van supplementen 
met phyto-oestrogen die reeds op de markt worden verkocht.  
ERs associëren met verschillende soorten coactivatoren en corepressoren, afhankelijk 
van bindingsaffiniteiten en relatieve overvloed van deze factoren (14, 15). Er zijn 
verscheidene coactivatoren en corepressoren van ERs (16). Verschillen tussen ERα en ERβ in 
de rekrutering van coactivatoren en corepressoren zijn ook beschreven (17, 18) en daarom zal 
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preferentiële binding van bepaalde coactivatoren en corepressoren aan één van de ERs, 
gevolgen hebben voor de specifieke ligandsignalering en het uiteindelijke biologische effect 
dat door de ligandbinding wordt veroorzaakt.  
  
NCoR en corepressors SMRT en de p160 familie van coactivatoren worden in veel 
biologische systemen tot expressie gebracht (19-21). Lage niveaus van SRC-3 zijn 
aangetoond in menselijk prolifererend endometrium met verhoogde expressie in de late 
secretorische fase (22) terwijl overexpressie van SRC-3 vaak in borst-, ovaria-, en prostaat 
kanker (23-25) wordt waargenomen. De gelijke expressieniveaus van CBP, p300, AIB1, 
GRIP1, p300, NCoR, en SMRT zijn gemeten voor de Ishikawa- baarmoeder- en MCF-7 
borstkankercellen (26). Hoge niveaus van SRC-1-expressie zijn gevonden in Ishikawa-cellen 
en dit zou met de agonistactiviteit van tamoxifen in deze cellenlijn kunnen correleren (26). 
Wij hebben in onze studies (Hoofdstuk 4) expressie van de ER coactivator, PRMT1 door de 
T47D-borstkankercellen gezien. De rekrutering van deze coactivator gaat vergezeld van 
histonmethylering (27, 28). Onlangs is de genexpressie van PRMT1 gebruikt als marker voor 
een ongunstige prognose voor darmkankerpatiënten (29).  
 
Aldus kunnen andere gebeurtenissen in de cel de transcriptionele respons van de 
nucleaire receptor beïnvloeden via wijziging in de expressie van bepaalde coregulatoren en 
daarom voorspelt men dat significante verschillen in coactivator- en corepressorexpressie in 
specifieke cel- en weefseltypes belangrijke determinanten zouden zijn van de specifieke 
receptormodulatoractiviteit.  
 
Bovendien zou de distributie van bepaalde splicing varianten van beide ERs in acht 
moeten worden genomen in het kader van de weefselreactie op oestrogenen en 
cofactorrekrutering, aangezien zij differentiële en soms antagonistische eigenschappen 
hebben en hun relatieve concentraties de biologische reacties op hormonen beduidend zou 
kunnen beïnvloeden. De belangrijke fysiologische rol van de splicing varianten van ERs in de 
ontwikkeling van borstkanker is echter momenteel verre van duidelijk en zou een essentiële 
determinant voor klinische parameters kunnen zijn.  
 
De volledige ERα- en ERβ-eiwitten zijn ongeveer 66 en 59 kDa, respectievelijk (30, 31), 
maar als gevolg van alternatieve splicing kunnen van beide receptoren verschillende 
isovormen ontstaan. Voor ERα zijn er meer dan 20 alternatieve splicing varianten in 
borstkanker en ander tumorweefsel aangetoond (32), drie van hen met relevante 
functionaliteit, terwijl minstens vijf varianten van ERβ bekend zijn in de mens  (33). De twee 
meest gerefereerde ERα- isovormen, die een bijzondere rol lijken te hebben, zijn ERα46 en 
ERα36 aangezien van deze varianten wordt gemeld dat ze de genomische acties van de 
volledige de ERα66 kunnen tegenwerken (Figuur 1).  
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Figuur 1: Schematische vergelijking tussen de volledige ERα en zijn meest gerefereerde kortere isovormen. 
 
De ERα46 isovorm is geïdentificeerd in de MCF7-borstkankercellijn (34), waarin de 
isovorm tegelijk met de volledige ERα66 tot expressie komt. De aanwezigheid van ERα46 is 
ook bevestigd in osteoblasten (35) en endotheelcellen (36). De ERα46  isovorm heeft geen 
AF-1-(ligand-onafhankelijk transactivatiedomein)activiteit. In tegenstelling tot de volledige 
ERα66, medieert isovorm ERα46 geen E2-afhankelijke celproliferatie en hoge niveaus van 
deze isovorm zijn aangetoond in de G0/G1-fase van de celcyclus. Net als ERβ, is ERα46 een 
potente ligandafhankelijke transcriptiefactor die gevoelig is voor AF-2 (ligand-afhankelijk 
transactivatiedomein) en een krachtige remmer van AF-1-afhankelijke transcriptie (36). 
Coexpressie van ERα46 met ERα66 in een SaOs-osteoblastcellijn resulteerde in 
receptorconcentratie- afhankelijke remming van E2-gestimuleerde celproliferatie (37). 
 
De tweede verkorte ERα-isovorm, ERα36, werd onlangs beschreven (35), en het is 
aangetoond dat deze vorm noch de AF-1- noch de AF-2- transactivatiefuncties van de 
volledige ERα heeft. Nochtans heeft het de functionerende DNA-bindende en ligandbindende 
domeinen (DBD en LBD). ERα36 bevat een exon coderend voor myristoyleringsplaatsen, 
waarmee een interactie met het plasmamembraan wordt gesuggereerd. Zonder functionele 
AF-1 en AF-2, heeft ERα36 geen directe transcriptionele activiteit. Desalniettemin is het een 
krachtige remmer van volledige afhankelijke ERα- en ERβ-transactivatie (38). Hoewel het de 
transcriptionele activiteit niet heeft, kan het de wel de niet-genome ER-routes activeren zoals 
MAPK/ERK- signalering als respons op E2, wat van bijzondere betekenis is als respons op 
antioestrogenen zoals tamoxifen, 4OH-tamoxifen en ICI-182.780 (38). 
 
De ERα80 isovorm werd ontdekt in de MCF7: 2A-cellijn, een subkloon van de MCF7- 
cellijn, geïsoleerd na lange tijd groei zonder E2. Deze ERα80 isovorm werd geproduceerd 
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door verdubbeling van exons 6 en 7 (39). Tot dusver is er geen duidelijke functionaliteit 
beschreven. Een lijst van geselecteerde ERα-splicing varianten en hun expressie in diverse 
borstweefsels (normaal en tumor) en in   borstkankercellijnen is weergegeven in Tabel 1.  
 
Tabel 1: Lijst van geselecteerde ERα-splicing varianten en hun expressie in diverse borstweefsels (normale en 
tumor) en in borstkankercellijnen.  
 
Splicing 
varianten 
B
or
st
  
M
C
F7
 
T
47
D
 
M
D
A
-M
B
-2
31
 
M
D
A
-M
B
-4
35
 
B
T
-4
74
 
B
T
20
 
Z
R
-7
5 
Referenties 
ERα36 +   +     (40, 38, 41) 
ERα46 (or 
ERα∆1) 
 +       (34) 
ERα∆2 + + +  +    (42, 43, 44, 45, 46, 32) 
ERα∆3 + + + +     (42, 45, 44, 43, 47, 48, 46, 49) 
ERα∆4  +   +   + (50, 43, 44, 32, 45) 
ERα∆5 + + + + + + + + (51, 43, 44, 45, 43, 52, 53) 
ERα∆6 +        (45, 44) 
ERα∆7 + + + +     (42, 54, 45, 44, 54, 46) 
ERα∆5,7 +        (43) 
 
De aanwezigheid van ERβ isovormen is bevestigd in diverse menselijke cellijnen evenals 
in een breed scala van weefsels (55, 56). Momenteel is hun functionele betekenis niet 
duidelijk. De enige volledig functionele ERβ-isovorm is ERβ1, een volledig eiwit met LBD 
en actief  AF-2-domein (Figuur 2). ERβ2, 4 en 5 hebben een verkorte Helix 11 en een 
volledige Helix 12 is slechts aanwezig in ER-β1 en β2. Hoewel de Helix 12 in ERβ2 een 
andere oriëntatie heeft dan in ERβ1, doordat die een kortere Helix 11 heeft. Men heeft 
gerapporteerd dat een verplaatste Helix 12 in ERβ2 de toegang van de ligand tot de 
bindingspocket beperkt. Als gevolg van deze veranderde structuur, kunnen ERβ2, 4 en 5 geen 
homodimeren vormen en hebben ze geen transcriptionele activiteit van zichzelf, hoewel wel 
is getoond dat zij kunnen heterodimeriseren met ERβ1 na E2-binding en de AF-2 bemiddelde 
transcriptionele activiteit kunnen verbeteren (56). De studies over de interactie tussen de 
verschillende ERβ isovormen met ERα zijn zeer beperkt. Echter van ERβ2 (ook wel ERβcx 
genoemd) is aangetoond dat het de DNA-binding van ERα66 beperkt en zijn transcriptionele 
activiteit remt op dezelfde manier als  beschreven voor ERβ1 (57). 
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Figuur 2: Vergelijking tussen volledige lengte ERβ en zijn gerefereerde isovormen.  
 
Twee nieuwe exon-deleted varianten werden ontdekt in de kankercellijn MDA-MB-231, 
ERβΔ1,2,5 en ERβΔ1,2,5,6 van ongeveer 35 en 28 kDa (58). Beide eiwitten bevatten 
mogelijk geen AF-1, en zijn het resultaat van deleties van DBD en LBD. Daarom wordt van 
deze twee varianten verwacht dat ze geen, of beduidend verminderde ligandafhankelijke en 
ligandonafhankelijke activiteiten hebben, en hun expressie beïnvloedde de groei van geteste 
kankercellijnen dan ook niet (Tabel 2). Een lijst van geselecteerde ERβ-splicingvarianten en 
hun expressie in diverse borstweefsels (normale en tumor) en borstkankercellijnen wordt 
gegeven in tabel 2.  
 
Alles bij elkaar kan geconcludeerd worden dat meer diepgaande analyse van de 
mechanismen en consequenties van oestrogeenreceptor splicingvarianten en 
corepressoren/coactivatoren nodig is, omdat zij mogelijk extra mechanismen aan het licht 
brengen die aan de weefselafhankelijke modulatie van de ER response ten grondslag liggen.  
 
In de toekomst zou het mogelijk kunnen zijn de aard van het ER-subtype door specifieke 
receptor-isovormtransfectie te bepalen, door technologieën zoals chromatin-
immunoprecipitatiestudies (Chip), en dan ook de effecten van gelijktijdige expressie van 
coactivatoren en repressoren in een specifiek celtype te gebruiken om verder inzicht te 
verkrijgen in het mechanisme op basis waarvan oestrogenen en oestrogeenachtige stoffen 
weefselspecifieke gevolgen veroorzaken. 
 
Literatuurgegevens laten verder zien dat de fysiologische niveaus van ERα en ERβ 
zodanig kunnen variëren, dat één van beide dominant is. Het moet nog worden onderzocht op 
welke manier de mogelijk range van ERα/ERβ-ratio's in de T47D-ERβ-cellijn met 
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toenemende concentraties tetracycline representatief zijn voor fysiologisch relevante variaties 
in de receptorverhouding in cellen en weefsels in vivo.  
 
Tabel 2: Lijst van geselecteerde ER splice-varianten en hun expressie in diverse borstweefsels (normale en 
tumor) en borstkankercellijnen. 
 
Splicing 
varianten 
B
or
st
  
M
C
F7
 
T
47
D
 
M
D
A
-M
B
-2
31
 
M
D
A
-M
B
-4
35
 
B
T
20
 
Referenties 
ERβ2 + + + +  + (59, 60, 61, 62, 7, 56) 
ERβ3 +      (61) 
ERβ4 +  +  +  (55, 61, 63) 
ERβ5 + + + + + + (59, 61, 55, 30, 56, 7) 
ERβ∆2 +   +   (64) 
ERβ∆3 +      (64, 65) 
ERβ∆4 +      (64, 65) 
ERβ∆5 + +  +   (64, 66, 67) 
ERβ∆6 +      (64, 67) 
ERβ∆1,2,5  +  +   (58) 
ERβ∆1,2,5,6  +  +   (58) 
 
 
Diverse studies laten zien dat fysiologische niveaus van ERα en ERβ afhankelijk kunnen 
zijn van het cel- of weefseltype, met bijvoorbeeld ERα die dominant is in de lever of in 
thecale en interstitiële cellen in de eierstok en ERβ die dominant is in geïsoleerde 
granulosecellen (68), in cellen van menselijk umbilical ader-endotheel, prostaattumoren (69) 
en in het epitheel van de dikke darm, prostaatcellen of granulosecellen binnen de eierstok 
(68) in normale secretorische luminale prostaatcellen (70) of in de menselijke testis in  zich 
ontwikkelende spermatiden (71). 
 
Aangezien de T47D-ERβ-cellijn uit een menselijke borsttumor (T47D) komt, reflecteren 
naar verwachting de niveaus van ERα en ERβ in de cellijn, wanneer deze gekweekt wordt in 
aanwezigheid van 1000 ng/ml tetracycline (geen extra ERβ- expressie) de fysiologische 
niveaus in dit tumorweefsel. De expressie van ERβ in de T47D wildtype cellen bleek onder 
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de detectielimiet (72) te liggen. Deze lage niveaus van ERβ-expressie in borsttumorweefsel 
komen overeen met het verlies van ERβ- expressie in kwaadaardige kankerweefsels in 
vergelijking met goedaardige tumoren of normale weefsels, en het feit dat de verhouding van 
ERα/ERβ-expressie in kwaadaardig weefsel hoger is dan in normale weefsels (6, 67, 73, 74). 
De informatie over de niveaus van ERα en ERβ in de T47D-cellen wanneer ze gekweekt 
worden zonder tetracycline (volledige expressie van ERβ) kan worden afgeleid uit de 
literatuur (72) waar men aantoonde dat, gebaseerd op mRNA-niveaus, de T47D-ERβ-cellijn 
bij 0 ng/ml tetracycline (volledige expressie van ERβ) slechts 4 keer meer ERβ dan ERα 
bevat. Een viervoudig verschil in het niveau van de twee receptoren lijkt fysiologisch relevant 
wanneer dit vergeleken wordt met literatuurgegevens over andere weefsels. Kwantificering 
van de niveaus van beide receptortypes in T47D-ERβ-cellen die worden gekweekt in 
aanwezigheid van variërende niveaus van tetracycline en het vergelijken van de niveaus die 
met dezelfde techniek in dezelfde studie in relevante weefsels worden gekwantificeerd, zal 
het modelsysteem dat in de huidige studies werd gebruikt verder optimaliseren en valideren. 
 
Tot slot kan men zich afvragen of de resultaten die in het huidige proefschrift worden 
verkregen, aanwijzingen verstrekken voor de huidige discussie over de zogenoemde riks-
benefit van phyto-oestrogensupplementen die reeds op de markt worden verkocht. 
Momenteel neigt de consument te geloven dat alleen omdat een product in de natuurlijke 
voedingswinkel verkocht wordt, het gezond is en dat "natuurlijk" equivalent is voor „veilig”. 
Niets is minder waar. Hoewel er verscheidene gezondheidsclaims worden gekoppeld aan 
phyto-oestrogene supplementen, bijvoorbeeld dat ze het risico om borstkanker te ontwikkelen 
verminderen of overgangssymptomen verminderen, is er ook bewijsmateriaal dat aangeeft dat 
phyto-oestrogenen kankerontwikkeling kunnen bevorderen en andere ongewenste 
bijwerkingen op bijvoorbeeld  het centrale zenuwsysteem en het immuunsysteem kunnen 
hebben. De resultaten van het huidige proefschrift wijzen er duidelijk op dat de verschillen 
tussen phyto-oestrogenen enerzijds en estradiol anderzijds kleiner kunnen zijn dan over het 
algemeen wordt gedacht, en dat het uiteindelijke biologische effect van deze oestrogenen 
sterk zal afhangen van het weefsel waarnaar wordt gekeken en dat de effecten van 
phytoestrogenen en estradiol mogeijk zelfs vergelijkbaar zouden kunnen zijn. De verkregen 
resultaten spreken daarmee het algemene idee tegen dat phyto-oestrogenen gezond zijn omdat 
zij ERβ  activeren, terwijl estradiol ongunstig kan zijn omdat het ERα activeert. Het 
uiteindelijke biologische effect wordt beïnvloed door een complexe interactie tussen de 
agonist kenmerken maar ook de kenmerken van de cellen en de weefsels zijn van belang, met 
inbegrip van de intracellulaire verhouding van de twee receptoren, de aanwezige receptor-
splicing varianten en de coactivatoren en corepressoren die aanwezig zijn. Daarom lijkt het 
waarschijnlijk dat de gevolgen van phytoestrogenen per weefsel zullen variëren en voor het 
ene weefsel en biologische eindpunt gunstig kunnen zijn, terwijl ze bij eenzelfde dosis juist 
ongunstig kunnen zijn voor een ander weefsel en biologisch eindpunt. Voorts is er behoefte 
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aan een beter inzicht in de gezondheidsimplicaties van de dosis, de biologische 
beschikbaarheid en de gevolgen op lange termijn van deze op phyto-oestrogen gebaseerde 
voedingssupplementen, en als gevolg daarvan, een behoefte aan een betere en meer 
gedetailleerde evaluatie van hun risico's en voordelen.  
 
De resultaten van het huidige proefschrift hebben mogelijke gelijkenissen tussen E2 en 
het phyto-oestrogen genisteïne laten zien, die zich niet alleen beperken tot gunstige effecten 
en dit zou moeten worden meegenomen in de veiligheidsbeoordeling van phyto-oestrogene 
voedingssupplementen. 
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Overview of completed training activities 
 
Discipline specific activities   
General toxicology (Wageningen, 2006)       
Pathobiology (PET-Utrecht, 2007)        
Medical & Forensic toxicology (PET-Utrecht, 2007)     
Organ toxicology (PET-Utrecht, 2006)       
Mutagenesis and carcinogenesis (PET-Leiden, 2007)     
           
 
Meetings 
User meeting Wageningen NMR center (Wageningen, 2007)    
Program proteomics tour, Thermo Fisher Scientific (Utrecht, 2008)   
NPC meeting (Utrecht, 2009)        
LC-MS/MS user meeting, Thermo Fisher Scientific (Breda, 2009)    
Nuclear Receptor Meeting Benelux (Leiden, 2009)      
Prote MMX: Strictly Quantitative  (Chester-UK, 2010)       
 
General courses 
VLAG AIO-week (VLAG-Ermelo, 2006)       
Proteomics (VLAG-Wageningen, 2008)       
Techniques for writing and presenting a scientific paper (VLAG,-Wageningen, 2007) 
Advanced visualisation, integration and biological interpretation of –omics data (VLAG-Wageningen, 2009) 
    
Training in mass spectrometry techniques (Biqualys-Wageningen, 2009)   
 
 
Optionals 
Two scientific presentations at Schering Plough      
Attending research discussions at Toxicology      
Attending research discussion at Biochemistry      
Preparation of research proposals        
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